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ABSTRACT 
 
Amine Nucleophilic Addition to Nitro-alkene as a New Reaction Mode 
for the Synthesis of N-heterocycles  
 
An efficient stereoselective synthesis of polycyclic lactams has been developed using 
Michael addition of conjugated amino-esters to nitro-alkenes. Using acyclic and cyclic 
aminoesters, this method provided a promising approach to the synthesis of bicyclic and 
tricyclic lactam core (5,5; 6,5; 5,5,5; 5,6,5; 6,5,5; 6,6,5 etc) in moderate to excellent yield 
(up to 95%) and excellent diastereoselectivities (up to 99:1 dr). The key steps in this 
asymmetric synthesis include a heteroatom Michael-Michael addition followed by 
reductive amidation to γ-lactams. Lactam cores are biologically active broad spectrum 
antibiotics. 
 
Enantioselective Synthesis of Piperidines by Exocyclic Chirality 
Transfer 
 
Piperidines are very important structural moieties contained in a wide range of 
biologically active and medicinally significant compounds. An efficient route to chiral 
piperidines was developed which involved diastereoselective synthesis of substituted 
piperidines (yields up to 75% with dr up to 10:1 of single isomer) followed by removal of 
one chiral fragment also called N-deprotection to enantiopure piperidine (yields up to 
92%) with 100% chirality retention. 
 
Unique Reactivity of Triazole Gold towards Alkyne Activation to 
Enones and Chiral Allenes 
 
1,2,3-Triazole coordinated gold(I) complexes were found as the effective catalysts in 
promoting propargylic ester/ether rearrangement and sequential allene hydration giving 
enones with excellent yields (up to 97% yields, 0.2% catalyst loading). This catalyst also 
catalyzed the more challenging Meyer-Schuster rearrangement (0.5% catalyst loading, up 
to 98% yields). Unlike other reported Au catalysts, the TA-Au complexes provided 
effective chirality transfer without racemization over a long period of time, giving 
enantioriched allenes with excellent stereoselectivity (1% catalyst loading, up to 99% ee). 
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Chapter 1: Amine Nucleophilic Addition to Nitroalkene as a 
New Reaction Mode for the Stereoselective Synthesis of N-
Heterocycles 
1.1 Introduction 
1.1.1 Organocatalysis in Organic Synthesis 
In modern synthetic chemistry, unique organic transformations building complex 
architectures continues to be of great interests as well as their applications in both industry 
and academia.
1
 One of the fastest growing techniques to date, asymmetric organo-cascade 
catalysis, has been widely used to build the large collection of complex and challenging 
natural and artificial products and medicinal agent (Scheme 1).
2
 They are metal free nitrogen 
containing small organic molecule based catalysts which by high atom-step economic, 
environmentally benign process perform various organic syntheses development.
3
  
Scheme 1: Complex natural and medicinal products 
 
The MacMillan and Jorgensen’s enamine/iminium pyrolidine type catalysts are perfect 
examples of amines used in cascade reactions (Scheme 2).
4 
Scheme 2: Example of Pyrolidine type catalysts 
 
 
2 
 
The α, β conjugated aldehydes can be densely functionalized with both nucleophiles and 
electrophiles in one pot with an excellent levels of enantio and diastereoselection via the 
appropriate selection of amine catalysts (Scheme 3). 
Scheme 3: Iminium and enamine organocatalysis 
 
 
In addition, H-bonding from amine tethered thiourea, SOMO activation and counter ion 
strategies have been used extensively in organocatalysis (Scheme 4).
5
 
Scheme 4: Other modes of organocatalysis 
 
3 
 
In this respect, proline, a privileged molecule has also been used widely as a universal 
asymmetric bifunctional catalyst in aldol type reactions because of its unique nucleophilic 
reactivity compared to other amines (Scheme 5).
6
 
Scheme 5: Modes of activation in proline catalysis 
 
Recently, enamine catalysis was combined together with other different catalysis 
successfully and discovered complicated molecules asymmetrically. For example, the 
addition of enamine to metal activated electrophile is a part of current catalysis research 
(Scheme 6).
7
 
Scheme 6: Metal catalysis combined with organocatalysis 
 
 
1.1.2 Lewis base catalysis of amines 
Though amines are well-known for enamine and iminium catalysis, there has been 
tremendous growth of nitrogen-containing Lewis-base catalysis over the past ten years. 
Actually, nitrogen containing Lewis bases accelerates the reaction by the action of an 
electron pair donor (of catalysts) to variety of unsaturated electron pair acceptors. Generally, 
they are called nucleophilic, n-π* interactions. In both cases the attack by the Lewis base 
4 
 
leads to the formation of zwitterion intermediate with enhanced nucleophilic character at the 
oxygen atom. If a leaving group is present, this intermediate collapses to a new ionic species 
with enhanced electrophilic character (Scheme 7A).
 8a
 One example is tertiary amines such 
as Et3N, or 1, 4-diazabicyclo[2.2.2]octane (DABCO), which are typically used for the 
activation of enones/enals for Baylis-Hillman reaction; another example is the sp
2
 amine like 
compounds, such as 4-dimethylaminopyridine (DMAP) or pyridine which activate carbonyl 
functionalities (Scheme 7B).
 8b-c
 
Scheme 7: Amine lewis base catalysis by organocatalysis 
 
 
1.2 Amine addition to Nitroalkene 
1.2.1 Unique Design of New Reaction Mode and mechanism 
In early 2007, our research group reported the first successful intermolecular double-Michael 
addition between nitro and carbonyl activated olefins through Lewis base (L-Proline)-
catalyzed cascade reactions.
9a
 In this new reaction mode, the rationale of Morita-Baylis-
Hillman reaction (Scheme 8A) were extended to cascade cross-conjugate addition (Scheme 
8B). As proposed, the reaction was set up between β-nitrostyrene and cyclohexanone, 
unfortunately only 32% isolated yield (Scheme 8C) of allylic nitro product obtained. In situ 
5 
 
NMR analysis showed cyclohexanone being a weaker Michael acceptor, favoring nitroalkene 
homopolymerization.
 9b
 After a careful investigation, it has been found that introducing 
methyl group to the α-position of β-nitrostyrene provided excellent yield (Scheme 8D). This 
discovery initiated the previously unexplored field of Lewis base catalysis with amines. 
Scheme 8: Extension of cross-conjugate addition 
 
 
 
6 
 
After a brief substrate scope development, a detailed mechanistic investigation was 
performed. It is found that secondary amine as a Lewis base activates nitroalkene and forms a 
zwitterion (A) and nitronate (B) which are stabilized by resonance and H-bond in equilibrium. 
Sequential addition of the proper electrophile followed by β-elimination releases the 
secondary amine catalyst to give the allylic nitro products (Scheme 9). During the reaction, 
the formation of a hydrogen bonded intermediate (B) prevented possible polymerization, 
which was the key side reaction with other nucleophilic catalysts, such as DMAP, PPh3 and 
DABCO.  
Scheme 9: Mechanism of amine activation of nitroalkenes 
 
 
1.2.2 Enantioselective cross-conjuagate addition of nitroalkenes to enals 
Based on the aforementioned study, asymmetric cross-conjugate reaction was explored in the 
presence of chiral secondary amines using dual activation approach to form chiral allylic 
nitro compounds. During transformation, the chiral secondary amine activated enal to form 
electron deficient iminium intermediate in one hand and nitroalkene to form carbanion 
nitronate for Michael addition on the other hand. With the aid of trimethoxyphosphine as a 
nucleophile, conjugated addition products were formed in good to excellent yields and 
enantioselectivity (Scheme 10).
10
 Aliphatic and aromatic disubstituted nitroalkenes as well as 
variety of enals performed this transformation. 
 
 
 
7 
 
Scheme 10: Selected substrates of cross-conjugate addition of nitroalkenes to enals 
 
1.2.3 Diastereoselective cascade synthesis of Nitro-substituted cyclohexanes 
With the foundation of proline promoted cross conjugate addition developed, the designed 
Michael-Michael-Aldol cascade condensation of nitroalkenes and enones were also finished 
successfully for the synthesis of multi-substituted cyclohexanes. In this strategy, the active 
nucleophile E, formed from Lewis base activation to nitroalkene followed by conjugate 
addition to Michael acceptor, added to the second Michael acceptor through Michael addition 
and formed dicarbonyl compound. Finally, intramolecular aldol reaction leads to the 
formation of substituted cyclohexanes G (Scheme 11).
11 
Scheme 11: Michael-Aldol condensation of nitroalkenes to enones 
 
8 
 
The optimal condition for this cascade synthesis is triethylamine (Et3N) or sodium azide 
(NaN3) in a stoichiometric amount with organocatyst L-proline in a catalytic amount (0.2 
mol%) in the presence of excess unsaturated enone. This Michael-Michael-Aldol 
condensation gave an excellent yield and diastereoselectivity (Scheme 12). Although 
enantioselective condensation of dicarbonyl compounds by L-proline were reported in the 
literature,
12
 poor enantioselectivity were obtained in this cross-conjugate reaction ( <20% ee 
in all cases). Further investigations are required to understand the mechanism  and 
stereochemistry. 
Scheme 12: Diastereoselective cross-conjugate addition of nitroalkenes to enones 
 
 
 
 
 
9 
 
1.2.4 One pot multicomponent condensation to the synthesis of substituted 
dihydrofurans and substituted triazoles 
The lesson learned from the Lewis base catalysed nitroalkene mechanism for the formation 
of the nitrodiene intermediate, various multicomponent cascade processes were invented with 
the incorporation of dinucleophile species as shown in Scheme 13 A, B and C below.
13
 
Scheme 13: Proposed DHF and Triazole synthesis 
 
 
 
With the application of 1, 3-diketones or β-ketoesters, successive addition to nitrodiene 
intermediate lead to the formation of varied dihydrofurans in one pot pattern. C-2 and C-3 
functionalized trans-isomers were obtained with great diversity, high efficiency and excellent 
diastereoselectivity (Scheme 14). 
 
 
 
 
 
 
 
 
10 
 
Scheme 14: Substrate scope of the three component dihydrofuran synthesis 
 
 
 
The discovery of click chemistry, from 1,3 dipolar addition of azides
14
 to triple bond which 
provided various five membered heterocycles, brought our research interest to recognize 
azides in our new Lewis base catalysis concept. Our strategy was based on azide anion (N3
-
 ) 
addition to a nitrodiene to give disubstituted  1,2,3-(NH)-triazole cycloaddition product in 
one pot with the elimination of nitrite anion (NO2
-
). A large number of aryl aldehydes and β-
alkyl nitroalkenes were suitable for this transformation to provide good yields under this mild 
cascade process (Scheme 15). This synthesis started the possibility of its use for promising 
chemical and biological applications.
15
 
 
 
 
11 
 
Scheme 15: One pot three component synthesis of 1,2,3 triazoles 
 
 
1.3 Stereoselective isoxazoline-N-oxide synthesis 
1.3.1 Introduction 
As mentioned earlier, reactions catalyzed by small chiral organic molecules so called proline 
analogues were rapidly uncovered due to their accessibility and synthetic efficiency. 
Iminium/enamine formation and Lewis base catalysis are the two fast growing areas in 
asymmetric organocatalysis. But, the application of secondary and primary amines as a 
Lewis base catalyst is much less developed. Experimental and computational studies 
suggested that L-proline served as an effective Lewis base catalyst for activation of the 
nitroalkene. In 2008, Shi’s group disclosed the reaction of nitroalkenes with electron 
enriched olefins to form isoxazoline-N-oxides based on plausible 1,3-dipolar site of  H-
bonded nitronate ion for cycloaddition via mechanistic interpretation, as shown below 
(Scheme 16).
16 
 
12 
 
Scheme 16: One step formation of isoxazoline-N-oxide 
 
The mechanistic investigation of this compelling conversion revealed that the [3+2] 
cyclization between the L-proline-activated nitroalkene and vinyl ester involved the 
formation of 1, 3-diene (A) as an active intermediate. Subsequent conjugate addition of the 
second α-nitro-carbanion leads to the formation of dinitro-intermediate (B). Additional 
intramolecular cyclizations give the isoxazoline-N-oxides (Scheme 17). This cascade route 
became more fascinating because it produces diene intermediate A in-situ which allowed the 
easy construction of N-oxides in contrast to the other challenging reported methods. 
Moreover, this reaction mode turned out to be milder and two vinyl groups were introduced 
at the C-3 and C-5 position. Nonetheless, even with the high potency of these isoxazoline-N-
oxides synthesis, this cascade reaction has faced three distinct problems. 
a) The C-4 substitution has to be aliphatic.(Aliphatic Vinyl acetate) 
b) C-3 & C-5 positions have to be the same. (Same nitroalkene) 
c) No enantioselectivity is observed when chiral secondary amines were used. 
If we were able to solve those innate problems, there will be the successful discovery of 
concise synthesis of the isoxazoline-N-oxide molecules. 
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Scheme 17: Proposed reaction mechanism for the synthesis of isoxazoline-N-oxides. 
 
 
1.4 Research objectives 
1.4.1 Asymmetric multicomponent synthesis of isoxazoline-N-oxide* 
To overcome the previous constraint, functional groups at the C-3, C-4, and C-5 positions 
have to be studied. Special exploration of chiral bases and auxiliaries needs to be done for 
asymmetric synthesis towards biologically active natural products and their derivatives 
synthesis. 
 
1.4.2 Application towards natural products synthesis 
After the recognition of broad synthetic strategy, a comprehensive study of natural products 
is necessary to find out a similar backbone or easier steps. The multi-functional nature of 
isoxazoline-N-oxide will help to devise synthetic routes to natural products synthesis. 
 
1.4.3 Henry aldol strategy to isoxazoline-N-oxide synthesis 
Similar to the nitro-aldol reaction, nitroalkene under organocatalytic condition produces a 
resonance stabilized anion which after reaction with carbonyl compounds especially aromatic 
                                                   
* Reproduced in parts with permission from Tetrahedron 2011, 67, 4402-4411. Copyright 2011, 
with permission from Science Direct/Elsevier B. V  
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aldehyde, produces homo-isoxazoline-N-oxide 1.4.3. So, broader substrate scope can be 
achieved on the C-4 position (Scheme 18). 
Scheme 18: Proposed proline catalysed Isoxoazoline-N-oxide syntheisis 
 
A reaction optimization study found that only proline or a weak base such as NaOAc had an 
incomplete reaction. Neutralization and polymerization were found as the major side 
reactions. However, on combining proline (0.2 eq.) and NaOAc (1.0 eq.) in DMSO the 
reaction was completed within three hours. Even the pyrrolidine with K2CO3 (0.5 eq.) was 
found effective for this transformation.  To confirm this reaction as a Lewis base catalyzed 
transformation, the allylic nitro compound was prepared and the reaction was performed. As 
intended, this reaction was slower with very low yield (Scheme 19). 
Scheme 19: Experimental confirmation of Lewis base catalysis 
 
As expected, with the optimal condition in hand, excellent diastereoselectivity was 
accomplished and only trans products were obtained. Both aliphatic and aromatic 
nitroalkenes provided reasonable yields. Simple aromatic to heteroaromatic aldehydes 
15 
 
performed well and gave good to excellent yields. Aliphatic aldehydes showed less reactivity. 
As a result, side reactions vanquished the desired route due to the formation of enamines. 
Overall, variety of functional groups can easily be incorporated into the C-4 position with 
high efficiency (Scheme 20). 
Scheme 20: Homo-isoxazoline-N-oxide scope 
 
Substrate scope study showed this route could be an alternative approach to our previously 
reported [3+2] cyclization strategy for the synthesis of desired products. So, large diversity in 
the synthesis of iso-oxazoline-N-oxides can be easily done with high efficiency and 
stereoselelctivity. 
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Scheme 21: Substrates screening for the third component (Nu-LG) 
 
 
1.4.4 Strategies for the third component (Nu-LG) to isoxazoline-N-oxide 
Based on the Lewis base catalyzed mechanism, thorough screenings of third components as a 
nucleophile were done (Scheme 21). Previous studies confirmed that diene A is the key 
reactive species.
16
 So, if the third component with the structural feature like Nu-LG (with 
nucleophile and leaving group on the same molecule) reacted with diene, there might be the 
variety of substitution on isoxazoline-N-oxide. 
Table 1: Screening of Lewis base catalysis with various third components (Nu-LG) 
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Multicomponent reaction over epoxidation and homo-N-oxides
 
As shown in Table 1, application of 1.4.4.2a and 1.4.4.2b, under the previously developed 
optimal condition, produced only the homoisoxazoline-N-oxide, which was probably due to 
the low reactivity of the sulfonate nucleophiles (entries 1 and 2). The phosphine ylide 
1.4.4.2c and amine ylide 1.4.4.2d did generate the desired product 1.4.4.3. However, the 
reaction suffered from the significant competition of homo-condensation (entries 3 and 4). 
Interestingly, application of sulfur ylides 1.4.4.2e and 1.4.4.2f gave the desired compound 
1.4.4.3 as the dominant product in excellent yields (entries 5 and 6) with only a trace amount 
homo-product. Notably, it was well known that the reaction between aldehyde and sulfur 
ylide 1.4.4.2e could produce the corresponding epoxides in good yields. However, under the 
reported reaction condition, no significant formation of epoxide was observed. In conclusion, 
the well documented epoxide formation by the action of ylide to aldehyde is completely 
conquered by our optimal condition of three component condensation. 
 
At this stage, versatile three-component cascade reactions were developed with different 
functionalities in the C-3, C-4 and C-5 position of the isoxoazoline-N-oxide. The summarized 
substrate scope varieties are shown in Table 2. Numerous aldehydes with aromatic and 
heteroaromatic substituents gave good to excellent yields. Similarly, different sulfur ylides 
were also tolerated. 
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Table 2: Substrate scope of the designed cascade reaction 
 
1.4.5 Asymmetric Synthesis of isoxazoline-N-oxide† 
Although excellent diastereoselectivity for the trans isomer was obtained with this method, 
enantioselective synthesis of isoxazoline derivatives is considered as challenging.
17
 However 
on screening with various chiral Lewis-base catalysts, discouraging enantioselectivity was 
observed (Figure 1, <15% ee in all cases). In addition, the quinine-derived chiral tertiary 
amine
18
 did not promote the heterocoupling reaction. This evidenced our previous 
observation of poor involvement of the catalysts during the formation of the C-4 stereogenic 
center as well as the poor Z/E selectivity of the nitrodiene intermediate. 
 
 
 
 
 
                                                   
† Reproduced in parts with permission from Chem. Eur. J. 2010, 16, 8605-8609. Copyright 2011, 
with permission from Willey-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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Figure 1: Tested Lewis Base Catalyst for Asymmetric Synthesis 
 
In the next step, to achieve enantioselective synthesis, different chiral ylides were 
synthesized and tested based on our previous report of ylides as a third nuclephilic reagent 
for the synthesis of fully substituted isoxazoline-N-oxides (Table 3). The quinine derived 
chiral tertiary amines (cat 6-9) and salts (aux-a) did not promote the desired reaction (entry1). 
However, readily available champhor-derived thioether ylides gave good yields and excellent 
enantioselectivity for three component condensation. Though ketone ylide (aux-b) did not 
promote the reaction, converting into ester and methylated ylide (aux-d) in pyrrolidine as 
Lewis base and cesium carbonate as pure base completed the reaction. In addition, X-ray 
crystallographic analysis of the related camphor derived auxiliary (aux-g) showed the 
evidence of optimal chemical yield and stereoselectivity from an intramolecular H-bonding 
between the alcohol and sulfonium. 
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Table 3: Condition optimization of different auxiliaries in asymmetric synthesis 
 
 
As shown in Table 4, the reaction worked efficiently with various nitroalkenes including aryl, 
alkyl and cyclic structures. Similarly, aliphatic, aromatic and heteroaromatic aldehydes 
substrates were also found satisfactory for this transformation. But, aliphatic aldehydes can 
easily be differentiated on comparing to nitroalkenes. This is because electron deficient 
nature of aldehyde (1.4.5h) gave excellent yield. However, enantioselectivity was slightly 
decreased. The high reactivity of the diene intermediate may lead to lower efficiency. 
Sterically hindered aldehydes (1.4.5f) promoted the enantioselectivity. This may be due to 
better spatial control. Similar asymmetric control was also achieved with aliphatic aldehyde. 
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Table 4: Substrate scope of N-oxides in asymmetric synthesis 
 
  
 
 
1.5 Total synthesis of (-) Clausenamide derivatives 
Aforementioned enantioselective isoxazoline-N-oxides provided a general and highly 
effective method to prepare varieties of enantiomeric derivatives. In addition, this 
comprehensive study led us to reach towards some complex, biologically and 
pharmaceutically important molecules in simple steps. One example we chose was the 
synthesis of all-cis -lactam, towards the construction of clausenamide derivatives (Scheme 
22 
 
22).
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Relevent literature searches and careful reaction condition optimization provided the 
desired molecule 1.5c in 57% yield with 85% ee (>99% ee after recrystalization).  
Scheme 22: Synthetic scheme of (-) Clausenamide derivatives 
 
Briefly, the isoxazoline-N-oxide 1.4.5a undergoes diastereoselective zinc reduction followed 
by base treatment towards pyrolidine molecule 1.5a. After N-methylation, the product was 
treated successively with osmium tetroxide and sodium periodate for compound 1.5b in 79% 
yield. Finally, simple borohydride reduction followed by careful recrystalization furnished 
the clausenamide in >98% yield and >99% ee. This synthesis is very simple, atom efficient 
and does not involve expensive reagents and protecting groups. 
 
1.6 Conclusion 
Various new molecules were developed by the use of proline Lewis base catalyzed, 
multicomponent condensation of nitroalkene, aldehyde and sulfur ylide. The three limitations 
associated with the first discovery of iso-oxazoline-N-oxide synthesis in 2007 were resolved. 
In addition, this powerful approach provided chemo and enantioselective synthesis of 
isoxazoline-N-oxide as well as synthesis of biologically active and enantiopure clausenamide 
with high atom economy and efficiency. 
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Chapter 2: Stereoselective N-heterocycle Syntheses through 
Cascade Amine Addition to Nitroalkene Cyclization 
2.1 Introduction 
2.1.1  Literature reported synthesis and designs towards N-heterocycles 
N-Heterocyclic structures are unique drug candidates with phenomenal importance in the 
fields of organic synthesis, catalysis, chemical-biology and pharmaceutical industry. Due to 
their critical role in medicinal research, continuous efforts have been put into the search and 
development of new synthetic methodologies for effective construction of heterocyclic 
natural product like compounds especially those with large substrate scope and good 
stereoselectivity. Among those privileged structures, pyrrolidine, indolizidine, quinolizidine, 
and piperidine alkaloids and their derivatives play an important medicinal role due to their 
interesting framework and biological activities (Scheme 23).
20
 These compounds are 
ubiquitous in nature and are found in a myriad of organisms. Although the literature 
describes a plethora of methods to synthesize these heterocyclic systems, a short, direct and 
diversity-oriented approach is scarce. 
Scheme 23: Some skeleton structures and important alkaloids 
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The synthesis of these bio-active and medicinally significant molecules has been of 
longstanding interest. Their construction requires the introduction of a nitrogen-containing 
moiety through carbon-carbon and carbon-nitrogen bond formation reactions. Many state-of–
the-art approaches for the construction of these heterocycles have been discovered. Among 
various synthetic routes, metal mediated or catalyzed intramolecular hydroamination for the 
direct formation of a new C-N bond by the addition of an amine to an unsaturated C-C bond, 
is one of the important methods. This reaction offers an atom-efficient pathway from readily 
accessible alkenes, allenes, alkynes and other conjugated systems (Scheme 24).
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Scheme 24: Intramolecular hydroaminations 
 
The second method to N-heterocycles is cycloaddition involving C=N or 1,3-dipoles also 
known as the Huisgen reaction. Because of the various possibilities of introducing popular 
dipoles, they are extremely powerful reactions that can generate multiple chiral centers, 
various heterocyclic or carbocyclic ring sizes as well as a wide array of pharmacologically 
active final products (Scheme 25).
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Scheme 25: Cycloaddition reaction involving C=N or 1,3-dipoles 
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Some recent examples are: 
 
 
Another approach towards the small molecular weight N-heterocycle scaffolds is the multiple 
components Michael addition cyclocondensation reaction. Common named reaction under 
this category include Ugi, Ugi-Smiles, Passerini, Groebcke, Heck, RCM, Wittig, 
Homologation and Aza-Diels-Alder (Scheme 26).
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Scheme 26: Multiple-component cyclocondensation reactions 
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As mentioned in the previous chapters, the past decade evidenced the fast growth of organo-
catalysis.
24
 Numerous new transformations have been reported with good stereoselectivity. 
Among the reported works, one of the most well studied reactions is the ketone/aldehyde 
nucleophilic addition to nitroalkenes in the presence of a chiral amine catalyst.
25
 As shown in 
Scheme 27, the amine catalyst promotes the formation of a nucleophilic enamine to react 
with the nitroalkene through conjugate addition. Although the nitroalkene is a highly reactive 
electrophile, it is generally assumed that no reaction occurred between the amine and 
nitroalkene.
26
  
 
2.1.2 Previous Study in Our group 
Our recent investigation on the intermolecular cross conjugate addition between nitroalkene 
and enone/enal confirmed that the nitroalkene is a more reactive Michael receptor than 
typical enone and enal towards nucleophiles.
27 
Scheme 27:  Previously reported approach: nitroalkene as receptor 
 
Interestingly, during our mechanistic investigations, we found that the secondary amine 
addition to the nitroalkene involved a rapid equilibrium.  The formation of an intermolecular 
H-bond successfully prevented polymerization of the nitroalkene, which was typically 
observed by other nucleophilic catalysts, such as PR3 and NR3 (Scheme 28).   
Scheme 28: Prevention of polymerization 
 
Although these methods have proven quite useful, their substrate scope, mild reaction 
condition and functional group tolerance is often limited. Therefore, the intellectual 
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challenge to invent concise, elegant and conceptually novel synthetic routes through 
mastering unusual combinations of elementary organic reactions has become a steadily 
increasing driving force both in academia and industry. Owing to its unique mechanism and 
efficiency, it is expected that intermolecular double Michael addition between amine tethered 
conjugated Michael acceptor to nitro-alkenes will lead to the discovery of heterocyclic 
architectures. 
 
2.2 Research Design 
2.2.1 Stereoselective synthesis of N-heterocycles by the action of amine to nitroalkene 
With this mechanistic discovery, we postulated that this new reaction mode could be applied 
in the synthesis of N-heterocycles through designated intermolecular condensation (Scheme 
29). In addition, we have previously demonstrated that the α,β-unsaturated esters were valid 
reaction partners for amine-activated nitroalkenes. It could be possible to vary the 
substituents and extend to the complex structures like alkaloids and lactams. Another 
objective could be variation in ring structure and fusion to synthesize conformationally 
locked rigid bicycle to polycyclic structures. A final application could be variation in 
pharmaceutically active functionalities like trifluoromethyl and ester groups. 
Scheme 29: Designed addition of amine to nitroalkene 
 
 
2.2.2 Confirmation of chirality retention 
Asymmetric synthesis needs to be done to confirm optically activity of the final products 
which is very important in medicinal and pharmaceutical chemistry. 
 
2.3 Results and Discussion 
2.3.1 Synthesis of diverse amino pendant conjugated esters 
The amino connected α,β-unsaturated ester 2.1 (Scheme 30 A) was first selected as the 
reaction partner with nitroalkene in this study. Various amino esters were readily prepared 
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from the commercially available amino acid/alcohol with excellent overall yield on a gram 
scale (Scheme 30 B & C), which makes the overall methodology feasible and practical.
28 
 
The reaction sequence for this process was Boc-protection of aminogroup, hydroboration of 
carboxylic acid to primary alcohol followed by Swern oxidation to aldehyde. Finally, a 
Wittig reaction followed by removal of the Boc group afforded the required molecule. To 
verify our hypothesis, proline derivative 2.1a was tested with nitroalkene. Nitroalkenes 
(Scheme 30 D) were also synthesized following the literature procedures.
29
  
Scheme 30: Synthesis of amino-tethered proline ester 2.1a 
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2.3.2 Reaction optimization for Aza-Michael addition 
The aza-Michael addition is one of the widely used reaction for carbon-nitrogen bond 
formation in recent organic synthesis. Conjugate reaction of various amines with α,β-
unsaturated carbonyl compounds provides β-amino carbonyl ingredients, which have 
attracted great attention for their use as key heterocyclic intermediates for anticancer agents, 
antibiotics and other drugs.
 30
  
Generally, aza-Michael additions have been catalyzed by strong bases or acids which are 
detrimental to the desired synthesis because of usual side reactions. Therefore, scientists have 
paid more attentions to the development of more mild, benign and facile catalytic systems for 
the aza-conjugate reaction. The reaction condition screening results are summarized in Table 
5.
 
We initially carried out several experiments at lower temperature (-10C) and did 
neutralization of the aminoester and treated with nitroalkene. We were not able to promote 
the reaction. When, we carried out the reaction at ambient temperature, interestingly, 
insignificant activities were obtained. Then we assumed there must be the necessity of a 
more equivalent base to promote the reaction. As expected, with the use of four equivalents 
of Hünig’s base (DIPEA) in dichloromethane (DCM), the cyclization product 2.3a was 
obtained in good yield at room temperature (entry 1). Although the product contained four 
stereogenic centers, this reaction exhibited excellent stereoselectivity with only two 
stereoisomers observed (2.3a and 2.3a') in a 3:1 ratio. The relative stereochemistry was 
verified by comprehensive NMR analysis and later confirmed by X-ray crystallography.
‡
 
Solvent screening revealed the more polar solvent acetonitrile optimizes the reaction 
condition giving improved yield and dr 9:1 (entry 5). In DMSO, no product was detected 
though reaction seems 100% conversion.  Switching to methanol also decreased the yield of 
the desired reaction. 
                                                   
‡  For NMR and X-ray see Experimental Section 
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The use of an inorganic base, such as potassium carbonate, sodium and ammonium acetate, 
resulted in very slow reaction rates and low overall yields (entries 6-7). This finding is 
consistent with our previous observation that buffered solutions generally give better results 
than a simple proton scavenger (the inorganic bases). Notably, the amount of base was 
critical for the overall performance. Four equivalents of DIPEA were identified as the 
optimal amount. Decreasing the amount of base caused slower formation of the desired 
product, which led to the observation of more nitroalkene polymerization side products. On 
the other hand, further addition of too much base (7 equiv., entry 11) was less effective and 
caused a decrease of the overall yield due to intramolecular cyclization towards the formation 
of the lactam and other side reactions. We are still investigating the mechanism behind this.
  
Table 5: Screening of reaction conditions
a 
 
entry  solvent  base (equiv.)  time(h)  conv
b
 (%)  yield
b
 (%)  dr
b
 2.3a:2.3a’  
1  DCM  DIPEA (4)  3  >99  63  3:1  
2  THF  DIPEA (4)  3  >99  65  4:1  
3  DMSO  DIPEA (4)  3  100  <1  n.a.  
4  MeOH  DIPEA (4)  3  100  61  5:1  
5  CH3CN  DIPEA (4)  3  100  91  9:1  
6  CH3CN  K2CO3 (4)  3  30
c
  18  n.d.  
7  CH3CN  NaOAc (4)  3  20
c
  15  n.d.  
8  CH3CN  Et3N (4)  3  100  56  2:1  
9  CH3CN  DIPEA (2)  3  100  51  5:1  
10  CH3CN  DIPEA (3)  3  100  66  6:1  
11  CH3CN  DIPEA (7)  3  100  47  1:1  
 
 
2.3.3 Reaction Substrate Scope 
With the optimized reaction condition, this transformation was subjected to wide varieties of 
amine connected α,β-conjugated esters with aromatic and heteroaromatic nitroalkenes 
(Scheme 30) to evaluate the reaction substrate scope, and the results are described below 
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(Figure 2 & Figure 3). The reaction tolerated a large substrate scope including aromatic 
nitroalkenes with either electron withdrawing (2.3aa, 2.3ac) or electron donating substituted 
groups (2.3ab). Heteroaromatic substituted nitroalkenes worked well under the optimal 
condition, giving the desired N-heterocycles in good to excellent yields (2.3ad, 2.3ae). 
Aliphatic nitroalkenes gave very low yields of the desired cyclization products. For example, 
with substrate 2.2b, complex reaction mixtures were observed, likely caused by the rapid 
polymerization of this highly reactive nitroalkene. The sterically hindered nitroalkene 
2.2c/2.2d gave a much slower reaction, and very little of the desired product. This result is 
likely caused by the amine β-elimination as previously reported.9-11, 31 
Figure 2: Substrate scope of Aza-Michael addition for bicyclic nitro-esters 
 
 
After we finished the substrate’s scope of the [5,5] bicyclic system, we moved to the [5,6] 
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system. The p-Cl substituted nitroalkene gave high yield (3bc) while high diastereoselectivity 
is obtained in the furan system (2.3bd). To our delight, for the [6,5] nitroester, high yield and 
diastereoselectivity (>99:1) was obtained in all cases. In the case of [6,6] bicycle, although 
yields were good, diastereoselectivities were discouraging. In addition, a heteroaromatic 
nitroalkene did not work under our reaction conditions. 
In monocyclic five membered ring cyclization, high yield and excellent diastereoselectivities 
were obtained while in six membered rings, decent yields were observed with lower 
diastereoselectivity. 
Figure 3: Substrate scope of Aza-Michael addition for Monocyclic nitro-esters 
 
 
To overcome the undesired β-elimination, β-nitro-α,β-unsaturated ester 2.2e 
(NO2CH=CHCOOMe) was prepared
32a
 to react with the amino-ester 2.1a. The desired 
cyclization products (2.4ab, 2.4bb, 2.4cb, 2.4db and 2.4eb) were obtained in good to 
excellent yields. As usual the five membered ring gave >99:1 diastereoselectivity. This result 
provided a potential alternative approach to introducing aliphatic groups through the 
sequential ester group transformations (such as reduction). Since the CF3 group has 
significant electronegativity (between Cl and F), it has strong acidity, lower basicity and 
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solvation properties that are found in most of the pharmaceutical drugs. Being CF3 a 
bioisostere of Cl
-
 and CH3, it adjusts steric and electronic properties as well as protects the 
reactive methyl group from metabolic oxidation. With these drug like significance in hand, 
we pursued towards the synthesis of nitroalkene with CF3 (2.2 e and 2.2f).
32b,c
 Notably, the 
CF3 modified nitroalkene 2.2f (NO2CH=CHCF3) could also give the corresponding 
cyclization products in excellent yields (2.4aa, 2.4ba, 2.4ca 2.4da and 2.4ea), with 2.4ea 
of >99:1 diastereoselectivity which provided an interesting new strategy to incorporate CF3 
group into the N-heterocycles under very mild conditions (Figure 4). Considering the 
importance of fluorine containing N-heterocycles, these results highlighted the apparent 
advantages of this new method. 
Figure 4: Substrate scope of with medicinally active function groups 
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In conclusion, besides the large substrate scope, this method also tolerated various ring sizes, 
giving the corresponding 5 or 6 exo-trig cyclization products in good yields. Both cyclic 
secondary amines and acyclic secondary amines were suitable for this transformation (2.3e to 
2.3f). With the application of cyclic amines, the 5-5, 5-6, 6-5 or 6-6 bicyclic structures could 
be readily prepared from the corresponding starting materials with good to excellent yields. 
The primary amine substrates (NH2CH2CH=CHCOOMe) did not work well under the 
optimal condition, which was consistent with our previous reports. However, this problem 
can be overcome by the application of protected amines. For example, the PMB (para-
methoxy benzyl) modified amine afforded the corresponding cyclization product in good 
yields. Followed by the deprotection of PMB as reported in literature, the corresponding NH-
amine can be achieved in good yields. The 7 and 8-exo-trig cyclization products were 
successfully isolated under the reaction conditions. However, the reaction proceeded very 
slowly (48 hr, RT) with poor isolated yields (< 25%). Increasing of the reaction temperature 
to 80 °C caused significant decomposition of the nitroalkenes. The use of amines with better 
leaving groups for the extended ring cyclization is currently under investigation. 
 
2.4 Application of our methodology in the synthesis of -lactam 
heterocyclic architectures 
In general, stereochemistry control is one critical factor for the evolution of any N-
heterocycle synthesis. As indicated in Table 5, this new method gave excellent 
stereoselectivity at C-2, C-4 and C-5 positions. The only isomerization observed at the C-3 
position, was caused by the racemization of a nitro group on the C-3 position. Since -NO2 is 
a highly versatile and sensitive functional group, this issue can be overcome by converting 
the diastereomeric mixture into other derivatives, such as to ketones (NEF reaction) and 
amides (reductive amidation). Given our interests in developing complex N-heterocyclic 
structures, we took the reductive cyclization route to further convert nitro esters into 
polycyclic -lactam (Scheme 31). 
 
 
 
36 
 
Scheme 31: Nitro-reduction and cyclization strategy 
   
 
2.4.1 Screening of condition for reductive cyclization 
At this stage we then began to investigate the reaction condition for route scouting or 
reduction and plausible cyclization. Initially, we tried a number of reducing reagents such as 
In, TiCl4/Zn, TiO2, SmI2, PtO2, N2H4, BH3/NaBH4 in different solvents (methanol, ethanol, 
DMF, acetic acid). They either gave low yields or did not react at all or serious problems due 
to side reactions and work-up. Screening of some of the other reagents under reflux for 
desired products is given below (Table 6). Tin/tin chloride gave low yield (entry 1, 9) while 
the reaction with palladium in ammonium formate remains problematic in yield, although 
conversion was good. Upon adding sodium borohydride, we observed only the free amine 
product. Similarly, Raney Ni/NiCl2 did not promote a reaction to the desired lactam. 
Interestingly, zinc reduction followed by basic treatment promoted the reaction. Finally, a 
more convenient procedure of refluxing in the presence of very cheap reagent iron/AcOH 
was identified as the optimal condition. In this case, the intermediately formed amines were 
not isolated, but immediately cyclized to lactams in 80% yields.
33 
The two nitro diastereomers were converted into a single stereoisomer. The relative 
stereochemistry of the final products was confirmed by 2D-NMR analysis and X-ray 
crystallography (Figure 5).
30 
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Table 6: Screening of reductive amidation 
 
 
SN  Screening with Diff. Reducing agents  Temp.(C)  Conversion (%)  Yield (%)  
1  SnCl2.2H2O (2 equiv.), EtOAc  74  72  47  
2  10% Pd/C, HCOONH4, MeOH  64  93  54  
3  10% Pd/C, NaBH4, THF  70  84  53  
4  Zn, AcOH then K2CO3, P
H
 8 - 9  80  81  62  
5  Fe, AcOH:EtOH,  H2O  90  83  60  
6  Fe, AcOH  90  >99  80  
7  Raney Ni, EtOH, 40-60 psi, then toluene  110  72  52  
8  NiCl2.6H2O (5 equiv.), MeOH  64  94  59  
9  Sn/HCl, EtOH  80  87  47  
General reaction condition: Nitroester 3aa (1.64 mmol, 1 equiv.), and metal powder (16.4 mmol, 10 equiv.) were added 
to solvent (4 mL), the reactions were stirred at the specified temperature and monitored by TLC unless otherwise 
mentioned. Conversion and yields were determined by NMR with 1,3,5-trimethoxybenzene as internal standard based 
on the consumption of bicyclic nitroester mixture. 
 
Figure 5: X-ray crystal structure of 5-6-5-tri-cyclic 2.5ba 
 
 
2.4.2 Substrate scope of polycyclic N-heterocycles 
Though, Aza-Michael condensations are known to be a challenging transformation, our 
optimized condition tolerated various kinds of substrates (Figure 6 & Figure 7). Those 
heterocyclic cores are very common to a number of alkaloids. We first examined the [5,5,5] 
system. Cyclization from [5,5] system gave products faster with decent yields. Lower yields 
were obtained in the case of a furan substituted nitro-ester. Reductive amidation to [5,6,5] 
reactions required longer reaction times though as expected a modest output was observed. In 
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all cases, it was found that the electron withdrawing group activated cyclization for 
amidation. In [6,5,5] satisfactory yields were attained. 
Figure 6: Reaction Substrate scope
a
 
aGeneral reaction conditions: 2.3 (0.5 mmol, 1.0 equiv.), iron powder (5 mmol, 10 equiv.) in   AcOH (5 mL) reflux for 
10 hr. 
 
In case of [6,6,5]  aromatic nitro-ester, reductive cyclization not only provided lower yields 
but were also found unsuitable for the  heteroaromatic system. N-ethyl substituted [6,5] 
reductive amidation process were also applicable with decent yield. In the case of [5,5] N-
methyl nitroester, a Hofmann degradation of so formed quaternary ammonium salt by β-
elimination arrested our desired route. Since p-methoxy benzene ring has less reactive 
substituents, it promoted lactam formation for a moderate yield. 
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Figure 7: Reaction Substrate scope
a
 
 
 
    
aGeneral reaction conditions: 2.3 (0.5 mmol, 1.0 equiv.), iron powder (5 mmol, 10 equiv.) in   AcOH (5 mL) reflux for 
10 hr. 
This method is straightforward and applicable where additional rings are fused through 
vicinal carbons. The higher thermodynamic stability of amide is the major driving force for 
this cyclization. Apparently, during the course of lactamization, cyclization from five 
membered nitroester took precedence over the six membered nitroester rings, a behavior 
consistent with that encountered in other indole ring closures.
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2.5 Asymmetric transformation 
With the very mild reaction conditions, this newly developed method could lead to an easy 
asymmetric synthesis of desired N-heterocycles from the readily available enantiomeric pure 
amino alcohol/acid. To confirm the stereochemistry retention, the enantiomerically pure 
amino alcohol 2.6 was used in our protocol for this transformation. As indicated in Scheme 
32, through the coupling with (-) Mosher’s acid, the single diastereomer was obtained, which 
confirmed the complete retention of stereochemistry throughout the overall operations. 
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Further absolute stereochemistry was determined by optical rotation and chiral HPLC. Thus, 
the reported method can be readily applied for the asymmetric synthesis of N-heterocycles 
from readily available, enantiomerically pure amino-esters. 
Scheme 32: Retention of stereochemistry in overall transformation 
 
 
2.6 Conclusion 
In short, a new, short and facile method for the direct synthesis of biologically relevant N-
heterocyclic scaffolds was developed by utilizing cheap and easily available materials for the 
first time from the Aza-Michael conjugate addition of amino-pendant conjugated ester 
reaction with nitroalkene followed by reductive amidation. This highly convergent design is 
based on the conjugate amine addition to nitroalkene, which is different and new from 
literature reported general strategies. This strategy demonstrated excellent efficiency, giving 
complex N-heterocycles with good to excellent yields and a broad substrate scope. The 
incorporation of CF3 and excellent stereoselectivity further highlighted the promising 
potential of this powerful method in the preparation of complex polycyclic N-heterocycles 
under mild conditions with high atom economy and stereoselectivity. The strength of this 
process is that it provides ample opportunities for the quick and easy synthesis and design of 
pharmaceutically and medicinally active fluorinated scaffolds by the use of trifluoromethyl 
and ester substituted nitroalkene.  
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Chapter 3: Synthesis of Enantiopure Piperidines by Exocyclic 
Chirality Induction 
3.1 Introduction 
3.1.1 Literature reported asymmetric synthesis of piperidine synthesis 
Piperidines are very important structural moieties contained in a wide range of biologically 
active and medicinally significant compounds. This importance is directly reflected in the 
investigation of over 12000 piperidine varieties in clinical or preclinical studies over a 13-
year period because of their wide range of physiological activities (Scheme 33).
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Scheme 33: Biologically active piperidine moieties containing Natural products 
 
In the past few years a burgeoning interest in chiral compounds emanated in synthetic 
organic chemistry has been strengthened by the more demand from the pharmaceutical 
companies to produce enantiomerically pure drugs since unwanted enantiomer can have 
harmful and sometimes fatal effects. Several synthetic strategies for the synthesis of 
piperidine derivatives have been developed.
36
 Most of these strategies rely extensively on the 
chiral starting materials
36b or use of chiral ligands,
36d  for the synthesis of a wide variety 
of heterocyclic compounds. Asymmetric syntheses to piperidines generally revolve around 
following four strategic categories.
36a 
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(a) Intramolecular SN2 reaction: it is the most useful and reliable method of preparation 
where ring formation occurs through amine attack to precursor containing better leaving 
group. As a result, pre-defined stereochemistry is established (Scheme 34). 
Scheme 34: Intramolecular SN2 reaction 
 
(b) Asymmetry generation in existing six- membered nitrogen heterocycle via lithiation. 
The addition of an electrophile to an α-lithiated 4-substituted piperidines could be the best 
way for the synthesis of substituted piperidines to occur. Depending upon the size of 
electrophile, cis or trans 2,4-disubstituted piperidines can be obtained (Scheme 35). 
Scheme 35: Asymmetry generation 
 
 (c) Rearrangement reactions: Ring expansion of pyrrolidine derivatives  
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Rearrangement of optically active prolinols under basic conditions undergoes ring expansion 
to piperidine derivatives (Scheme 36). 
Scheme 36: Rearrangement of prolinols and their derivatives to piperidines 
 
 
(d) Ring closing-metathesis (RCM) on dialkyl substituted nitrogen derivatives where each 
alkyl group contains an appropriately positioned alkene functional group. 
N-Boc or N-tosyl-protected unsaturated amines undergo RCM to produce the desired 
piperidines in high yield. This methodology is particularly useful in producing piperidines 
from N-allyl and N-butenylamines. The resulting unsaturated piperidines can be 
functionalized to highly substituted piperidines (Scheme 37). 
Scheme 37: Ring closing metathesis for piperidine synthesis 
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Some other examples are: 
 
Although the literature describes plenty of methods to prepare these heterocyclic systems, 
short, direct, multi-substituted and diversity-oriented asymmetric piperidine syntheses are 
scarce. One explanation for this is the lack of practical methods that give access to optically 
pure materials. In pursuit of a general, cheap and scale up friendly method for the synthesis 
of piperidines, we undertook the synthesis of an enantiopure form. 
 
3.1.2 Rationale for enantiopure piperidine synthesis  
Our group developed a novel cascade approach for the stereoselective synthesis of the 
substituted and N-protected piperidine moiety, based on the development of an 
intermolecular double-Michael addition between α,β-unsaturated carbonyl compounds and 
nitroalkenes, facilitated by amines as Lewis bases.
9, 37
 The mechanistic hypothesis to this 
approach is that the amine reacts with nitro-alkene to form intermediate A in equilibrium 
which further reacts with electrophiles to nitro-substituted intermediate. Then, allylic nitro 
products are generated in this process via the β-elimination of the LB (Scheme 38).  
Scheme 38: Intermolecular cross-double-Michael addition by amines via β-
elimination 
 
This phenomenon of formation of A encouraged us to apply this unique site for the 
construction of nitrogen heterocycles (Scheme 38). The reaction of primary amine with 
nitroalkene produces intermediate Aʹ which under reaction with the appropriate Michael 
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acceptor generates adduct Bʹ. Finally, nucleophilic addition to ring closure provided the 
substituted piperidine in one pot (Scheme 39).   
Scheme 39: One pot cascade piperidine synthesis 
 
As proposed, varieties of substituted piperidines were synthesized with excellent yields and 
diastereoselectivities. Although three stereogenic centers were generated in piperidine only 
two C-4 diastereoisomers were obtained with the control of exocyclic chiral center, of which 
the cis isomer of C-3 nitro and C-4 hydroxy groups was the major product. Mechanistic 
investigation suggested that cyclization is rate determining step (RDS), which in turn 
confirmed diastereoselectivity of this reaction is controlled by the chair like transition state. 
Thus, it is possible to control stereochemistry of the piperidine by choosing an appropriate 
chiral amine (Scheme 40).  
Scheme 40: Asymmetric synthesis of substituted piperidine moiety 
 
As expected, the reaction showed excellent yields and diastereoselectivity of the C-4 position 
in dr > 10:1. In addition, modest chirality induction by the C-7 position was observed with dr 
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= 4:1. X-ray analysis of the piperidine crystals revealed that the exocyclic C-7 adopted a 
staggered conformation with respect to the ring. This data suggested that the N1-C7 σ-bond 
rotation was restricted. The N-1 nitrogen lone pair electrons were placed in the axial position 
and the preferred staggered N1-C7 conformation could be achieved when the small group on 
C-7 was placed anti (axial orientation) to the N-1 nitrogen lone pair. Three syn-pentane 
interactions were relieved in this staggered conformation. Complete chirality induction was 
achieved through this control of exocyclic asymmetry. This new one-pot method will open 
the door for the asymmetric synthesis of several natural products that contain a piperidine 
moiety. 
Although, we were successful in the synthesis substituted piperidines, the development of 
enantioselective route through proposed the chirality induction by exocyclic asymmetry as 
well as the cleavage or deprotection of N-substituted chiral moiety still remained a challenge 
to generate enantiopure piperidine. 
 
3.2 Research objectives 
Various substrates from chiral amines will be developed and then plausible deprotection 
pathways for the removal of exocyclic fragment to piperidines would be investigated. After 
the preparation of enantiopure piperidines, HPLC method would be developed to confirm 
enantioselectivity (Scheme 41). 
Scheme 41: Reaction hypothesis for enantiopure piperidine synthesis 
 
 
3.3 Result and Discussion 
3.3.1 Substrate Scope 
Based on our previous reaction methodology, various substrate scopes were developed 
starting with enantiopure amine. As summarized in Figure 8, a large group of substrates 
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were suitable for this chiral transformation, including aromatic and heteroaromatic 
nitroalkenes. Good to excellent diastereoselectivity were observed in all cases with only 
C-4 isomers obtained. Aliphatic nitroalkene did not work under this condition. It could be 
due an electron-donating inductive effect of nitro-alkene. Similar observations were 
obtained when para-methoxy nitroalkene was used. 
Figure 8: Representative substrates 
 
The reaction is extremely slow and a limited yield was produced even after increasing the 
reaction time. p-Chloro-substituted nitroalkene reacted faster and higher yield was obtained. 
Indole and protected indole nitroalkene also seemed to be unreactive under this condition. 
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Aromatic vinyl ketones did not promote the reaction. It could be due an electron-withdrawing 
inductive effect of aromatic group. Neither electron releasing nor electron withdrawing 
groups in the β-position of the Michael acceptor tolerated this optimized reaction condition. 
There could be the plausible stereoelectronic effect during the chair like transition state 
formation (Scheme 42). 
Scheme 42: Unreactive nitroalkenes and Michael acceptor in cascade synthesis 
 
 
3.3.2 N-Deprotection of exocyclic tethered chiral group  
With the successful development of diastereomeric substrate compounds, we set forth to find 
the best method of N-deprotection reaction condition searching through suitable literature 
procedures (Table 7).
38
 While these approaches offer versatile routes for amines, there are 
certain limitations regarding the innate sensitive functionalities due to possible side reactions.  
In addition, we have to choose those reagents which do not change the stereochemistry of the 
product in presence of intact reactive functional groups like -NO2 and -OH. With Raney 
nickel, hydrogenation of -NO2 became more prominent over debenzylation (entry 1). 
Similarly, palladium became a nonspecific catalyst under both basic and acidic condition 
(entry 2). We can, however, argue that acidic conditions gave some desired product. 
Reductive deprotection under the Birch condition gave byproducts as we observed the 
hydrogenation of aromatic systems. Silicon hydride under acidic conditions did not promote 
the reaction (entry 5). Most literature procedures described the deprotection with ceric 
ammonium nitrate (CAN) though it is expensive, but we got an α-hydroxy unprotected 
molecule most of the time. In addition, it produced highly toxic waste during column work. 
DDQ proved to be non-effective reagent to promote asymmetric deprotection. Recently, a 
mild and efficient deprotection using TMSCl and hydrochloric acid was reported. It was 
found that, HCl improved our aimed route on comparing with TMSCl (entry 8, 9). In the 
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pursuit of finding a very acidic organic reagent, TFA in CH2Cl2 stimulated our work. We got 
90% yield with the retention of configuration. It could be the appropriate environmentally 
benign condition because it requires only acid/base extraction, leading to an overall reduction 
of costs. Since angular methyl group is increasingly being used near the nitrogen protecting 
group for amines, this acidic condition could be the rapid and versatile N-deprotection 
strategy to produce free secondary amine which will preserve the stereochemistry of pre-
settled functional groups. Increasing the concentration of TFA decreased the yield of the 
piperidine product because of side reactions as caused by the elimination of tertiary alcohol 
group. 
Table 7: N-deprotection of angular methyl PMB group 
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3.3.3 Substrate scope of representative enantiopure piperidines 
With optimum reaction condition in hand, various enantiopure piperidines were prepared and 
their structures were confirmed by 
1
H-NMR, 
13
C-NMR and HRMS as well as their 
enantioselectivities were determined by chiral HPLC as shown in Figure 9. 
As usual chloro and fluoro substituted piperidines performed excellently for this reaction. To 
our delight the enantioselectivity is >99% in all cases. The electron donating group in 
piperidines like toluene and para methoxy benzene gave good yield. But, in the case of furan 
substituted piperidine the product yield is low whereas thiophene gave decent yield. This low 
yield of furan may be due to secondary rearrangement reaction under strongly acidic 
condition. 
Figure 9: Reaction substrate scope for the formation of enantiopure piperidine 
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3.4  Application of piperidines towards the synthesis of chiral thiourea-
based catalyst 
Remarkable advances have been realized by the use of small privileged organic molecules to 
catalyze asymmetric reactions. This development of organocatalysts in asymmetric reactions 
have attracted much attention in recent years because they are are generally non-toxic, highly 
efficient, selective, environmentally friendly and durable in aerobic and aqueous reaction 
conditions.
39 
Encouraged by the decent yield and enantioselectivity of piperidine, we first moved towards 
the synthesis of catalyst 3.4b. The chiral piperidine under zinc reduction produced amine 
3.4A which upon treatment with 3,5-di-trifluromethyl-pheny thiocyanate resulted in the 
desired molecule 3.4b in over 95% yield (Scheme 43). To run the reaction, we chose 
Michael addition between chalcone and nitroalkane as being one of the most efficient and 
powerful atom-economic carbon-carbon bond forming reactions in organic chemistry. Our 
hypothesis behind the chiral transformation could be the nitroalkane co-ordinated to tertiary 
protonated amine or alcohol group to furnish nucleophilic site while the diamine thiourea by 
the coordination through H-bond provide electrophilic site and the reaction happened in 
linear fashion to produce the chiral product (Scheme 44). In addition, a solvent-free 
condition was found to be a very effective reaction due to the intimacy of the reactants.  
As proposed, high yield (80%) and enatioselectivity (ee 90%) of 3.4d were observed from 
the conjugate reaction between chalcone and nitroalkane in the presence of our catalyst 3.4b. 
Scheme 43: Short synthesis of thiourea based piperidine organocatalyst 
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The design and synthesis of highly stereoselective, readily accessible and tunable catalysts 
are always desirable for asymmetric catalysis. In this direction, we have developed an 
efficient synthesis of piperidine based thiourea organocatalyst 3.4b (Table 8). 
Scheme 44:  Hypothetical proposition of transition state for the control of 
enantioselectivity 
                             
 
Table 8: Reaction of chalcone with nitroalkane under organocatalyst
a
 
 
 
3.5 Conclusion 
We have developed the novel method for the synthesis of enantiopure piperidine. The wide 
substrate scope, excellent yields and enantioselectivity showed it as a unique strategy. We 
have also demonstrated a practical synthesis and application of organocatalyst 3.4b for 
Michael additions of nitromethane to chalcone to produce a product with high to excellent 
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chemical yields and high level of enantioselectivity under solvent-free conditions. This 
represents an alternative, attractive method for asymmetric Michael addition. Further studies 
of the newly developed catalyst in organocatalysis are currently underway.  
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Chapter 4: Unique Reactivity of Triazole gold towards Alkyne 
Activation to Allene and Enone: Chemoselectivity, Acidity and 
Ligand Economy 
4.1 Introduction 
Homogeneous gold catalysis, being unique and versatile as evidenced by immense organic 
transformations and its use in total synthesis, has gained extensive popularity among 
synthetic and pharma-academia community.
40
 Out of the two oxidation states Au(I) and 
Au(III), the former is widely utilized in academic and industrial field due to its exclusive 
characteristics including: ease of preparation, better pre-catalytic stability, strong tuning with 
phosphine ligands (L), solubility, chemo  and stereo selectivity, soft carbophillic nature 
towards the π-activation of C-C multiple bonds, high oxidation potential of Au(I) and Au(III) 
and  good catalytic turnover. It is currently accepted that the Au (I) complexes adopt one of 
the two co-ordination sites in 180 linear geometry (Scheme 45). The actual catalyst in 
alkyne and alkene activation are of type [L-Au]
+
,  generated from stable precursors L-Au-X 
or [L-Au-X]
+
. A
-
, with the open co-ordination site on the opposite side of the ligand (L) for 
substrate binding.
41
 While the ligands (L) are certainly considered critical in gold catalysis, 
more and more attention is being paid to the evaluation of whether the choice of counter 
ligand “X” can be used to adjust the overall catalyst reactivity. 
Scheme 45: The counter ligands and modes of reactivity in Au(I) catalysis 
 
Generally, the triphenyl phosphine compounds can be applied as a ligand in Au (I) catalysis. 
The recent development of N-heterocyclic carbene (NHC) derivatives commonly described 
as excellent -donors have significantly expanded the choice of ligands by improving the 
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catalytic stability through metal-ligand backbonding (Figure 10).
42 
The cationic and carbene 
character of gold catalyst were confirmed separately by Fürstner et al. using alkyl gold 
complex and later by Toste et al. as a carbocation-carbenoid continuum.
43 
Figure 10: Triphenyl phosphine and NHC gold (I) catalysts 
 
Even though there is a high efficiency when using phosphine gold (I) complexes the active 
catalysts are typically prepared by the addition of a silver activator to a gold halide 
precatalyst.  This system has certain limitations: the hygroscopic nature of silver and the 
decreasing stability as well as catalytic activity of gold (I).
44
 As a result, researchers are 
constantly on the quest for excellent catalytic systems to accomplish the active gold (I) 
species. In this regard, we pursued towards the application of triazoles as ligands in Au (I) 
complexes. Since triazole possesses a strong dipole moment with nitrogen -donor and a 
lower LUMO aromatic antibonding orbital for potentially improved metal backbonding, we 
envisioned triazoles as good binding ligands to produce new cationic Au (I) catalysts with 
improved stability and effective reactivity, especially at high temperatures (Figure 11).
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Figure 11: 1,2,3-triazole gold(I) catalysts 
 
Our group systematically developed the new synthetic methods  for the substituted 1,2,3-
triazole coordinated gold(I) complexes.
13, 46-50
 X-ray crystal structures revealed (Figure 12) 
that both neutral and anionic triazoles can coordinate with an Au(I) cation, forming stable 
TA–Au complexes. The preparation of these complexes was very straightforward. Simply 
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treating the NH-triazoles with PPh3AuCl in methanol under basic conditions (K2CO3, 1 equiv) 
at room temperature gave the neutral TA–Au-1 in >90% yield. The “cationic” complex TA–
Au-2 was prepared either from the addition of HOTf to TA–Au-1 or by the reaction between 
PPh3Au–OTf (prepared from PPh3–Au–Cl and AgOTf) and benzotriazole. Both complexes 
were stable and could be further purified by recrystallization to ensure no extra Ag
+
 or acid in 
the catalyst. The crystal structures revealed nearly identical Au–P bond length for both the 
anionic and neutral triazole coordinated Au (I) complexes. The longer Au–N bond in TA–
Au-2 implies that the neutral triazole dissociates more easily to release the coordination site 
for substrate activation. This new class of NH-triazole Au compounds offer improved 
thermal stability and substrate stability as ligands in transition metal coordination.
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Preliminary studies have also shown that triazole-Rh(I) complexes provide much better 
stability while retaining good catalytic reactivity (Scheme 46). In comparison with the more 
expensive NHC ligands, simple triazole compounds possess σ-donor from nitrogen lone pair 
electrons and the π-receptor from highly electron deficient aromatic system.  
Figure 12: X-ray crystal structures of the two different types of 1,2,3 triazole-Au 
complexes 
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Scheme 46: Rh(I) complexes and Pauson-Khand reaction 
 
The first successful example of using triazoles as ligand to produce new cationic Au catalysts 
with improved stability and effective reactivity, especially at higher temperatures was for 
intermolecular hydroamination of unprotected amines with both terminal and internal alkynes 
(Scheme 47).
48
 
Scheme 47: Au(I) complexes and Hydroamination of alkynes 
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Early on, in 2010 Shi et al. reported the application of 1,2,3-triazole bound Au(I) complexes 
as effective precatalysts in promoting chemoselective intramolecular furan-alkyne cyclization, 
which provided (a) clear evidence for the Au(I) cation as a possible catalyst in this 
transformation and (b) a practical alternative solution that allows simple, inexpensive PPh3 as 
an effective ligand (Scheme 48).
49 
Scheme 48:  Au(I) complexes  for Hashmi Phenol Synthesis 
 
In the meantime, the triazole-gold complexes were discovered as precatalyst in promoting 
cascade vinyliodination reaction in propargyl acetate rearrangement in the presence of NXS. 
This transformation is unique mode which furnishes challenging kinetic E-isomers with good 
to excellent selectivity (Scheme 49).
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Scheme 49: Chemoselective alkyne activation to trans α-haloenones 
 
This new class of catalysts exhibited significantly improved thermal stability and substrate 
tolerance. These results opened up a new strategy in tuning gold reactivity through the 
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counter ligand instead of the primary ligand. The TA-Au catalyst has a significantly lower 
cost than other ligands. In comparision, the combination of the PPh3 primary ligand and 
triazole counter ligand can be >1000 times cheaper than the NHC primary ligand. 
 
4.2 Research objectives 
In continuation of extension of application of 1,2,3-triazole, we wanted to study the 
following three aspects of the reaction in order to determine whether TA-Au could promote 
transformations that previously required the expensive NHC primary ligands which 
substantially improve the ligand economy of the overall reaction. 
4.2.1 Propargylic ester rearrangement and sequential hydration to form enones. 
4.2.2 Meyer-Schuster rearrangement of propargylic alcohols to enones. 
4.2.3 Asymmetric synthesis of substituted allenes 
 
4.3 Results and Discussions 
4.3.1 Optimization for Enone synthesis with TA-Au catalyst § 
The gold catalyzed propargylic ester 3,3-rearrangement is a well-studied transformation.
40, 51
 
One application of this process was the synthesis of enones from sequential hydration of the 
allene-acetate intermediates (Scheme 50). Although this direct transformation provided one 
attractive strategy in preparing enones under mild conditions, it suffered from limited 
substrate scope due to the side reactions caused by the gold-promoted allene activation. One 
side reaction was the intramolecular Friedel-Crafts cyclization of allene (path B) giving the 
indene 4.3.3a.
52
 As a result, a simple Au(I) catalyst, such as PPh3Au
+
, gave  poor overall 
yields of the desired enones (5% Ph3PAuCl/AgOTf, <40% yields). To overcome this 
problem, Nolan and co-workers investigated different N-heterocyclic carbene ligands.
53
 
 
 
 
 
                                                   
§ Reproduced in parts with permission from Adv. Synth. Catal. 2011, 353, 2584-2588. Copyright 
2011, with permission from Willey-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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Scheme 50: Au(I) catalysis for activation of both alkyne and allene 
 
The more sterically hindered [(I
t
Bu)Au]
+
 complex was revealed as the optimal catalyst for 
the formation of enones with high efficiency (1% loading, up to 98% yields). The 
comprehensive mechanistic investigations, both through experimental and computational 
studies, showed that the SN2' water addition to the gold activated alkyne was the mechanism 
by avoiding the formation of allene (Scheme 51A). Two experimental observations 
supported this mechanism: (i) no enone formation with t-Bu-substituted alkyne 4.3.1b 
(Scheme 51B), and (ii) treating an allene ester 4.3.2a with the NHC-Au catalyst did not give 
enone 4.3.4a (Scheme 51C). 
Scheme 51: Proposed SN2ʹ addition mechanism by Nolan 
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Recently, our group reported the synthesis of E-α-iodoenone from a propargylic ester 3,3-
rearrangement followed by the iodination of the allene ester. Interestingly, while all other [L-
Au]
+
 catalysts (such as [NHC-Au]
+
 and [PPh3-Au]
+
) gave only the thermodynamically stable 
Z-isomers, the application of the TA-Au led to the effective formation of the kinetically 
favored E-isomers. These results suggested that TA-Au was a chemo selective catalyst, 
which could effectively promote alkyne activation without interrupting the inherent reactivity 
of the allene intermediates. Moreover, as shown in Scheme 52A, although the allene ester 
4.3.2a was rather stable even at elevated temperatures, treatment of this compound with a 
catalytic amount of acid could effectively convert the allene to the desired enone with 
excellent yields. Contrastingly, unlike the previously reported NHC-Au complexes (Scheme 
52B), TA-Au could effectively catalyze the hydration of 4.3.2a at either room temperature or 
elevated temperature, giving the desired enone in excellent yields. This was likely caused by 
the equilibrium shown in Scheme 52B, where a catalytic amount of HOTf was released to 
serve as the Bronsted acid in promoting the hydration. We then postulated that TA-Au might 
be an effective catalyst for promoting propargylic ester rearrangement and hydration to give 
enones. Unlike the [(I
t
Bu)Au]
+
 catalyst, TA-Au promoted this reaction through a chemo 
selective rearrangement followed by an effective hydration with the same pre-catalysts, 
which therefore provides an alternative pathway to prepare enones compared with the SN2' 
mechanism by the more expensive [(I
t
Bu)Au]+ catalysts. 
Scheme 52: Triazole-Gold Catalysis and acidic character 
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4.3.2 Substrate Scope of Enone synthesis from the propargylic ester   
As expected, with the triazole gold catalyst, enone 4.3.4 was obtained in excellent yields as 
shown in Figure 13 below. No indene by-products were observed, which highlighted the 
chemoselective nature of the TA-Au catalyst. TfOH was not a suitable catalyst for this 
reaction since the 3,3-rearrangement did not occur with only TfOH. Screening of solvent 
revealed that MeOH was the optimal choice. The reaction worked smoothly at room 
temperature and gave the enone products in excellent yields over 24 hours. Raising the 
temperature decreased the reaction time to 3-6 hours. As a result, the enones 4.3.4 were 
obtained with near quantitative yields (>99% NMR yields) at very low catalyst loading 
(0.2%). 
Figure 13: Substrate Scope of propargyl ester hydrolysis 
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As shown in Figure 13, the reaction tolerated variety of substrates, giving the desired enone 
in excellent yields with good double-bond selectivity (dominant trans-isomers). The t-Bu-
substituted alkyne which was not suitable with the NHC-Au catalyst due to the SN2' 
mechanism, proceeded smoothly under these alternative conditions although with slightly 
decreased Z/E selectivity (4.3.4b). The high efficiency makes TA-Au a very attractive and 
practical catalyst for this transformation: at least five times lower catalyst loading values than 
NHC-Au
+
 with much less expensive ligands. 
 
4.3.3 Meyer-Schuster rearrangement with TA-Au catalyst** 
Heating the [(IPr)AuCl]/AgBF4 in wet MeOH at 60C produced a black solution/precipitate 
within 30 min, indicating the rapid decomposition of catalyst. TA-Au on the other hand, 
showed much improved stability, with no decomposition after more than 6 hr under the same 
conditions. Considering the good thermal stability of TA-Au, we wondered whether this 
catalyst could also be used to promote the challenging Meyer-Schuster rearrangement of 
propargylic alcohols 4.3.5 at a high temperature. Impressively, the desired enone products 
were formed with excellent yields (Figure 14). The reaction tolerated a large group of 
substrates. Surprisingly, the bulky t-butyl substituted alkyne 4.3.5b was also suitable for this 
reaction, which suggested the effective water addition to the sterically hindered alkyne at a 
higher temperature. The terminal alkyne gave enals in modest yields which were likely 
produced by the longer reaction time required for the unfavored anti-Markovnikov addition. 
Continuous addition of catalysts could improve the overall yields. 
 
 
 
 
 
 
                                                   
** Reproduced in parts with permission from Adv. Synth. Catal. 2011, 353, 2584-2588. Copyright 
2011, with permission from Willey-VCH Verlag GmbH & Co. KGaA, Weinheim 
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Figure 14: Substrate Scope of TA-Au catalyzed Meyer-Schuster rearrangement of 
propargyl alcohol 
 
Nevertheless, the feasibility of this challenging substrate highlighted the strength of the TA-
Au catalyst over the [NHC-Au]
+
 catalysts (Table 9) by tolerating the much harsher 
conditions. 
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Table 9: Comparision with the best results obtained in the literature 
 
                                             
 
 
4.3.4 Asymmetric Synthesis of Substituted allenes †† ‡‡ 
In homogeneous gold catalysis, both experimental and theoretical investigations confirmed 
the reversibility between allene and propargyl ester (Scheme 53) led to the considerable 
challenge of achieving chemoselective activation of alkyne over allene.
 51, 54 
Scheme 53: Challenge in homogeneous gold catalysis for selective acitvation 
 
According to the literature, the current strategy was the introduction of proper reaction 
partners to trap the Au activated allene intermediates. The indene synthesis reported by 
                                                   
†† Reproduced in parts with permission from Org. Lett. 2011, 13, 2618-2621. Copyright 2011, 
with permission from American Chemical Society. 
‡‡
 This work was highlighted in Organic Chemistry Portal by Douglass F Taber. 
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Nolan and co-workers along with the cyclopropanyl propargyl ester rearrangement reported 
by Toste and co-workers are two examples that highlight the power of this transformation in 
complex molecule synthesis (Scheme 54).
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Scheme 54: Trapping the Allene by Proper Synthetic Partners 
 
 
However, the lack of chemoselectivity by cationic Au catalysts generated significant 
limitations for this transformation: (a) the Au catalyzed 3,3-rearrangement was not 
considered as a practical approach for allene synthesis due to the good reactivity of the Au 
activated allene toward many other groups (even a simple benzene ring, Scheme 54A); (b) 
the rapid equilibrium between alkyne and allene under the reaction conditions caused poor 
stereoselectivity due to the rapid racemization on the propargyl stereogenic center (Scheme 
54B; complete racemization at the propargyl position occurred in 2 min). Therefore, effective 
new catalytic systems that can achieve selective alkyne activation over allene are highly 
desirable.  
With the interest of 1,2,3-triazole-Au (TA-Au) complexes in finding new reaction modes and 
strategies, recently our group found that the TA-Au catalyzed synthesis of kinetically favored 
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E-α-haloenones did not interrupt the allene reactivity.50 Encouraged by this result, we 
decided to investigate whether the triazole-Au complexes could be applied as effective 
chemoselective catalysts for propargyl ester 3,3-rearrangement. The reactions of 4.3.1a were 
set up with TA-Au as the catalysts. The results are shown in Scheme 55. 
Scheme 55: Proposed SN2ʹ Addition Mechanism by Nolan 
 
 
As shown in Figure 12, both 4.1b and 4.1bʹ catalysts demonstrated good reactivity toward 
alkyne activation, promoting the 3,3-rearrangement with high efficiency (1% loading). 
Impressively, excellent chemoselectivity was achieved, where no further reaction to enone 
proceeded, giving the desired allene product in excellent yields. This simple modification of 
catalysts (4.1b') provided one effective strategy in the preparation of functional allenes. 
Encouraged by good chemoselectivity, we then wondered whether TA-Au could be used as 
an effective catalyst for the chiral transformation of propargyl alcohol/acetate by overcoming 
the rapid racemization associated with other reported cationic Au catalysts. The example 
shown in Scheme 54B highlighted the challenges for this proposed chirality transfer: rapid 
epimerization on the propargyl position (2 min) due to the Au activation of allene caused a 
loss of stereochemistry at the propargyl position. To investigate the chirality transfer, 
enantiomeric enriched 4.3.1a was first used to react with TA-Au 4.1b' (Scheme 56). 
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Scheme 56: Proposed SN2' Addition Mechanism by Nolan 
 
Unfortunately, allene 4.3.2a was obtained as racemic mixtures (0% ee) even with TA-Au as 
the catalyst at low temperature (-40C). However, a closer look of this reaction revealed a 
rather surprising observation: no epimerization of propargyl ester occurred during the 
reaction, which strongly suggested the lack of equilibrium between allene 4.3.2a and 
propargyl ester 4.3.1a while TA-Au catalysts were used. The loss of allene 4.3.2a 
stereochemistry was likely caused by the low energy barrier for the allene racemization 
process (no enantiomeric enriched allene acetates have ever been reported). This hypothesis 
was supported by the DFT computational studies, where the relative low energy barrier (5 
kcal/mol) was revealed between the two resonance structures of allene acetate. 
Later, we proposed that if the resulting allenes have a high epimerization barrier, asymmetric 
synthesis of allenes could be achieved. To verify this hypothesis, propargyl-vinyl-ether 4.5a 
was prepared. As expected, excellent chirality transfer was obtained with propargyl vinyl 
ether 4.5a while TA-Au was used (1% catalyst, Scheme 57). It has been reported that gold-
oxo complex [(Ph3PAu)3-O]BF4 4c could also promote this reaction with good to modest 
yields and good chirality transfer.
55f
 However, this complex was not a chemoselective 
catalyst.  
As demonstrated in Scheme 57, treating the allene 4.9a with the gold-oxo catalyst 4c resulted 
in significant racemization of the allenes over time. Overall, the gold-oxo complexes were 
the precatalysts, which could slowly release the L-Au
+
 and adopted catalysis. This lack of 
chemoselectivity with gold-oxo catalysts was further demonstrated by the synthesis of 
dihydropyran 4.7 from intramolecular trapping of gold activated allenes (Scheme 57A).
16
 
Despite providing very attractive new synthetic methods, this reaction highlighted the strong 
desire for a “true” chemoselective gold catalyst. The TA-Au catalyst not only could 
effectively promote this transformation with excellent chirality transfer but also successfully 
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avoid the undesired racemization of allene 4.9a over a long period of time (12 h, Scheme 
57B). These results suggested TA-Au as the first successful chemoselective catalyst, for 
selectively activating alkyne over allenes and promote chiral transformation. 
Scheme 57: Screening of gold catalysts to propargyl ethers and test of racemization 
 
 
To explore the reaction substrate scope, various chiral/achiral propargyl vinyl ethers were 
prepared (Scheme 58). The results are summarized in Figure 15. The TA-Au was an 
effective catalyst for a large scope of substrates. Both terminal and internal alkynes were 
suitable for this transformation, giving the allene products in good to excellent yields. 
Effective chirality transfers were observed in terminal alkynes and alkyl substituted internal 
alkynes.  
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Scheme 58: Synthesis protocol of Chiral and Achiral propargyl vinyl ethers 
 
 
 
 
 
 
 
The excellent diastereoselectivity obtained in 4.10b suggested a chair like transition state in 
this rearrangement.
55
 Racemic allenes were obtained with phenyl substituted internal alkynes, 
which implied possible higher reactivity or a different mechanism
56
 for these substrates. 
Nevertheless, the high efficiency and good stereoselectivity made this strategy as one of a 
practical approach for the asymmetric synthesis of chiral allenes. These results opened the 
possibility for the development of new reactions that could take advantage of the good 
reactivity of a gold cation towards alkyne activation without suffering the undesired 
sequential allene activation by the same catalyst. 
 
 
 
71 
 
Figure 15: Reaction Substrate Scope of Chiral allenes 
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4.4 Conclusion 
In conclusion, the application of 1,2,3-tri-azole coordinated PPh3-Au (TA-Au)  as an 
effective catalyst in promoting the propargylic ester rearrangement and sequential hydration 
to form the enone with high efficiency, mild reaction conditions with unique reactivity 
(combining the chemoselectivity and acidity), and improved ligand-economy. In addition, 
with the significantly improved thermal stability, TA-Au was further applied as the effective 
catalyst in promoting the propargylic alcohol Meyer–Schuster rearrangement to give the 
enones which highlighted the strength of this complex compared with other conventional Au 
(I) catalysts. Moreover, with the view of extension of application this catalyst was applied as 
chemoselective and asymmetric catalyst for propargyl ether rearrangements to chiral allenes. 
These aforementioned applications of triazole gold not only provided an efficient strategy for 
the synthesis of challenging enantio-enriched allenes, but also confirmed as a new class of 
mild catalyst in promoting alkyne activation with different reactivity than other Au catalysts, 
which could likely benefit the world in the discovery of new efficient organic 
transformations. 
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APPENDIX: EXPERIMENTAL SECTION 
Appendix 1 
A1.1: General Methods and materials 
 
All of the reactions dealing with air and/or moisture-sensitive reactions were carried out 
under an atmosphere of nitrogen using oven/flame-dried glassware and standard 
syringe/septa techniques. Unless otherwise noted, all commercial reagents and solvents 
were obtained from the commercial provider and used without further purification. 
1
H-
NMR and 
13
C-NMR spectra were recorded on Varian 600 MHz spectrometers. Chemical 
shifts were reported relative to internal tetramethylsilane (δ 0.00 ppm) or CDCl3 (δ 7.26 
ppm) for 
1
H and CDCl3 (δ 77.0 ppm) for 
13
C. Flash column chromatography was 
performed on 230-430 mesh silica gels. Analytical thin layer chromatography was 
performed with precoated glass baked plates (250μ) and visualized by fluorescence and 
by charring after treatment with potassium permanganate stain. Rf  values were obtained 
by elution in the stated solvent ratios. Optical rotations were measured on a commercial 
automatic polarimeter and reported as follows: [α]TD (c = mg/mL, solvent). Melting 
points were measured on a Mel-Temp 1001D apparatus and uncorrected. HRMS were 
recorded on LTQ-FTUHRA spectrometer. Anhydrous hexane, tetrahydrofuran (THF), 
toulene, EtOAc, Acetonitrile and methanol were purchased from Acros and distilled with 
sodium, immediately before use. Anhydrous dichlomethane (CH2Cl2) was distilled with 
CaH2. High Pressure Liquid chromatography (HPLC) was performed on a SHIMADZU 
SPD-M20A (LC-20AB) chromatographs using a chiral column (50 cm) and guard 
column (5 cm) as noted for each compound. Enantiomeric excess was determined by 
HPLC analysis, described below in detail. The configuration of products was determined 
by comparison of rotation sign with the literature data or by analogue. 
 
The nitroalkene starting materials were prepared according to the following reported 
procedures: a) Ohta, H.; Kobayashi, N.; Ozaki, K. J. Org. Chem. 1989, 54, 1802-1804. b)  
Lucet, D.; Sabelle, S.; Kostelitz, O.; Gall, T. L.; Mioskowski, C. Eur. J. Org. Chem. 1999, 
2583-2591. c) Jang, Y. J.; Lin, W. W.; Shih, Y. K.; Liu, J. T.; Hwang, M. H.; Yao, C. F. 
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Tetrahedron, 2003, 59, 4979–4992. Substrates 4.3.1 and 4.3.5 were synthesized 
according to the literature as below: (Propargyl acetate and alcohol): a) M. Yu, G. Zhang, 
L. Zhang Org. Lett. 2007, 9, 2147-2150. b) N. Marion, P. Carlqvist, R. Gealageas, P. 
Fremont, F. Maseras, S. P. Nolan, Chem. Eur. J. 2007, 13, 6437-6451. c) Nonoshita, K.; 
Banno, H.; Maruoka, K.; Yamamoto, H. J. Am. Chem. Soc. 1990, 112, 316-322. d) 
Sherry, B. D.; Toste, F. D. J. Am. Chem. Soc. 2004, 126, 15978-15979. e) Sherry, B. D.; 
Maus, L.; Laforteza, B. N.; Toste, F. D. J. Am. Chem. Soc. 2006, 128, 8132-8133. f) 
Mauleon, P.; Krinsky, J. L.; Toste, F. D. J. Am. Chem. Soc. 2009, 131, 4513-4520. 
 
A1.2: General Experimental Procedures 
A1.2.1: General Procedure for preparation of homo-isoxazoline-N-oxide (1.4.3) 
 
The nitroalkene 1.2.1a' (1.1 mmol, 1.1 eq.) was added to aldehyde 1.2.4b' (0.5 mmol, 0.5 
eq.), in DMSO solution followed by L-proline (25 mg, 0.22 mmol, 0.2 eq.), and K2CO3 
(35 mg, 0.25 mmol, 0.5 eq.), with a concentration of 0.1 M for aldehyde. The resulting 
reaction mixture was stirred at room temperature and monitored by TLC. Then, the 
mixture was diluted with EtOAc (100 mL). The organic phase was washed by HCl 
solution (1.0 M), saturated NaHCO3 (aq.) and brine and then dried over anhydrous 
Na2SO4. The solvent was removed under reduced pressure to give a residue. Flash 
column was then applied to give the product 1.4.3. 
 
A1.2.2: General Procedure for preparation of isoxazoline-N-oxide) 
A1.2.2.1: Racemic N-oxide preparation 1.4.4.3 
 
The nitroalkene 1.2.1a' (0.6 mmol, 1.2 eq.) was added to a solution of the corresponding 
sulfur ylide 1.4.4.2f (0.55 mmol, 1.1 eq.)  in DMSO (0.2 M for nitroalkene) solution, till 
the ylide is all dissolved. L-Proline (12 mg, 0.1 mmol, 0.2 eq.) and K2CO3 (35 mg, 0.25 
mmol, 0.5 eq.) were then added in and stir for 5 minutes. The aldehyde 1.2.4b' (0.5 mmol, 
1.0 eq.) in DMSO solution (0.2 M) was added drop wise and stirred at RT until TLC 
showed all consumed, the mixture was diluted with EtOAc (100 mL). The organic phase 
was washed by HCl solution (1.0 M), saturated NaHCO3 (aq.) and brine and then dried 
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under anhydrous Na2SO4. The solvent was removed under reduced pressure to give a 
residue. Flash silica gel chromatography was then applied to give the product 1.4.4.3. 
 
A1.2.2.2: Optical sample preparation 1.4.5 
 
The nitroalkene 1.2.1a' (0.7 mmol, 1.4 eq.) was added to a solution of the sulfur ylide 
aux-d (0.6 mmol, 1.2 eq.) MeOH solution (0.4 M for nitroalkene), till the ylide is all 
dissolved. The mixture was cooled down to -25°C. Pyrrolidine (7 mg, 0.1 mmol, 0.2 eq.) 
and K2CO3 (35 mg, 0.25 mmol, 0.5 eq.) were then added in and stir for 30 minutes. The 
aldehyde (0.5 mmol, 1.0 eq.) MeOH solution (0.4 M) was added drop wise. The resulting 
reaction mixture was stirred at -25°C for 2 days and monitored by TLC. EtOAc 
extraction followed by drying over anhydrous Na2SO4. The solvent was removed under 
reduced pressure to give a residue. Flash silica gel chromatography furnished the product, 
which were then examined for e.e values. 
 
A1.2.2.3:  Procedure for Synthesis of 1.5c 
 
The isozaxoline-N-oxide 1.4.5a (323 mg, 1.0 mmol, 1.0 equiv.) was dissolved in MeOH 
(20 ml) at -15°C and keep stirring for 10 min. Zn dust (975 mg, 15 mmol, 15 equiv., 
activated) was and 5M HCl in MeOH (5 ml, 25 mmol, 25 equiv.) added and stirred for 6 
hrs. Et3N (2500 mg, 25 mmol, 25 equiv.) was then added and stirred to another 5 hours. 
Extraction, work-up and vacuum furnished a residue. Flash silica gel chromatography 
was then applied to give the product lactam 1.5a as white solid 160 mg, in 57% yield. 
Then, 1.5a (160 mg, 0.57 mmol, 1.0 equiv.) in acetone at 0°C added t-BuONa (55 mg, 
0.57 mmol, 1.0 equiv.) and MeI (81 mg, 0.58 mmol, 1.0 equiv.) The reaction was 
monitored by TLC and quenched by adding H2O. Carefully vacuumed out acetone and 
dilute the mixture with EtOAc 20 ml for extraction. The water phase was extracted with 
EtOAc (20 mL x 3). Acid-base work up and vacuum gave the crude product which then 
dissolved in THF and H2O (1:1) solution (10 ml in total). At room temperature, NaIO4 
(487 mg, 2.28 mmol, 4.0 equiv.) and OsO4 (8 mg, 0.029 mmol, 0.05 equiv.) was added in 
the reaction mixture. Monitored by TLC, the reaction was quenched by Na2S2O3 
saturated solution after 4 hours. Brine addition, extraction with EtOAc (20 mL x 3), dry 
83 
 
out over anhydrous Na2SO4 and solvent evaporation under reduced pressure to give a 
residue. Flash silica gel chromatography gave 79% (132 mg) of the product 1.5b as white 
solid. To ketone 1.5b (132 mg, 0.45 mmol, 1.0 equiv.) in 5 ml of MeOH/DCM (1:1) at 
0°C added NaBH4 (20 mg, 0.52 mmol, 1.1 equiv.). Five hours later, TLC indicated the 
ketone 9d all consumed, warmed up and added EtOAc (50 ml) then 50 ml of brine. 
Complete work up gives a residue. Flash silica gel chromatography was then applied to 
give 1.5c (132 mg, >98% yield) as white crystals. 
 
A1.2.3: Representative procedure of stereoselective synthesis of N-
heterocycles 
A1.2.3.1: Experimental Procedure for Aza-Michael addition 
 
 
To a well-stirred solution of aminoester salt 2.1a (300 mg, 1.57 mmol, 1 equiv.) in dry 
acetonitrile were added nitro-alkene 2.2a (306 mg, 2 mmol, 1.3 equiv.) pre-cooled to 0C 
and kept stirring until the solution became clear. Then, appropriate amount of DIPEA 
(1.15 ml, 6.28 mmol, 4 equiv.) was added slowly over 5 minute time period. Stirring was 
maintained for 5 hr, meanwhile rose temperature from 0C to RT until complete 
consumption of 2.1a.  Then, let the reaction mixture and residue passed through the pad 
of cotton plug, sand and silica gel and washed with EtOAc, concentrated under vacuum. 
Column chromatography (Hexane/EtOAc, 15:1 to 5:1) of the crude product over SiO2 
afforded pure 430 mg aza-Michael adducts 2.3aa/2.3aa' as solid (91%). 
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A1.2.3.2: Representative procedure for the synthesis of -lactam 
 
 
A diastereomeric mixture of bicyclic nitroester 2.3aa/2.3aa' (500 mg, 1.64 mmol, 1 
equiv.) and iron powder (921 mg, 16.4 mmol, 10 equiv.) in acetic acid (5 mL) was heated 
to 90 C and stirred for 12 hr. After complete consumption of 2.3aa/2.3aa', celite 
filtration was performed to filter off the solid impurities, followed by washing with THF. 
A residue was obtained after the removal of solvent under vacuum. Then, silica gel flash 
column chromatography was employed (CH2Cl2/MeOH = 20:1, v/v) to afford single -
lactam 5aa as solid (320 mg, 80% based on the amount of 2.3aa/2.3aa' mixture, Rf = 0.30, 
CH2Cl2/MeOH = 9:1). 
 
A1.2.3.3: Typical Procedure for Asymmetric Synthesis of N-Heterocycles 
 
 
The compounds 2.8 and 2.9a were prepared according to the procedures described as 
above (Yield of 2.8 = 74%; Yield of 2.9a = 71%). A solution of -lactam 2.9a (200 mg, 
0.7 mmol, 1.0 equiv.) in tetrahydrofuran (10 mL) was cooled to 0 °C under nitrogen 
atmosphere. Lithium aluminum hydride powder (150 mg, 3.7 mmol, 5.3 equiv.) was 
added slowly while continuously stirring. Contents of the reaction flask were first 
warmed to RT for 1 hr then heated to 65 °C for 24 hr. Then, the reaction was cooled to 
0 °C and quenched by drop wise addition of 2 N sodium hydroxide (3 mL), and water (1 
mL). Content of the reaction flask was warmed to room temperature, filtered by filter 
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paper, and the filtrate dried with anhydrous magnesium sulfate. After removal of the 
magnesium sulfate, concentration was taken under reduced pressure and flash column 
chromatography (CH2Cl2/MeOH = 9:1, v/v) afforded the diamine 2.9b as colorless oil, 
130 mg (68% yield).  
To a flame-dried flask was added N, N’-dicyclohexylcarbodiimide, 57 mg (0.30 mmol, 
1.1 equiv.) in equimolar solution of tetrahedron furan and dichloromethane (5.0 ml, v/v = 
1/1). Diamine 2.9b (70 mg, 0.27 mmol, 1.0 equiv.) was added in one portion at room 
temperature. Then, Chiral (R)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetic acid (64 
mg, 0.27 mmol, 1.0 equiv.) was added in one portion. It caused immediate turbidity. The 
reaction was stirred at room temperature for 24 hr. The reaction mixture was then diluted 
with 15 ml CH2Cl2 and washed with 20 ml 1.0 M HCl, 20 ml saturated aqueous sodium 
bicarbonate and 20 ml of brine. The CH2Cl2 layer was dried over anhydrous magnesium 
sulfate, filtered through a fine sintered glass funnel, and the solvent was removed under 
vacuum. The crude product was redissolved in hexanes and filtered again to remove 
dicyclohexylurea. The hexanes were removed under vacuum to afford chiral amide 2.9c 
(105 mg, 0.22 mmol, 80% yield) of a glassy solid. NMR and Mass analysis was 
performed on the pure product 2.9c after column chromatography (CH2Cl2/ MeOH =15:1, 
v/v). 
 
A1.2.4: Experimental procedures for enantioselective synthesis of 
piperidine 
A1.2.4.1: Procedure for Synthesis of Substituted Racemic and Chiral N-protected 
piperidine 
 
Chiral Synthesis: 
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Racemic Synthesis: 
 
 
To a solution of nitroalkene 3.1 (149 mg, 1 mmol, 1 eq.) in dry THF (5 mL), was added 
successively Chiral 4-methoxy-phenylethanamine  (158 mg, 1.5 mmol, 1.5 eq.) and MVK 
(140 mg, 2.0 mmol, 2.0 eq.) under N2 atmosphere. The mixture was stirred at room 
temperature for 36 hr and monitored by TLC. After removing the solvent, the residue was 
purified by flash silica gel chromatography (Hexane-EtOAc v/v 8:1) gave a major 
diastereomeric piperidine (266 mg, 0.97 mmol, yield: 71%) as white solids. Racemic 
sample 3.2a' was also prepared using racemic amine following same procedure.  
 
A1.2.4.2: Experiment for N-deprotection to piperidine (both chiral and racemic) 
 
TFA was added drop wise to a stirred solution of the substrate 3.2a (266 mg, 0.97 mmol) 
in minimum amount of DCM and stirred at room temperature 24hr (TFA:DCM, 1:1). 
After concentration in rotary evaporator, the residue was partitioned between saturated 
aquous sodium bicarbonate solution (8ml) and Dichloromethane (8ml). 
 
The separted aqueous phase was extracted with Dichloromethane (3 ×8ml), and the 
combined organic extracts dried over sodium or magnesium sulfate for 2hr then filtered 
through the cotton plug. Finally, the dilute solution is concentrated in rotavapor and the 
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residue was purified by column chromatography using solvent system (Dichloromethane: 
Methanol; 200:1 to 50:1) to afford racemic piperidine 3.3a for % ee measurement. Using 
the same mentioned procedure 3.3a' was prepared from 3.2a'. 
 
A1.2.4.3: Representative Procedure for the synthesis of thioureabased piperidine 
 
To a solution of 3.3a (major) (800 mg, 2.16 mmol, 1eq) added 1N HCl in MeOH (25 
mL, >10 eq.) and Zn powder (2.10 gm, 7.5 mmol, 15 eq.) were added at .The mixture 
was then stirred at room temperature and monitored by TLC. After the complete 
consumption of 3.3a, MeOH was completely evaporated followed by treatment with 
NaHCO3 (aq) was added until pH > 10, and CH2Cl2.  Organic layer was extracted with 
CH2Cl2 (30 mL x 5). The combined organic layer was washed with brine and then dried 
over anhydrous Na2SO4. After filtration and evaporation, the residue was dissolved in 
minimum CH2Cl2 (25 mL) and purified by flash silica gel chromatography (CH2Cl2-
MeOH v/v 100:1) gave almost quantitative amount of 3.4a (700 mg, 2.0 mmol, yield: 
95%). 
To a solution of amine 3.4a (700mg, 2.0mmol) in 25ml dichloromethane added 3,5 di-
trifluoromethyl-phenyl isothiocyanate (557mg, 2.0mmol, 1 eq.) and stirred it overnight. 
After, TLC showed the disappearance of 3.4a, the solution was evaporated and the 
residue was chromatographed in solvent system (EtoAc: Hexane, v/v 5:1 to 1:1) to afford 
white solid 3.4b (1.092 mg, 1.78 mmol, yield: 86%). 
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A1.2.4.4: Procedure for Racemic product 3.4d synthesis 
 
 
To a 50 mL Pyrex flask, chalcone (500mg, 2.4mmol, 1eq.) in CH3NO2:CH2CL2 
(6ml:14ml, excess), was added followed by DBU (365mg/0.36ml, 2.4mmol, 1eq.). The 
mixture was stirred at the temperature -30°C for the period of 1.5hr. TLC monitored until 
chalcone was disappeared indicated by TLC. After warming upto RT, the mixture was 
quenched with water to neutral, dried, and evaporated to form a residue.  After 
purification by flash chromatography on silica gel using 15% ethyl acetate in petroleum 
ether, the Michael adduct was obtained. The authenticity of the products was established 
by comparison of NMR and melting points with literature value. 
 
A1.2.4.5: Asymmetric Michael addition of nitromethane to chalcone for Chiral 3.4d  
 
 
To a solution of chalcones 3.4c (1 mmol, 1.0 equiv) and nitromethane (915mg/0.80ml, 15 
mmol, 15.0 equiv) added thiourea-catalyst 3.4b (122mg, 0.2 mmol, 20 mol%). The 
reaction mixture was stirred in capped vial for 240 h at 50°C. Then the volatiles was 
removed by concentration and the residue purified by silica gel flash column 
chromatography (ethyl acetate-petroleum ether 1:15 V/V) to afford the product 3.4d as 
white solid (63.1 mg, 94% yield). Enantiomeric excess was determined by HPLC on 
Chiralpak AS-H column (n-hexane-isopropanol 90:10 V/V, flow rate 1.0 mL/min, 220 
nm), major enantiomer tr = 10.3 min, minor enantiomer tr = 13.6 min, >90% ee. 
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A1.2.5: Representative procedures for Triazole-Gold(I) Catalysis 
A1.2.5.1: Representative procedure for α,ß-unsatured ketone 4.3.4a from 4.3.1 
 
 
 
To a solution of 4.3.1a (288 mg, 1.25 mmol) in wet MeOH (5 mL, 0.25 M, MeOH:H2O = 
100:1), was added Au(I) catalyst (1.8 mg, 0.0025 mol, 0.2 mol%) at 60°C. The reaction 
mixture was stirred at 60°C and monitored by TLC. After the reaction was completed 
(4h), the solvent was removed under reduced pressure and the residue was purified by 
flash chromatography on silica gel (ethyl acetate/hexane = 1:20, V/V) to give 4.3.4a (92% 
yield) as colorless oil. 
 
A1.2.5.2: Representative procedure for α,ß-unsatured ketone 4.3.4a from 4.3.5 
 
To a solution of 4.3.5 (94 mg, 0.5 mmol) in wet MeOH (2.5 mL, MeOH: H2O = 100:1), 
was added Au(I) catalyst (1.8 mg, 0.0025 mol, 0.5 mol%) at 60°C. The reaction mixture 
was stirred at 60°C and monitored by TLC. After the reaction was completed (3 h), the 
solvent was removed under reduced pressure and the residue was purified by flash 
chromatography on silica gel (ethyl acetate/hexane = 1:20, V/V) to give 4.3.4a (89% 
yield) as colorless oil. 
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A1.2.5.3: Representative procedure for the preparation of Allene 4.3.2a from 4.3.1a 
 
 
To a solution of 4.3.1a (58 mg, 0.25 mmol) in dry CH2Cl2 (2.5 mL, 0.1 M), was added 
Au(I) catalyst (1.9 mg, 0.0025 mol, 1.0 mol%) at RT. The reaction mixture was stirred at 
RT and monitored by TLC. After the reaction was completed (2-10 h), the solvent was 
removed under reduced pressure and the residue was purified by flash chromatography 
on silica gel (ethyl acetate/hexane = 20:1, V/V) to give 4.3.2a (91% yield) as colorless oil. 
 
A1.2.5.4: Representative procedure for the preparation of Chiral Allene 4.8a from 
4.5a 
 
 
To a solution of 4.5a (54 mg, 0.25 mmol) in dry CH2Cl2 (2.5 mL, 0.1 M), was added 
Au(I) catalyst (1.9 mg, 0.0025 mol, 1.0 mol%) at RT. The reaction mixture was stirred at 
RT and monitored by TLC. After the reaction was completed (0.5-10 h), NaBH4 (10 mg, 
0.25 mmol) was added to the reaction at RT. Then MeOH (1 mL) was added to dilute the 
mixture. The reaction mixture was stirred at RT and monitored by TLC (10 min). Then 
the solvent was removed under reduced pressure and the residue was purified by flash 
chromatography on silica gel (ethyl acetate/hexane = 5:1, V/V) to give 4.8a (93% yield) 
as colorless oil. 
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Appendix 2: Compound Characterization (
1
H-NMR, 
13
C-NMR, HRMS) 
A2.1: Stereoselective N-heterocycles synthesis 
 
 
Methyl 2-((1R, 2S, 3R, 7aS)-2-nitro-3-phenylhexahydro-1H-pyrrolizin-1-yl) acetate 
(2.3aa) was purified by flash chromatography (Hexane/EtOAc = 7:1, v/v) as light yellow 
liquid. Reaction time 3 hr; Isolated yield 91%, dr = 9:1; 
1
H-NMR (600 MHz, CDCl3) δ 
7.37-7.25 (m, 5H), 5.47-5.44 (dd, J = 9.07 Hz, 6.59 Hz, 1H), 4.73 (d, J = 6.89 Hz, 1H), 
3.68 (s, 3H), 3.40-3.37 (m, 1H), 2.83-2.78 (m, 1H), 2.59-2.53 (m, 1H), 2.50 (d, J = 7.6 
Hz, 1H), 2.48-2.44 (m, 1H), 2.41-2.38 (m, 1H), 2.08-2.02 (m, 1H), 1.99-1.88 (m, 2H), 
1.62-1.56 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 171.98, 136.91, 129.06, 128.62, 
127.93, 94.38, 70.62, 69.75, 52.20, 47.49, 43.90, 32.71, 28.88, 26.35; HRMS Calculated 
for C16H20N2O4 [M+H]
+
: 305.1457, Found: 305.1495. 
 
Methyl 2-((1R, 2S, 3R, 7aS)-3-(4-methoxyphenyl)-2-nitrohexahydro-1H-pyrrolizin-
1-yl) acetate (2.3ab) was purified by flash chromatography (Hexane/EtOAc = 5:1, v/v) 
as yellow liquid. Reaction time 4 hr; Isolated yield 79%, dr = 3:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.28 (d, J = 8.64 Hz, 2H), 6.87 (d, J = 8.64 Hz, 2H), 4.67 (t, J = 8.05 Hz, 1H), 
4.20 (d, J = 5.85 Hz, 1H), 3.79 (s, 3H), 3.67 (s, 3H), 3.44-3.40 (m, 1H), 2.97-2.94 (m, 
1H), 2.85-2.81 (m, 1H), 2.69-2.65 (m, 1H), 2.59-2.53 (m, 2H), 2.09-2.01 (m, 2H), 1.85-
1.80 (m, 2H); 
13
C-NMR (150 MHz, CDCl3) δ 176.68, 159.74, 129.55, 114.45, 77.55, 
60.61, 51.88, 42.66, 37.96, 31.59, 24.88, 21.19, 14.14; HRMS Calculated for C17H22N2O5 
[M+H]
+
: 335.1562, Found: 335.1601. 
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Methyl 2-((1R, 2S, 3R, 7aS)-3-(4-chlorophenyl)-2-nitrohexahydro-1H-pyrrolizin-1-yl) 
acetate (2.3ac) was purified by flash chromatography (Hexane/EtOAc = 7:1, v/v) as 
yellow liquid. Reaction time 2.5 hr; Isolated yield 94%, dr = 7:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.37-7.28 (m, 4H), 4.65 (t, J = 10.39 Hz, 1H), 4.25 (d, J = 9.66 Hz, 1H), 3.66 (s, 
3H), 3.46-3.41 (m, 1H), 2.98-2.93 (m, 1H), 2.87-2.82 (m, 1H), 2.66-2.61 (m, 2H), 2.56-
2.53 (m, 1H), 2.10-1.99 (m, 2H), 1.86-1.78 (m, 2H); 
13
C-NMR (150 MHz, CDCl3) δ 
171.36, 138.06, 134.43, 129.15, 128.71, 96.74, 72.36, 68.46, 53.40, 52.10, 46.83, 36.19, 
32.52, 25.77; HRMS Calculated for C16H19ClN2O4 [M+H]
+
: 340.1004, Found: 339.1106 . 
 
Methyl 2-((1R, 2S, 3S, 7aS)-3-(furan-2-yl)-2-nitrohexahydro-1H-pyrrolizin-1-yl) 
acetate (2.3ad) was purified by flash chromatography (Hexane/EtOAc = 4:1, v/v) as 
yellow liquid. Reaction time 3.5 hr; Isolated yield 87%, dr = 7:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.39 (t, J = 3.6 Hz, 1H), 6.32-6.29 (m, 2H), 4.95 (t, J = 7.06 Hz, 1H), 4.56 (d, J 
= 4.54 Hz, 1H), 3.67 (s, 3H), 3.45-3.42 (m, 1H), 3.26-3.23 (m, 1H), 2.96-2.92 (m, 1H), 
2.69-2.65 (m, 2H), 2.61-2.54 (m, 1H), 2.53-1.49 (m, 1H), 2.10-2.01 (m, 1H), 2.00-1.97 
(m, 1H), 1.88-1.78 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 171.73, 138.02, 134.59, 
129.19, 128.70, 96.81, 72.28, 68.52, 53.42, 52.02, 46.82, 36.24, 32.44, 25.85; HRMS 
Calculated for C14H18N2O5 [M+H]
+
: 295.1249, Found: 295.1288. 
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Methyl 2-((1R, 2S, 3S, 7aS)-2-nitro-3-(thiophen-2-yl) hexahydro-1H-pyrrolizin-1-yl) 
acetate (2.3ae) was purified by flash chromatography (Hexane/EtOAc = 4 : 1, v/v) as 
yellow liquid. Reaction time 3.0 hr; Isolated yield 78%, dr = 9:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.24 (d, J = 5.12 Hz, 1H), 6.93-6.91 (m, 2H), 4.69 (t, J = 9.37 Hz, 1H), 4.57 (d, 
J = 8.78 Hz, 1H), 3.65 (s, 3H), 3.46-3.42 (m, 1H), 2.96-2.91 (m, 2H), 2.79-2.75 (m, 1H), 
2.65-2.61 (m, 1H), 2.58-1.51 (m, 1H), 2.08-2.04 (m, 1H), 2.01-1.97 (m, 1H), 1.86-1.77 
(m, 2H); 
13
C-NMR (150 MHz, CDCl3) δ 171.32, 127.42, 125.66, 125.52, 125.43, 96.73, 
68.65, 68.34, 53.53, 52.07, 46.72, 36.40, 32.48, 25.55; HRMS Calculated for 
C14H18N2O4S [M+H]
+
: 311.1021, Found: 311.1060. 
 
Methyl 2-((5R, 6S, 7S, 8aS)-6-nitro-5-phenyloctahydroindolizin-7-yl) acetate (2.3ba) 
was purified by flash chromatography (Hexane/EtOAc = 6 : 1, v/v) as light yellow liquid. 
Reaction time 4 hr; Isolated yield 88 %, dr = 3:1; 
1
H-NMR (600 MHz, CDCl3) δ 7.40-
7.25 (m, 5H), 5.49 (t, J = 9.51 Hz, 1H), 3.66 (s, 3H), 3.52 (d, J = 8.93 Hz, 1H), 2.68-2.60 
(m, 2H), 2.41-2.38 (m, 1H), 2.29-2.24 (m, 1H), 2.18-2.16 (m, 1H), 1.98-1.91 (m, 2H), 
1.68-1.62 (m, 3H), 1.47-1.44 (m, 1H), 1.29-1.27 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 
171.45, 137.78, 128.90, 128.75, 128.15, 95.06, 71.20, 65.49, 63.40, 52.16, 38.21, 36.99, 
34.48, 30.31, 21.24; HRMS Calculated for C17H22N2O4 [M+H]
+
: 319.1613, Found: 
319.1652. 
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Methyl 2-((5R, 6S, 7S, 8aS)-5-(4-methoxyphenyl)-6-nitrooctahydroindolizin-7-yl) 
acetate (2.3bb) was purified by flash chromatography (Hexane/EtOAc = 4 : 1, v/v) as 
yellow liquid. Reaction time 4 hr; Isolated yield 79 %, dr = 6:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.22 (d, J = 7.96 Hz, 2H), 6.80 (d, J = 7.76 Hz, 2H), 4.45 (t, J = 9.08 Hz, 1H), 
3.46 (d, J = 8.93 Hz, 1H), 3.74 (s, 3H), 3.64 (s, 3H), 2.66-2.59 (m, 2H), 2.39-2.35 (m, 
1H), 2.27-2.23 (m, 2H), 2.15 (d, J = 5.12 Hz,  1H), 2.00-1.80 (m, 2H), 1.68-1.61 (m, 2H), 
1.45-1.44 (m, 1H), 1.26-1.24 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 171.45, 159.91, 
130.11, 129.21, 114.21, 95.13, 70.58, 64.83, 63.42, 55.37, 52.13, 38.21, 37.01, 34.27, 
30.50, 21.20; HRMS Calculated for C18H24N2O5 [M+H]
+
: 349.1719, Found: 349.1757. 
 
Methyl 2-((5R, 6S, 7S, 8aS)-5-(4-chlorophenyl)-6-nitrooctahydroindolizin-7-yl) 
acetate (2.3bc) was purified by flash chromatography (Hexane/EtOAc = 7 : 1, v/v) as 
yellow liquid. Reaction time 2.5 hr; Isolated yield 93 %, dr = 6:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.28-7.23 (m, 4H), 4.42 (t, J = 10.10 Hz, 1H), 3.65 (s, 3H), 3.50 (d, J = 9.37 Hz, 
1H), 2.65-2.58 (m, 2H), 2.39-2.36 (m, 1H), 2.27-2.23 (m, 2H), 2.15 (d, J = 9.37 Hz, 1H), 
1.92-1.88 (m, 2H), 1.69-1.62 (m, 2H), 1.45-1.41 (m, 1H), 1.29-1.23 (m, 1H); 
13
C-NMR 
(150 MHz, CDCl3) δ 171.35, 136.40, 134.60, 129.17, 129.00, 94.93, 70.43, 63.36, 52.11, 
52.04, 38.15, 36.87, 34.27, 30.40, 21.23; HRMS Calculated for C17H21ClN2O4 [M+H]
+
: 
354.1160 , Found: 353.1262. 
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Methyl 2-((5S, 6S, 7S, 8aS)-5-(furan-2-yl)-6-nitrooctahydroindolizin-7-yl) acetate 
(2.3bd) was purified by flash chromatography (Hexane/EtOAc = 4 : 1, v/v) as yellow 
liquid. Reaction time 4 hr; Isolated yield 89 %, dr = 7:1; 
1
H-NMR (600 MHz, CDCl3) δ 
7.40-7.30 (m, 1H), 6.32-6.20 (m, 2H), 4.72 (t, J = 9.95 Hz, 1H), 3.68 (d, J = 9.95 Hz, 1H), 
3.64 (s, 3H), 2.66-2.61 (m, 2H), 2.41-2.38 (m, 1H), 2.29-2.25 (m, 2H), 2.17-2.09 (m, 2H), 
1.92-1.88 (m, 1H), 1.76-1.65 (m, 2H), 1.50-1.47 (m, 1H), 1.27-1.21 (m, 1H); 
13
C-NMR 
(150 MHz, CDCl3) δ 171.30, 149.91, 143.43, 110.32, 110.01, 91.74, 63.96, 63.31, 52.14, 
52.05, 38.01, 37.04, 34.17, 30.09, 21.13; HRMS Calculated for C15H20N2O5 [M+H]
+
: 
309.1406, Found: 309.1444. 
 
Methyl 2-((5S, 6S, 7S, 8aS)-6-nitro-5-(thiophen-2-yl)octahydroindolizin-7-yl) acetate 
(2.3be) was purified by flash chromatography (Hexane/EtOAc = 4 : 1, v/v) as yellow 
liquid. Reaction time 3.0 hr; Isolated yield 84 %, dr = 4:1; 
1
H-NMR (600 MHz, CDCl3) δ 
7.26 (d, J = 4.98 Hz, 1H), 6.85 (t, J =  4.25 Hz, 1H), 6.94-6.88 (br s, 1H), 4.49-4.45 (t, J = 
10.25 Hz, 1H), 3.89 (d, J = 9.22 Hz, 1H), 3.65 (s, 3H), 2.84 (t, J = 8.20 Hz, 1H), 2.66-
2.63 (m, 1H), 2.37 (d, J = 3.37 Hz, 2H), 2.28-2.24 (m, 2H), 2.02-1.99 (m, 2H), 1.73-1.63 
(m, 2H), 1.48-1.45 (m, 1H), 1.27-1.22 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 171.34, 
141.17, 127.04, 126.50, 126.37, 95.98, 66.55, 63.52, 52.36, 52.05, 38.20, 36.47, 34.31, 
30.27, 21.10; HRMS Calculated for C15H20N2O4S [M+H]
+
: 325.1177, Found: 325.1216. 
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Methyl 2-((1R, 2S, 3R, 8aS)-2-nitro-3-phenyloctahydroindolizin-1-yl) acetate (2.3ca) 
was purified by flash chromatography (Hexane/EtOAc = 7 : 1, v/v) as light yellow liquid. 
Reaction time 4 hr; Isolated yield 77 %, dr > 99:1; 
1
H-NMR (600 MHz, CDCl3) δ 7.30-
7.26 (m, 5H), 5.04-5.02 (dd, J = 8.49 Hz, 5.85 Hz, 1H), 3.76 (d, J = 8.64 Hz, 1H), 3.64 (s, 
3H), 3.05 (d, J = 8.64 Hz, 1H), 2.83 (d, J = 10.83 Hz, 1H), 2.66-2.63 (dd, J = 16.54 Hz, 
4.24 Hz, 1H), 2.45-2.41 (dd, J = 16.54 Hz, 9.59 Hz, 1H), 1.93-1.87 (m, 3H), 1.77-1.72 (m, 
1H), 1.61-1.46 (m, 3H), 1.29-1.21 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 171.99, 
135.19, 128.76, 128.57, 94.34, 73.02, 67.83, 52.65, 51.42, 44.75, 34.69, 29.89, 25.09, 
24.26; HRMS Calculated for C17H22N2O4 [M+H]+: 319.1613, Found: 319.1652. 
 
Methyl 2-((1R, 2S, 3R, 8aS)-3-(4-methoxyphenyl)-2-nitrooctahydroindolizin-1-yl) 
acetate (2.3cb) was purified by flash chromatography (Hexane/EtOAc = 6 : 1, v/v) as 
light yellow liquid. Reaction time 4 hr; Isolated yield 69 %, dr > 99:1; 
1
H-NMR (600 
MHz, CDCl3) δ 7.21 (d, J = 8.05 Hz, 2H), 6.82 (d, J = 8.78 Hz, 2H), 4.99-4.97 (dd, J = 
8.64 Hz, 5.85 Hz, 1H), 3.76 (s, 3H), 3.70 (d, J =  8.49 Hz, 1H), 3.63 (s, 3H), 3.02-3.01 (m, 
1H), 2.80-2.79 (br d, 1H), 2.65-2.61 (dd, J = 16.54 Hz, 4.24 Hz, 1H), 2.43-2.39 (dd J = 
16.54 Hz, 9.95 Hz, 1H), 1.88 (t, J = 9.66 Hz, 3H), 1.72 (t, J = 12.88 Hz, 1H), 1.58-1.40 
(m, 3H), 1.31-1.17 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 172.03, 159.89, 129.58, 
127.08, 113.99, 94.35, 72.53, 67.77, 55.34, 51.35, 44.68, 34.72, 29.89, 25.11, 24.27; 
HRMS Calculated for C18H24N2O4 [M+H]+: 349.1719, Found: 349.1735. 
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Methyl 2-((1R, 2S, 3R, 8aS)-3-(4-chlorophenyl)-2-nitrooctahydroindolizin-1-yl) 
acetate (2.3cc) was purified by flash chromatography (Hexane/EtOAc = 7 : 1, v/v) as 
light yellow liquid. Reaction time 4 hr; Isolated yield 78 %, dr > 99:1; 
1
H-NMR (600 
MHz, CDCl3) δ 7.28-7.23 (m, 4H), 5.03-5.01 (dd, J = 8.64 Hz, 6.00 Hz, 1H), 3.73 (d, J = 
8.64 Hz, 1H), 3.64 (s, 3H), 3.03-3.01 (m, 1H), 2.76 (d, J = 10.83 Hz, 1H), 2.66-2.62 (dd, 
J = 16.54 Hz, 4.24 Hz, 1H), 2.40-2.44 (td, J = 16.54 Hz, 9.81 Hz, 1H), 1.94-1.87 (m, 3H), 
1.75 (t, J = 4.83 Hz, 1H), 1.60-1.48 (m, 3H), 1.26-1.23 (m, 1H); 
13
C-NMR (150 MHz, 
CDCl3) δ 171.94, 134.56, 133.82, 129.90, 128.85, 94.13, 72.18, 67.67, 52.10, 51.34, 
44.70, 34.54, 29.86, 25.06, 24.17; HRMS Calculated for C17H21ClN2O4 [M+H]+: 
354.1160, Found: 353.1265. 
 
Methyl 2-((1R, 2S, 3S, 8aS)-3-(furan-2-yl)-2-nitrooctahydroindolizin-1-yl) acetate 
(2.3cd) was purified by flash chromatography (Hexane/EtOAc = 5 : 1, v/v) as light 
yellow liquid. Reaction time 4 hr; Isolated yield 68 %, dr > 99:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.34 (d, J = 4.98 Hz, 1H), 6.30-6.29 (m, 2H), 5.02-4.99 (dd, J = 8.34 Hz, 5.71 
Hz, 1H), 3.86 (d, J = 8.34 Hz, 1H), 3.62 (s, 3H), 3.06-3.01 (m, 1H), 2.86 (d, J = 10.83 Hz, 
1H), 2.63-2.59 (dd, J = 16.54 Hz, 4.24 Hz, 1H), 2.42-2.37 (m, 1H), 1.86-1.76 (m, 4H), 
1.60-1.56 (m, 2H), 1.50-1.44 (m, 1H), 1.24-1.19 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 
171.61, 148.81, 143.01, 110.53, 109.37, 91.94, 67.47, 66.76, 51.81, 51.33, 44.11, 34.17, 
29.33, 24.61, 23.86; HRMS Calculated for C15H20N2O5 [M+H]+: 309.1406, Found: 
309.1444. 
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Methyl 2-((1R, 2S, 3S, 8aS)-2-nitro-3-(thiophen-2-yl)octahydroindolizin-1-yl) acetate 
(2.3ce) was purified by flash chromatography (Hexane/EtOAc = 5 : 1, v/v) as light 
yellow liquid. Reaction time 4 hr; Isolated yield 64%, dr > 99:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.24 (d, J = 4.10 Hz, 1H), 7.00 (d, J = 3.22 Hz, 1H), 6.94 (t, J = 3.66 Hz, 1H), 
5.03-5.01 (dd, J = 8.64 Hz, 6.29 Hz, 1H), 4.09 (d, J = 8.64 Hz, 1H), 3.63 (s, 3H), 3.07-
3.02 (m, 1H), 2.95 (d, J = 10.83 Hz, 1H), 2.63-2.60 (dd, J = 16.54 Hz, 12.30 Hz, 1H), 
2.42-2.36 (m, 1H), 1.93-1.79 (m, 4H), 1.61-1.45 (m, 3H), 1.24-1.21 (m, 1H); 
13
C-NMR 
(150 MHz, CDCl3) δ 171.90, 138.75, 127.05, 126.96, 126.30, 93.76, 68.07, 67.51, 52.07, 
51.75, 44.47, 34.44, 29.79, 25.05, 24.19; HRMS Calculated for C15H20N2O4S [M+H]+: 
325.1177, Found: 325.11216. 
 
Methyl 2-((2S, 3S, 4R, 9aS)-3-nitro-4-phenyloctahydro-1H-quinolizin-2-yl) acetate 
(2.3da) was purified by flash chromatography (Hexane/EtOAc = 8 : 1, v/v) as light 
yellow liquid. Reaction time 4 hr; Isolated yield 66 %, dr = 3:2; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.40-7.26 (m, 5H), 4.46 (t, J = 10.39 Hz, 1H), 3.68 (s, 3H), 3.46 (d, J = 10.69 
Hz, 1H), 2.68 (d, J = 7.32Hz, 1H), 2.56 (d, J = 10.83 Hz, 1H), 2.37-2.33 (dd, J = 16.54 
Hz, 12.30 Hz, 1H), 2.23-2.16 (m, 1H), 1.79-1.72 (m, 1H), 1.70-1.63 (m, 2H), 1.47 (t, J = 
12.15 Hz, 1H), 1.36-1.23 (m, 6H); 
13
C-NMR (150 MHz, CDCl3) δ 171.79, 137.91, 
129.01, 128.49, 125.90, 94.99, 71.89, 61.41, 55.84, 52.64, 51.86, 36.94, 36.71, 33.10, 
25.73, 24.22; HRMS Calculated for C18H24N2O4 [M+H]+: 333.1770, Found: 333.1808. 
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Methyl 2-((2S, 3S, 4R, 9aS)-4-(4-methoxyphenyl)-3-nitrooctahydro-1H-quinolizin-2-
yl) acetate (2.3db) was purified by flash chromatography (Hexane/EtOAc = 8 : 1, v/v) as 
light yellow liquid. Reaction time 4 hr; Isolated yield 61 %, dr = 2:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.50-7.15 (m, 2H), 6.81 (d, J = 7.03 Hz, 2H), 4.32 (t, J = 10.10 Hz, 1H), 3.77 (s, 
3H), 3.67 (s, 3H), 3.40 (d, J = 9.37 Hz, 1H), 2.67 (d, J = 10.83 Hz, 1H), 2.56 (d, 1H), 
2.36-2.33 (dd, J = 16.52 Hz, 12.28 Hz, 1H), 2.15 (m, 1H), 1.93 (d, J = 10.10 Hz, 1H), 
1.69-1.63 (m, 4H), 1.49-1.46 (m, 1H), 1.34-1.23 (m, 4H); 
13
C-NMR (150 MHz, CDCl3) δ 
171.14, 159.61, 159.56, 129.97, 129.71, 95.04, 71.27, 61.48, 55.14, 52.72, 51.77, 36.95, 
36.24, 33.08, 33.06, 25.75, 24.23; HRMS Calculated for C19H26N2O5 [M+H]+: 363.1875, 
Found: 363.1914. 
 
Methyl 2-((2S, 3S, 4R, 9aS)-4-(4-chlorophenyl)-3-nitrooctahydro-1H-quinolizin-2-yl) 
acetate (2.3dc) was purified by flash chromatography (Hexane/EtOAc = 8 : 1, v/v) as 
light yellow liquid. Reaction time 4 hr; Isolated yield 66%, dr = 3:2; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.80-7.60 (m, 4H), 4.39 (t, J= 10.25 Hz, 1H), 3.66 (s, 3H), 3.43 (d, J = 9.66 Hz, 
1H), 2.64 (d, J = 7.61 Hz, 1H), 2.51-2.44 (dd, J = 28.10 Hz, 11.71 Hz, 1H), 2.24-2.11 (m, 
2H), 1.91 (d, J = 13.32 Hz, 1H), 1.75-1.64 (m, 4H), 1.45 (t, J = 10.83 Hz, 3H), 1.32-1.22 
(m, 2H); 
13
C-NMR (150 MHz, CDCl3) δ 171.31, 162.50, 137.34, 134.58, 134.26, 95.09, 
71.34, 61.61, 56.02, 53.14, 52.08, 37.10, 36.81, 33.50, 32.54, 25.92, 24.40; HRMS 
Calculated for C18H23ClN2O4 [M+H]+: 368.1317, Found: 363.1419. 
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Methyl 2-((3R, 4S, 5R)-1-ethyl-4-nitro-5-phenylpyrrolidin-3-yl) acetate (2.3ea) was 
purified by flash chromatography (Hexane/EtOAc = 7 : 1, v/v) as light yellow liquid. 
Reaction time 4 hr; Isolated yield 86%, dr > 99:1; 
1
H-NMR (600 MHz, CDCl3) δ 7.41-
7.26 (m, 5H), 4.93-4.90 (dd, J = 8.34 Hz, 4.39 Hz, 1H), 4.16 (d, J = 4.25 Hz, 1H), 3.68 (s, 
3H), 3.50-3.48 (dd, J = 8.78 Hz, 6.44 Hz, 1H), 3.12-3.08 (m, 1H), 2.71-2.65 (m, 1H), 
2.57-2.54 (dd, J = 10.98 Hz, 8.78 Hz, 1H), 2.46-2.41 (m, 3H), 1.03 (t, J = 7.17 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 171.54, 140.44, 128.77, 128.16, 127.17, 95.49, 73.10, 
56.35, 51.95, 47.50, 37.63, 32.13, 13.45; HRMS Calculated for C15H20N2O4 [M+H]
+
: 
293.1457, Found: 293.1339. 
 
Methyl 2-((3R, 4S, 5R)-1-ethyl-5-(4-methoxyphenyl)-4-nitropyrrolidin-3-yl) acetate 
(2.3eb) was purified by flash chromatography (Hexane/EtOAc = 7 : 1, v/v) as light 
yellow liquid. Reaction time 4 hr; Isolated yield 76%, dr > 99:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.25 (d, J = 8.64 Hz, 2H), 6.85 (d, J = 8.74 Hz, 2H), 4.88-4.86 (dd, J = 8.49 Hz, 
4.68 Hz, 1H), 4.06 (d, J = 4.68 Hz, 1H), 3.78 (s, 3H), 3.66 (s, 3H), 3.47-3.45 (dd, J = 
8.64 Hz, 6.44 Hz, 1H), 3.09-3.07 (m, 1H), 2.66-2.61 (m, 1H), 2.51-2.48 (dd, J = 10.98 Hz, 
8.78 Hz, 1H), 2.44-2.40 (dd, J = 7.32 Hz, 3.51 Hz, 2H), 2.39-2.35 (m, 1H), 1.01 (t, J 
=7.17 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 171.58, 159.52, 132.28, 128.33, 114.14, 
95.54, 72.76, 56.42, 55.27, 51.93, 47.34, 37.45, 32.22, 13.39; HRMS Calculated for 
C16H22N2O5 [M+H]
+
: 323.1562, Found: 323.1444. 
 
101 
 
 
Methyl 2-((3R, 4S, 5R)-5-(4-chlorophenyl)-1-ethyl-4-nitropyrrolidin-3-yl) acetate 
(2.3ec) was purified by flash chromatography (Hexane/EtOAc = 6 : 1, v/v) as light 
yellow liquid. Reaction time 4 hr; Isolated yield 81%, dr > 99:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.30-7.23 (m, 4H), 4.95-4.98 (dd, J = 8.64 Hz, 5.85 Hz, 1H), 4.25 (d, J = 8.64 
Hz, 1H), 3.81 (d, J = 9.08 Hz, 1H), 3.65 (s, 3H), 3.49-3.46 (m, 1H), 2.61-2.50 (m, 3H), 
2.05-1.99 (m, 2H), 1.03 (t, J = 7.17 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 171.48, 
134.40, 134.11, 129.49, 128.68, 94.75, 72.05, 56.75, 51.92, 47.63, 38.01, 35.73, 12.94; 
HRMS Calculated for C15H19ClN2O4 [M+H]
+
: 328.1004, Found: 327.0949. 
 
Methyl 2-((3R, 4S, 5S)-1-ethyl-5-(furan-2-yl)-4-nitropyrrolidin-3-yl) acetate (2.3ed) 
was purified by flash chromatography (Hexane/EtOAc = 6 : 1, v/v) as light yellow liquid. 
Reaction time 4 hr; Isolated yield 76%, dr > 99:1; 
1
H-NMR (600 MHz, CDCl3) δ 7.37 (d, 
J = 3.07 Hz, 1H), 6.30-6.28 (m, 2H), 5.16-5.14 (dd, J = 8.05 Hz, 3.66 Hz, 1H), 4.26 (d, J 
= 3.66 Hz, 1H), 3.67 (s, 3H), 3.41-3.39 (dd, J = 8.78 Hz, 6.44 Hz, 1H), 3.17-3.13 (m, 1H), 
2.80-2.77 (m, 1H), 2.55-2.49 (m, 2H), 2.40 (t, J = 5.56 Hz, 2H), 2.03 (t, J = 7.32 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 171.34, 152.43, 142.96, 110.24, 108.34, 92.15, 66.17, 
55.98, 51.97, 47.91, 37.94, 32.01, 13.31; HRMS Calculated for C13H18N2O5 [M+H]
+
: 
283.1249, Found: 283.4311. 
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Methyl 2-((3R, 4S, 5S)-1-ethyl-4-nitro-5-(thiophen-2-yl)pyrrolidin-3-yl) acetate 
(2.3ee) was purified by flash chromatography (Hexane/EtOAc = 6 : 1, v/v) as light 
yellow liquid. Reaction time 4 hr; Isolated yield 76%, dr > 99:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.24 (t, J = 3.66 Hz, 1H), 6.99 (d, J = 3.51 Hz, 1H), 6.93 (d, J = 3.56 Hz, 1H), 
5.02-4.99 (dd, J = 8.64 Hz, 6.44 Hz, 1H), 4.25 (d, J = 8.78 Hz, 1H), 3.66 (s, 3H), 3.62 (t, 
J = 8.64 Hz, 1H), 3.52-3.50 (m, 1H), 2.76-2.73 (m, 1H), 2.56-2.54 (m, 2H), 2.16-2.08 (m, 
2H), 1.06 (t, J = 7.17 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 171.46, 139.34, 135.00, 
126.82, 126.10, 94.01, 67.46, 56.35, 51.92, 47.91, 37.64, 35.66, 12.85; HRMS Calculated 
for C13H18N2O4S [M+H]
+
: 299.1021, Found: 299.0903. 
 
Methyl 2-((2R, 3S, 4S)-1-ethyl-3-nitro-2-phenylpiperidin-4-yl) acetate (2.3fa) was 
purified by flash chromatography (Hexane/EtOAc = 10 : 1, v/v) as light yellow liquid. 
Reaction time 4 hr; Isolated yield 74%, dr = 3:1; 
1
H-NMR (600 MHz, CDCl3) δ 7.36-
7.26 (m, 5H), 4.44 (t, J = 9.95 Hz, 1H), 3.68 (s, 3H), 3.60 (d, J = 9.66 Hz, 1H), 3.20-3.06 
(br m, 1H), 2.52-2.42 (m, 2H), 2.38-2.35 (m, 3H), 2.11-2.05 (m, 3H), 0.91 (t, J = 7.03 Hz, 
3H); 
13
C-NMR (150 MHz, CDCl3) δ 171.16, 138.00, 128.79, 128.59, 128.18, 95.32, 
70.12, 63.76, 51.81, 50.54, 48.01, 37.64, 36.77, 31.79, 10.54; HRMS Calculated for 
C16H22N2O4 [M+H]
+
: 307.1613, Found: 307.1652. 
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Methyl 2-((2R, 3S, 4S)-1-ethyl-2-(4-methoxyphenyl)-3-nitropiperidin-4-yl) acetate 
(2.3fb) was purified by flash chromatography (Hexane/EtOAc = 10 : 1, v/v) as light 
yellow liquid. Reaction time 4 hr; Isolated yield 68%, dr = 3:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.14 (d, J = 8.78 Hz, 2H), 6.85 (d, J = 7.32 Hz, 2H), 4.45-4.36 (m, 1H), 3.78 (s, 
3H), 3.67 (s, 3H), 3.58-3.50 (m, 1H), 3.12-3.08 (m, 1H), 2.63-2.40 (m, 3H), 2.38-2.20 (m, 
3H), 2.11-2.06 (m, 2H), 0.88 (t, J = 6.59 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 171.17, 
129.82, 129.24, 114.15, 112.92, 95.40, 69.48, 63.09, 55.18, 51.80, 50.60, 47.83, 37.40, 
36.82, 29.23; HRMS Calculated for C17H24N2O5 [M+H]
+
: 337.1719, Found: 337.1757. 
 
Methyl 2-((2R, 3S, 4S)-2-(4-chlorophenyl)-1-ethyl-3-nitropiperidin-4-yl) acetate 
(2.3fc) was purified by flash chromatography (Hexane/EtOAc = 10 : 1, v/v) as light 
yellow liquid. Reaction time 4 hr; Isolated yield 73%, dr = 3:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 7.29 (d, J = 6.73 Hz, 2H), 7.24 (d, J = 8.05 Hz, 2H), 4.38 (t, J = 9.95 Hz, 1H), 
3.68 (s, 3H), 3.58 (d, J = 8.78 Hz, 1H), 3.11 (d, J = 10.10 Hz, 1H), 2.58-2.50 (m, 2H), 
2.45-2.22 (m, 3H), 2.11-2.04 (m, 2H), 1.84 (d, J = 13.76 Hz, 1H), 0.88 (t, J = 7.06 Hz, 
3H); 
13
C-NMR (150 MHz, CDCl3) δ 171.07, 136.21, 134.36, 129.47, 129.09, 95.17, 
69.39, 51.84, 50.48, 48.00, 37.58, 36.66, 29.11, 10.58; HRMS Calculated for 
C16H21ClN2O4 [M+H]
+
: 342.1160, Found: 341.1262. 
 
Methyl 2-((2S, 3S, 4S)-1-ethyl-2-(furan-2-yl)-3-nitropiperidin-4-yl) acetate (2.3fd) 
was purified by flash chromatography (Hexane/EtOAc = 10 : 1, v/v) as light yellow 
liquid. Reaction time 4 hr; Isolated yield 72%, dr = 3:1; 
1
H-NMR (600 MHz, CDCl3) δ 
7.27 (d, J = 5.50 Hz, 1H), 7.05 (d, J = 5.70 Hz, 1H), 6.90 (t, J = 1.02 Hz, 1H), 4.43 (t, J = 
8.34 Hz, 1H), 3.66 (s, 3H), 3.12 (d, J = 7.76 Hz, 1H), 2.65-2.55 (m, 1H), 2.37-2.32 (m, 
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3H), 2.25-2.19 (m, 4H), 2.04 (m, 1H), 0.94 (t, J = 7.17 Hz, 3H); 
13
C-NMR (150 MHz, 
CDCl3) δ 178.06, 144.40, 126.60, 126.04, 125.84, 89.68, 66.87, 60.80, 52.43, 48.15, 
43.34, 38.35, 28.18, 11.43; HRMS Calculated for C14H20N2O5 [M+H]
+
: 297.1406, Found: 
297.1444. 
 
Methyl 2-((2S, 3S, 4S)-1-ethyl-3-nitro-2-(thiophen-2-yl)piperidin-4-yl) acetate (2.3fe) 
was purified by flash chromatography (Hexane/EtOAc = 10 : 1, v/v) as light yellow 
liquid. Reaction time 4 hr; Isolated yield 69%, dr = 3:1; 
1
H-NMR (600 MHz, CDCl3) δ 
7.29 (d, J = 4.42 Hz, 1H), 7.25 (t, J = 3.84 Hz, 1H), 6.99 (d, J = 5.12 Hz, 1H), 4.43 (t, J = 
8.24 Hz, 1H), 3.96 (d, J = 6.73 Hz, 1H), 3.65 (s, 3H), 3.13-3.11 (m, 1H), 2.66-2.62 (m, 
1H), 2.57-2.53 (m, 1H), 2.37-2.30 (m, 2H), 2.26-2.16 (m, 2H), 2.06-2.02 (m, 2H), 0.94 (t, 
J = 6.74 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 171.28, 135.06, 128.66, 127.88, 126.68, 
94.85, 65.65, 52.06, 50.82, 48.46, 41.61, 37.79, 29.18, 11.02; HRMS Calculated for 
C14H20N2O4S [M+H]
+
: 313.1177, Found: 313.1216. 
 
Methyl 2-((1R, 2S, 3S, 7aS)-2-nitro-3-(trifluoromethyl)hexahydro-1H-pyrrolizin-1-yl) 
acetate (2.4aa) was purified by flash chromatography (Hexane/EtOAc = 7 : 1, v/v) as 
light yellow liquid. Reaction time 4 hr; Isolated yield 86%, dr = 17:1; 
1
H-NMR (600 
MHz, CDCl3) δ 5.01-4.98 (dd, J = 9.51 Hz, 6.73 Hz, 1H), 4.07-4.01 (m, 1H), 3.67 (s, 3H), 
3.43-3.41 (m, 1H), 3.23-3.21 (m, 1H), 2.92-2.90 (m, 1H), 2.82-2.79 (m, 1H), 2.62-2.53 
(m, 2H), 2.01-2.00 (m, 2H), 1.94-1.91 (m, 1H), 1.78-1.70 (m, 1H); 
13
C-NMR (150 MHz, 
CDCl3) δ 170.90, 124.23, 91.26, 70.64, 69.25, 55.96, 52.20, 48.15, 35.00, 30.18, 26.01; 
HRMS Calculated for C11H15F3N2O4 [M+H]
+
: 297.1017, Found: 297.1056. 
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(1R, 2S, 3S, 7aS)-methyl 1-(2-methoxy-2-oxoethyl)-2-nitrohexahydro-1H-pyrrolizine 
-3-carboxylate (2.4ab) was purified by flash chromatography (Hexane/EtOAc = 15 : 1, 
v/v) as light yellow liquid. Reaction time 4 hr; Isolated yield 71%, dr > 99:1; 
1
H-NMR 
(600 MHz, CDCl3) δ 3.77 (s, 3H), 3.70-3.66 (m, 1H), 3.63 (s, 3H), 3.63-3.62 (m, 2H), 
4.55 (d, J = 7.03 Hz, 1H), 2.60-2.58 (m, 1H), 2.56-2.48 (m, 1H), 1.88-1.80 (m, 1H), 1.80-
1.72 (m, 1H), 1.62-1.52 (m, 2H), 1.42-1.36 (m, 2H); 
13
C-NMR (150 MHz, CDCl3) δ 
172.73, 165.72, 89.87, 77.60, 76.89, 53.81, 52.64, 52.48, 52.09, 50.47, 34.39, 23.50; 
HRMS Calculated for C12H18N2O6 [M+H]
+
: 287.1198, Found: 287.1237. 
 
Methyl 2-((5S, 6S, 7S, 8aS)-6-nitro-5-(trifluoromethyl) octahydroindolizin-7-yl) 
acetate (2.4ba) was purified by flash chromatography (Hexane/EtOAc = 8 : 1, v/v) as 
light yellow liquid. Reaction time 4 hr; Isolated yield 84%, dr > 99:1; 
1
H-NMR (600 
MHz, CDCl3) δ 4.97 (d, J = 2.78 Hz, 1H), 4.27-4.23 (dd, J = 18.00 Hz, 8.93 Hz, 1H), 
3.68 (s, 3H), 3.18-3.16 (m, 1H), 3.09-3.04 (m, 1H), 2.62-2.58 (m, 1H), 2.46-2.42 (m, 1H), 
2.03-1.98 (m, 1H), 1.80-1.76 (m, 1H), 1.76-1.68 (m, 2H), 1.64-1.59 (m, 2H), 1.51-1.47 
(m, 1H), 1.43-1.39 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 172.5, 126.91, 80.78, 60.72, 
54.34, 52.09, 51.44, 36.95, 32.40, 32.10, 31.46, 22.73; HRMS Calculated for 
C12H17F3N2O4 [M+H]
+
: 311.1174, Found: 311.1213. 
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(5S, 6S, 7S, 8aS) -methyl 7-(2-methoxy-2-oxoethyl)-6-nitrooctahydroindolizine-5-
carboxylate (2.4bb) was purified by flash chromatography (Hexane/EtOAc = 8 : 1, v/v) 
as light yellow liquid. Reaction time 4 hr; Isolated yield 79%, dr = 6:1; 
1
H-NMR (600 
MHz, CDCl3) δ 4.65-4.62 (dd, J = 11.42 Hz, 9.66 Hz, 1H), 3.72 (s, 3H), 3.67 (s, 3H), 
3.37 (d, J = 9.66 Hz, 1H), 2.96-3.02 (td, J = 8.78, 2.44 Hz, 1H), 2.64-2.56 (m, 1H), 2.47-
2.43 (m, 1H), 2.30-2.21 (m, 3H), 2.12-2.08 (m, 1H), 1.90-1.73 (m, 3H), 1.46-1.44 (m, 
1H), 1.25-1.19 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 171.23, 169.65, 89.25, 86.70, 
62.75, 59.12, 52.98, 52.12, 37.19, 36.92, 33.95, 29.56, 21.42; HRMS Calculated for 
C13H20N2O6 [M+H]
+
: 301.1355, Found: 301.1394. 
 
Methyl 2-((1R, 2S, 3S, 8aS)-2-nitro-3-(trifluoromethyl) octahydroindolizin-1-yl) 
acetate (2.4ca) was purified by flash chromatography (Hexane/EtOAc = 8 : 1, v/v) as 
light yellow liquid. Reaction time 4 hr; Isolated yield 91%, dr = 6:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 5.12-5.10 (dd, J = 8.78 Hz, 3.22 Hz, 1H), 4.47-4.43 (m, 1H), 3.71 (s, 3H), 3.30-
3.26 (m, 1H), 3.24-3.17 (m, 2H), 2.93-2.85 (td, J = 16.10 Hz, 2.78 Hz, 1H), 2.47-2.38 (m, 
2H), 1.87-1.84 (m, 2H), 1.57-1.51 (m, 1H), 1.43 (d, J = 13.47 Hz, 1H), 1.37-1.28 (m, 1H), 
1.24-1.15 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 171.66, 87.50, 64.36, 64.16, 61.67, 
52.29, 47.35, 41.27, 30.06, 24.81, 23.77, 21.72; HRMS Calculated for C12H17F3N2O4 
[M+H]
+
: 311.1174, Found: 311.1213. 
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(1R, 2S, 3S, 8aS)-methyl 1-(2-methoxy-2-oxoethyl) – 2 - nitrooctahydroindolizine-3-
carboxylate (2.4cb) was purified by flash chromatography (Hexane/EtOAc = 14 : 1, v/v) 
as light yellow liquid. Reaction time 4 hr; Isolated yield 78%, dr > 99:1; 
1
H-NMR (600 
MHz, CDCl3) δ 4.92-4.91 (dd, J = 5.56 Hz, 1.90 Hz, 1H), 4.28-4.27 (m, 1H), 3.73 (s, 3H), 
3.65 (s, 3H), 2.96-2.94 (m, 1H), 2.83-2.78 (m, 1H), 2.62-2.55 (m, 2H), 2.44 (t, J = 10.39 
Hz, 1H), 2.22 (t, J = 11.56 Hz, 1H), 2.79 (q, J = 7.46 Hz, 2H), 1.61-1.58 (m, 1H), 1.53-
1.46 (m, 1H), 1.26-1.12 (m, 2H); 
13
C-NMR (150 MHz, CDCl3) δ 171.98, 170.21, 90.12, 
68.83, 64.26, 52.10, 48.04, 46.48, 35.24, 30.50, 25.07, 23.59; HRMS Calculated for 
C13H20N2O6 [M+H]
+
: 301.1355, Found: 301.1394. 
 
Methyl 2-((2S, 3S, 4S, 9aS)-3-nitro-4-(trifluoromethyl)octahydro-1H-quinolizin-2-yl) 
acetate (2.4da) was purified by flash chromatography (Hexane/EtOAc = 10 : 1, v/v) as 
light yellow liquid. Reaction time 4 hr; Isolated yield 86%, dr = 15:1; 
1
H-NMR (600 
MHz, CDCl3) δ 5.02-4.98 (m, 1H), 4.19-4.12 (m, 1H), 3.69 (s, 3H), 2.92 (t, J = 10.54 Hz, 
1H), 2.80 (d, J = 11.86 Hz, 1H), 2.75-2.69 (m, 3H), 2.60-2.53 (m, 2H), 1.71-1.57 (m, 2H), 
1.44-1.39 (m, 2H), 1.27-1.22 (m, 2H), 1.14-1.06 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 
172.38, 126.04, 81.92, 77.49, 65.23, 61.02, 53.21, 52.68, 52.06, 36.76, 34.75, 33.35, 
30.37, 26.59, 23.99; HRMS Calculated for C13H19F3N2O4 [M+H]
+
: 325.1330, Found: 
325.1369. 
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(2S, 3S, 4S, 9aS)-methyl 2-(2-methoxy-2-oxoethyl)-3-nitrooctahydro-1H-quinolizine-
4-carboxylate (2.4db) was purified by flash chromatography (Hexane/EtOAc = 16 : 1, 
v/v) as light yellow liquid. Reaction time 4 hr; Isolated yield 84%, dr = 17:1; 
1
H-NMR 
(600 MHz, CDCl3) δ 4.75-4.72 (dd, J = 11.86 Hz, 4.98 Hz, 1H), 4.02 (d, J = 5.12 Hz, 1H), 
3.66 (s, 3H), 3.65 (s, 3H), 3.10-3.07 (m, 1H), 2.73-2.71 (m, 1H), 2.43 (d, J = 15.52 Hz, 
1H), 2.34 (t, J = 11.71 Hz, 1H), 2.19 (q, J = 8.49 Hz, 1H), 1.91 (m, 1H), 1.68-1.45 (m, 
6H), 1.27-1.22 (br m, 1H), 1.08-1.02 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 171.44, 
169.30, 88.26, 65.10, 52.89, 25.66, 51.98, 51.82, 37.07, 33.50, 31.15, 26.06, 24.02; 
HRMS Calculated for C14H22N2O6 [M+H]
+
: 315.1511, Found: 315.1550. 
 
Methyl 2-((2S, 3S, 4S)-1-ethyl-3-nitro-2-(trifluoromethyl)piperidin-4-yl) acetate 
(2.4ea) was purified by flash chromatography (Hexane/EtOAc = 11 : 1, v/v) as light 
yellow liquid. Reaction time 4 hr; Isolated yield 86%, dr > 99:1; 
1
H-NMR (600 MHz, 
CDCl3) δ 5.00-4.96 (m, 1H), 4.20-4.10 (dd, J = 18.00 Hz, 8.93 Hz, 1H), 3.68 (s, 3H), 
2.96 (t, J = 12.30 Hz, 1H), 2.85-2.81 (m, 2H), 2.75-2.72 (m, 1H), 2.68-2.64 (m, 1H), 
2.57-2.51 (m, 2H), 2.01-1.98 (m, 1H), 1.54 (d, J = 13.17 Hz, 1H), 1.03 (t, J = 7.18 Hz, 
3H); 
13
C-NMR (150 MHz, CDCl3) δ 172.20, 125.28, 81.65, 61.98, 61.80, 52.04, 49.46, 
45.10, 36.82, 31.38, 25.23, 13.55; HRMS Calculated for C11H17F3N2O4 [M+H]
+
: 
299.1174, Found: 299.1213. 
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(2S, 3S, 4S)-methyl 1-ethyl-4-(2-methoxy-2-oxoethyl) – 3 – nitropiperidine – 2 - 
carboxylate (2.4eb) was purified by flash chromatography (Hexane/EtOAc = 15 : 1, v/v) 
as light yellow liquid. Reaction time 4 hr; Isolated yield 71%, dr > 99:1; 
1
H-NMR (600 
MHz, CDCl3) δ 5.04 (t, J = 3.66 Hz, 1H), 4.31 (d, J = 3.51 Hz, 1H), 3.75 (s, 3H), 3.67 (s, 
3H), 3.10-2.85 (m, 2H), 2.70-2.58 (m, 3H), 2.50-2.40 (m, 1H), 2.10-1.90 (m, 1H), 1.24-
1.23 (m, 2H), 0.99 (t, J = 7.17 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 172.40, 170.22, 
84.69, 63.62, 52.01, 49.16, 46.24, 36.20, 32.29, 26.64, 12.95; HRMS Calculated for 
C12H20N2O6 [M+H]
+
: 289.1355, Found: 289.1394. 
 
(3aS, 3bR, 8R, 8aS)-8-phenyloctahydropyrrolo[3,2-a]pyrrolizin-2(1H)-one (2.5aa) 
was purified by flash chromatography (CH2Cl2/MeOH = 25:1, v/v) as white semisolid. 
Reaction time 8 hr; Isolated yield 81%; 
1
H-NMR (600 MHz, CDCl3) δ 7.36-7.33 (m, 4H), 
7.29-7.24 (m, 1H), 6.83 (s, 1H), 4.35-4.32 (dd, J = 8.64 Hz, 6.15 Hz, 1H), 3.79 (d, J = 
6.15 Hz, 1H), 3.12 (q, J = 7.03 Hz, 1H), 2.72-2.67 (m, 1H), 2.56-2.51 (m, 2H), 2.30-2.25 
(m, 2H), 2.08-2.04 (m, 1H), 2.00-1.97 (m, 1H), 1.93-1.89 (m, 1H), 1.60-1.59 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 177.76, 138.23, 129.02, 128.28, 128.01, 73.62, 72.92, 
67.04, 47.03, 42.11, 34.46, 28.54, 26.20; HRMS Calculated for C15H18N2O [M+H]
+
: 
243.1453, Found: 243.1491. 
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(3aS, 3bR, 8R, 8aS)-8-(4-methoxyphenyl)octahydropyrrolo[3,2-a]pyrrolizin-2(1H)-
one (2.5ab) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as white 
semisolid. Reaction time 8 hr; Isolated yield 76%; 
1
H-NMR (600 MHz, CDCl3) δ 7.32 (d, 
J = 8.64 Hz, 2H), 6.89 (d, J = 8.64 Hz, 1H), 4.93 (s, 1H), 4.23-4.21 (dd, J = 6.59 Hz, 5.12 
Hz, 1H), 3.79 (s, 3H), 3.39 (t, J = 7.46 Hz, 1H), 2.97-2.91 (m, 1H), 2.88-2.83 (m, 1H), 
2.69-2.64 (m, 2H), 2.38-2.35 (dd, J = 17.42 Hz, 15.52 Hz, 1H), 2.08-2.03 (m, 1H), 2.01-
1.94 (m, 2H), 1.79-1.73 (m, 1H), 1.62-1.56 (m, 2H); 
13
C-NMR (150 MHz, CDCl3) δ 
176.67, 171.32, 159.73, 129.43, 114.46, 73.64, 64.90, 60.63, 55.64, 51.89, 42.62, 37.99, 
31.57, 24.98; HRMS Calculated for C16H20N2O2 [M+H]
+
: 273.1558, Found: 273.1593. 
 
(3aS, 3bR, 8R, 8aS)-8-(4-chlorophenyl)octahydropyrrolo[3,2-a]pyrrolizin-2(1H)-one 
(2.5ac) was purified by flash chromatography (CH2Cl2/MeOH = 25:1, v/v) as white 
semisolid. Reaction time 8 hr; Isolated yield 84%; 
1
H-NMR (600 MHz, CDCl3) δ 7.33-
7.29 (m, 4H), 6.82 (s, 1H), 4.24-4.21 (dd, J = 8.78 Hz, 6.00 Hz, 1H), 3.60 (d, J = 5.27 Hz, 
1H), 2.97 (d, J = 6.73 Hz, 1H), 2.69-2.64 (m, 1H), 2.56-2.51 (m, 2H), 2.25-2.18 (m, 2H), 
2.05-2.00 (m, 2H), 1.97-1.92 (m, 1H), 1.60-1.56 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 
177.82, 137.57, 133.96, 129.17, 129.15, 74.27, 72.62, 68.32, 46.73, 41.45, 34.20, 27.99, 
26.50; HRMS Calculated for C15H17ClN2O [M+H]
+
: 278.1000, Found: 277.1102. 
 
(3aS, 3bR, 8S, 8aS)-8-(furan-2-yl)octahydropyrrolo[3,2-a]pyrrolizin-2(1H)-one 
(2.5ad) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as yellow 
semisolid. Reaction time 8 hr; Isolated yield 69%; 
1
H-NMR (600 MHz, CDCl3) δ 7.41 (d, 
111 
 
J = 0.88 Hz, 1H), 6.45 (s, 1H), 6.36-6.34 (m, 1H), 4.48-4.46 (dd, J = 8.20 Hz, 5.12 Hz, 
1H), 4.20 (d, J = 5.12 Hz, 1H), 3.38-3.34 (dd, J = 12.88 Hz, 6.15 Hz, 1H), 2.84-2.82 (m, 
1H), 2.62-2.52 (m, 3H), 2.29-2.26 (dd, J = 17.56 Hz, 14.04 Hz, 1H), 2.15-2.10 (m, 1H), 
1.87-1.82 (m, 2H), 1.71-1.67 (m, 2H); 
13
C-NMR (150 MHz, CDCl3) δ 177.35, 151.50, 
143.05, 110.65, 109.50, 73.01, 66.48, 64.35, 48.12, 43.62, 35.26, 30.06, 25.98; HRMS 
Calculated for C13H16N2O2 [M+H]
+
: 233.1245, Found: 233.1284. 
 
(3aS, 3bR, 8S, 8aS)-8-(thiophen-2-yl)octahydropyrrolo[3,2-a]pyrrolizin-2(1H)-one 
(2.5ae) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as brown 
semisolid. Reaction time 8 hr; Isolated yield 74%; 
1
H-NMR (600 MHz, CDCl3) δ7.29 (d, 
J = 5.12 Hz, 1H), 7.05 (d, J = 2.93 Hz, 1H), 6.99 (s, 1H), 6.51 (s, 1H), 4.38-4.36 (dd, J = 
8.64 Hz, 6.15 Hz, 1H), 4.17 (d, J = 6.15 Hz, 1H), 3.21 (q, J = 13.32 Hz, 6.59 Hz, 1H), 
2.97-2.75 (m, 1H), 2.63-2.55 (m, 2H), 2.50-2.46 (m, 1H), 2.29-2.25 (dd, J = 17.56 Hz, 
13.47 Hz, 1H), 2.14-2.09 (m, 1H), 2.00-1.90 (m, 2H), 1.70-1.65 (m, 1H); 
13
C-NMR (150 
MHz, CDCl3) δ 177.56, 141.71, 127.20, 126.14, 125.82, 73.44, 68.83, 67.53, 47.41, 
42.76, 34.70, 29.22, 25.89; HRMS Calculated for C13H16N2OS [M+H]
+
: 249.1017, Found: 
249.1056. 
 
(3aS, 4aR, 9R, 9aS)-9-phenyloctahydro-1H-pyrrolo[2,3-f]indolizin-2(3H)-one (2.5ba) 
was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as brown semisolid. 
Reaction time 8 hr; Isolated yield 84%; 
1
H-NMR (600 MHz, CDCl3) δ 7.30-7.24 (m, 5H), 
5.38 (s, 1H), 3.31 (t, J = 8.78 Hz, 1H), 3.02 (d, J = 9.07 Hz, 1H), 2.73 (t, J = 8.64 Hz, 
1H), 2.40-2.37 (dd, J = 14.71 Hz, 5.51 Hz, 1H), 2.36-2.28 (m, 1H), 2.15-2.02 (m, 3H), 
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1.99-1.85 (m, 2H), 1.73-1.67 (m, 1H), 1.65-1.59 (m, 1H), 1.55-1.50 (m, 1H), 1.47-1.41 
(m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 178.94, 139.61, 129.04, 128.38, 127.67, 71.36, 
65.55, 65.40, 50.73, 44.07, 37.94, 32.93, 29.92, 21.33; HRMS Calculated for C16H20N2O 
[M+H]
+
: 257.1609, Found: 257.1648. 
 
(3aS, 4aR, 9R, 9aS)-9-(4-methoxyphenyl) octahydro-1H-pyrrolo[2,3-f]indolizin-
2(3H)-one (2.5bb) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as 
brown semisolid. Reaction time 8 hr; Isolated yield 76%; 
1
H-NMR (600 MHz, CDCl3) δ 
7.22 (d, J = 8.34 Hz, 2H), 6.85 (d, J = 8.34 Hz, 2H), 5.20 (s, 1H), 3.77 (s, 3H), 3.28 (t, J 
= 6.44 Hz, 1H), 2.96 (d, J = 6.88 Hz, 1H), 2.71 (t, J = 6.44 Hz, 1H), 2.39-2.36 (dd, J = 
14.93 Hz, 9.07 Hz, 1H), 2.32-2.24 (m, 1H), 2.14-2.01 (m, 3H), 1.93-1.86 (m, 3H), 1.72-
1.56 (m, 1H), 1.54-1.36 (m, 2H); 
13
C-NMR (150 MHz, CDCl3) δ 178.65, 159.61, 131.75, 
128.70, 114.38, 70.69, 65.51, 65.34, 55.49, 50.71, 44.05, 37.49, 33.03, 30.00, 21.29; 
HRMS Calculated for C17H22N2O2 [M+H]
+
: 287.1715, Found: 287.1754. 
 
(3aS, 4aR, 9R, 9aS)-9-(4-chlorophenyl) octahydro-1H-pyrrolo[2,3-f]indolizin-2(3H)-
one (2.5bc) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as brown 
semisolid. Reaction time 8 hr; Isolated yield 89%; 
1
H-NMR (600 MHz, CDCl3) δ 7.29 (d, 
J = 8.64 Hz, 2H), 7.25 (d, J = 8.64 Hz, 2H), 5.26 (br s, 1H), 3.21 (t, J = 8.78 Hz, 1H), 
2.98 (d, J = 8.93 Hz, 1H), 2.67 (t, J = 8.05 Hz, 1H), 2.37-2.34 (dd, J = 14.64 Hz, 9.22 Hz, 
1H), 2.29-2.28 (br d, 1H), 2.11-2.00 (m, 3H), 1.93-1.83 (m, 2H), 1.70-1.59 (m, 2H), 1.50-
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1.38 (m, 2H); 
13
C-NMR (150 MHz, CDCl3) δ 178.64, 138.40, 133.94, 129.22, 129.00, 
70.63, 65.56, 65.24, 50.66, 43.95, 37.83, 32.95, 29.93, 21.33; HRMS Calculated for 
C16H19ClN2O [M+H]
+
: 292.1156, Found: 291.1288. 
 
(3aS, 4aR, 9S, 9aS)-9-(furan-2-yl) octahydro-1H-pyrrolo[2,3-f]indolizin-2(3H)-one 
(2.5bd) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as brown 
semisolid. Reaction time 8 hr; Isolated yield 84%; 
1
H-NMR (600 MHz, CDCl3) δ 7.37 (d, 
J =  1.32, Hz, 1H), 6.32-6.28 (m, 2H), 5.47 (s, 1H), 3.60-3.52 (s, 1H), 3.18 (d, J =  8.93 
Hz, 1H), 2.76 (br t, 1H), 2.41-2.37 (dd, J = 15.66 Hz, 9.22 Hz, 1H), 2.34-2.28 (m, 1H), 
2.15 (t, J = 12.88 Hz, 2H), 2.05-2.01 (m, 2H), 1.92-1.86 (m, 1H), 1.80-1.74 (m, 1H), 
1.70-1.64 (m, 1H), 1.60-1.54 (m, 1H), 1.50-1.40 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 
178.53, 152.22, 142.90, 110.40, 108.45, 65.41, 64.20, 62.17, 50.95, 44.14, 37.75, 32.76, 
29.72, 21.17; HRMS Calculated for C14H18N2O2 [M+H]
+
: 247.1402, Found: 247.1441. 
 
(3aS, 4aR, 9S, 9aS)-9-(thiophen-2-yl) octahydro-1H-pyrrolo[2,3-f]indolizin-2(3H)-
one (2.5be) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as brown 
semisolid. Reaction time 8 hr; Isolated yield 79%; 
1
H-NMR (600 MHz, CDCl3) δ 7.23 (d, 
J = 5.12 Hz, 1H), 6.95 (d, J = 5.12 Hz, 1H), 6.90-6.88 (dd, J = 5.12 Hz, 3.51 Hz, 1H), 
5.77 (s, 1H), 3.35-3.30 (m, 1H), 2.85 (t, J = 8.93 Hz, 1H), 2.38-2.34 (dd, J = 15.37 Hz, 
6.99 Hz, 1H), 2.29-2.28 (m, 1H), 2.12 (t, J = 12.88 Hz, 1H), 2.05-1.96 (m, 3H), 1.87-1.81 
(m, 1H), 1.71-1.67 (m, 1H), 1.63-1.59 (m, 1H), 1.52-1.42 (m, 2H); 
13
C-NMR (150 MHz, 
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CDCl3) δ 179.04, 143.34, 126.65, 125.70, 125.53, 66.69, 66.33, 65.57, 50.90, 43.97, 
37.91, 32.61, 29.87, 21.23; HRMS Calculated for C14H18N2OS [M+H]
+
: 263.1173, Found: 
263.1212. 
 
(3aS, 3bR, 9R, 9aS)-9-phenyloctahydro-1H-pyrrolo[3,2-a]indolizin-2(3bH)-one 
(2.5ca) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as brown 
semisolid. Reaction time 8 hr; Isolated yield 81%; 
1
H-NMR (600 MHz, CDCl3) δ 7.33-
7.24 (m, 5H), 6.30 (s, 1H), 3.78-3.76 (dd, J = 8.64 Hz, 5.12 Hz, 1H), 3.02 (d, J = 5.42 Hz, 
1H), 2.67 (d, J = 8.93 Hz, 1H), 2.58-2.46 (m, 1H), 2.17-2.13 (dd, J = 16.98 Hz, 2.20 Hz, 
1H), 1.97 (t, J = 10.98 Hz, 1H), 1.91-1.88 (m, 2H), 1.82-1.78 (m, 2H), 1.55-1.53 (m, 1H), 
1.45-1.40 (m, 1H), 1.34-1.31 (m, 1H), 1.25-1.20 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 
177.70, 140.82, 128.93, 127.96, 127.80, 70.66, 65.56, 51.50, 50.93, 42.64, 33.50, 30.36, 
25.43, 24.30, 22.92; HRMS Calculated for C16H20N2O [M+H]
+
: 257.1609, Found: 
257.1648. 
 
(3aS, 3bR, 9R, 9aS)-9-(4-methoxyphenyl) octahydro-1H-pyrrolo[3,2-a]indolizin-
2(3bH)-one (2.5cb) was purified by flash chromatography (CH2Cl2/MeOH = 17:1, v/v) 
as brown semisolid. Reaction time 8 hr; Isolated yield 69%; 
1
H-NMR (600 MHz, CDCl3) 
δ 7.21 (d, J = 8.20 Hz, 2H), 6.90 (s, 1H), 6.85 (d, J = 8.20 Hz, 2H), 3.76 (s, 3H), 2.96 (d, 
J = 4.98 Hz, 1H), 2.65 (d, J = 9.66 Hz, 1H), 2.51-2.47 (m, 2H), 2.15 (d, J = 14.78 Hz, 
1H), 2.10-1.86 (m, 2H), 1.78-1.74 (m, 2H), 1.54-1.52 (m, 2H), 1.45-1.11 (m, 3H); 
13
C-
NMR (150 MHz, CDCl3) δ 178.35, 159.43, 132.63, 128.86, 114.29, 78.12, 70.60, 65.80, 
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55.47, 50.86, 42.40, 33.08, 30.30, 25.39, 24.30; HRMS Calculated for C17H22N2O2 
[M+H]
+
: 287.1715, Found: 287.1754. 
 
(3aS, 3bR, 9R, 9aS)-9-(4-chlorophenyl) octahydro-1H-pyrrolo[3,2-a]indolizin-
2(3bH)-one (2.5cc) was purified by flash chromatography (CH2Cl2/MeOH = 25:1, v/v) 
as brown semisolid. Reaction time 8 hr; Isolated yield 84%; 
1
H-NMR (600 MHz, CDCl3) 
δ 7.47 (s, 1H), 7.27-7.22 (m, 4H), 3.66 (t, J = 8.78 Hz, 1H), 3.00 (d, J = 5.27 Hz, 1H), 
2.63 (d, J = 5.27 Hz, 1H), 2.50-2.44 (m, 2H), 2.16-2.13 (m, 1H), 1.94 (t, J = 8.78 Hz, 1H), 
1.87 (d, J = 10.63 Hz, 1H), 1.78 (t, J = 8.78 Hz, 2H), 1.53-1.50 (m, 1H), 1.45-1.16 (m, 
3H); 
13
C-NMR (150 MHz, CDCl3) δ 178.63, 139.41, 133.51, 130.23, 129.07, 128.40, 
77.78, 70.37, 65.98, 50.87, 42.46, 33.65, 30.27, 25.36, 24.21; HRMS Calculated for 
C16H19ClN2O [M+H]
+
: 292.1156, Found: 291.1258. 
 
(3aS, 3bR, 9S, 9aS)-9-(furan-2-yl) octahydro-1H-pyrrolo[3,2-a]indolizin-2(3bH)-one 
(2.5cd) was purified by flash chromatography (CH2Cl2/MeOH = 12:1, v/v) as brown 
semisolid. Reaction time 8 hr; Isolated yield 64%; 
1
H-NMR (600 MHz, CDCl3) δ 7.36 (d, 
J = 3.22 Hz, 1H), 6.60 (s, 1H), 6.29-6.28 (m, 1H), 6.23 (d, J = 3.22 Hz, 1H), 4.13-4.10 
(dd, J = 8.93 Hz, 5.56 Hz, 1H), 3.10 (d, J = 5.42 Hz, 1H), 2.81 (d, J = 10.98 Hz, 1H), 
2.56 (q, J = 9.07 Hz, 1H), 2.50-2.47 (m, 1H), 2.13-2.10 (dd, J = 17.27 Hz, 2.34 Hz, 1H), 
1.90-1.83 (m, 2H), 1.79-1.76 (m, 2H), 1.58-1.50 (m, 1H), 1.50-1.40 (m, 1H), 1.40-4.30 
(m, 1H), 1.24-1.14 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 177.84, 152.32, 143.00, 
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110.35, 108.69, 71.82, 70.77, 61.61, 51.37, 42.15, 33.39, 29.92, 25.11, 24.18; HRMS 
Calculated for C14H18N2O2 [M+H]
+
: 247.1402, Found: 247.1441. 
 
(3aS, 3bR, 9S, 9aS)-9-(thiophen-2-yl) octahydro-1H-pyrrolo[3,2-a]indolizin-2(3bH)-
one (2.5ce) was purified by flash chromatography (CH2Cl2/MeOH = 15:1, v/v) as brown 
semisolid. Reaction time 8 hr; Isolated yield 69%; 
1
H-NMR (600 MHz, CDCl3) δ 7.12 (d, 
J = 4.98 Hz, 1H), 7.05 (s, 1H), 6.95-6.89 (m, 2H), 3.84-3.81 (m, 1H), 3.36 (d, J = 3.12 
Hz, 1H), 2.84 (d,  J = 10.83 Hz, 1H), 2.54-2.42 (m, 2H), 2.13 (d, J = 10.84 Hz, 1H), 1.94 
(t, J = 8.78 Hz, 1H), 1.83 (t, J = 11.86 Hz, 1H), 1.80-1.70 (m, 2H), 1.54 (t, J = 13.17 Hz, 
1H), 1.43-1.40 (m, 1H), 1.31-1.29 (m, 1H), 1.22-1.17 (m, 1H); 
13
C-NMR (150 MHz, 
CDCl3) δ 178.53, 145.48, 127.25, 126.93, 125.42, 73.85, 70.62, 66.32, 51.12, 42.13, 
33.66, 30.23, 25.32, 24.22; HRMS Calculated for C14H18N2OS [M+H]
+
: 263.1173, Found: 
263.1212. 
 
(3aS, 4aR, 10R, 10aS)-10-phenyldecahydropyrrolo[3,2-b]quinolizin-2(1H)-one 
(2.5da) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as brown 
semisolid. Reaction time 8 hr; Isolated yield 69%; 
1
H-NMR (600 MHz, CDCl3) δ 7.48-
7.09 (m, 5H), 4.94 (s, 1H), 3.15 (t, J = 9.51 Hz, 1H), 2.95 (d, J = 9.51 Hz, 1H), 2.69 (d, J 
= 11.42 Hz, 1H), 2.38-2.34 (dd, J = 14.05 Hz, 4.98 Hz, 1H), 2.20 (t, J = 10.54 Hz, 1H), 
2.09-1.97 (m, 2H), 1.82 (d, J = 12.73 Hz, 1H), 1.75 (t, J = 12.00 Hz, 1H), 1.67 (t, J = 
16.83 Hz, 2H), 1.51-1.36 (m, 4H), 1.29-1.23 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 
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178.25, 140.66, 129.75, 128.55, 128.20, 126.22, 72.91, 65.60, 63.76, 52.88, 42.63, 38.08, 
36.19, 33.93, 26.31, 25.03; HRMS Calculated for C17H22N2O [M+H]
+
: 271.1766, Found: 
271.1804. 
 
(3aS, 4aR, 10R, 10aS)-10-(4-methoxyphenyl) decahydropyrrolo[3,2-b]quinolizin-
2(1H)-one (2.5db) was purified by flash chromatography (CH2Cl2/MeOH = 10:1, v/v) as 
brown semisolid. Reaction time 8 hr; Isolated yield 63%; 
1
H-NMR (600 MHz, CDCl3) δ 
7.38 (br s, 1H), 7.04-6.79 (m, 3H), 4.94 (s, 1H), 3.78 (s, 3H), 3.14 (t, J = 9.51 Hz, 1H), 
2.89 (d, J = 9.51 Hz, 1H), 2.69 (d, J = 11.42 Hz, 1H), 2.38-2.34 (dd, J = 15.08 Hz, 5.85 
Hz, 1H), 2.18 (t, J = 10.10 Hz, 1H), 2.09-2.01 (m, 2H), 1.82 (d, J = 12.73 Hz, 1H), 1.75-
1.64 (m, 3H), 1.48 (t, J = 11.56 Hz, 2H), 1.42-1.35 (m, 2H), 1.27-1.23 (m, 1H); 
13
C-NMR 
(150 MHz, CDCl3) δ 178.27, 159.89, 132.52, 130.42, 127.26, 115.83, 113.17, 72.23, 
65.57, 63.85, 60.60, 55.51, 52.69, 42.65, 38.14, 36.20, 33.42, 26.33, 25.03; HRMS 
Calculated for C18H24N2O2 [M+H]
+
: 301.1871, Found: 301.1910. 
 
(3aS, 4aR, 10R, 10aS)-10-(4-chlorophenyl) decahydropyrrolo[3,2-b]quinolizin-
2(1H)-one (2.5dc) was purified by flash chromatography (CH2Cl2/MeOH = 15:1, v/v) as 
brown semisolid. Reaction time 8 hr; Isolated yield 73%; 
1
H-NMR (600 MHz, CDCl3) δ 
7.44-7.04 (m, 4H), 4.99 (s, 1H), 3.10 (t, J = 9.51 Hz, 1H), 2.94 (d, J = 9.37 Hz, 1H), 2.62 
(d, J = 11.42 Hz, 1H), 2.37-2.34 (dd, J = 14.64 Hz, 5.56 Hz, 1H), 2.20 (t, J = 10.68 Hz, 
1H), 2.07-2.02 (m, 2H), 1.82 (d, J = 12.73 Hz, 1H), 1.79-1.72 (td, J = 11.86 Hz, 14.34 Hz, 
2.49 Hz, 1H), 1.67 (t, J = 17.71 Hz, 2H), 1.47-1.43 (m, 2H), 1.41-1.34 (m, 2H), 1.28-1.23 
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(m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 178.28, 139.31, 133.82, 130.49, 130.09, 128.60, 
127.73, 72.20, 65.51, 63.70, 52.86, 42.50, 37.96, 36.08, 33.90, 26.28, 24.96; HRMS 
Calculated for C17H21ClN2O [M+H]
+
: 306.1313, Found: 305.1415. 
 
(3aR, 6R, 6aS)-6-(4-methoxyphenyl)-5-methylhexahydropyrrolo[3,4-b]pyrrol-2(1H)-
one (2.5ea) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as brown 
semisolid. Reaction time 8 hr; Isolated yield 64%; 
1
H-NMR (600 MHz, CDCl3) δ 7.21 (d, 
J = 8.64 Hz, 2H), 6.89 (d, J = 8.64 Hz, 2H), 5.85 (s, 1H), 3.86 (t, J = 7.61 Hz, 1H), 3.79 
(s, 3H), 3.55 (t, J = 8.64 Hz, 1H), 3.14-3.06 (m, 1H), 2.86 (d, J = 5.71 Hz, 1H), 2.59-2.54 
(dd, J = 17.86 Hz, 10.39 Hz,  1H), 2.22-2.18 (m, 2H), 2.10 (s, 3H); 
13
C-NMR (150 MHz, 
CDCl3) δ 177.40, 163.25, 159.70, 128.85, 114.49, 79.29, 66.97, 63.91, 55.52, 39.85, 
35.50, 35.18; HRMS Calculated for C14H18N2O2 [M+H]
+
: 247.1402, Found: 247.1441. 
 
(3aS, 7R, 7aS)-6-ethyl-7-phenylhexahydro-1H-pyrrolo[2,3-c]pyridin-2(3H)-one 
(2.5fa) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as brown 
semisolid. Reaction time 8 hr; Isolated yield 71%; 
1
H-NMR (600 MHz, CDCl3) δ 7.34-
7.24 (m, 5H), 4.93 (s, 1H), 3.24 (d, J = 11.71 Hz, 1H), 3.17 (t, J = 9.51 Hz, 1H), 3.08 (d, 
J = 9.22 Hz, 1H), 2.54 (hex, 1H), 2.40-2.32 (m, 2H), 2.16-2.07 (m, 2H), 1.98-1.95 (m, 
1H), 1.90 (d, J = 12.73 Hz, 1H), 1.80-1.70 (m, 1H), 0.90 (t, J = 7.03 Hz, 3H); 
13
C-NMR 
(150 MHz, CDCl3) δ 178.23, 140.10, 129.11, 128.34, 127.81, 71.25, 65.80, 52.28, 47.91, 
43.53, 38.10, 28.46, 11.33; HRMS Calculated for C15H20N2O [M+H]
+
: 245.1609, Found: 
245.1648. 
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(3aS, 7R, 7aS)-6-ethyl-7-(4-methoxyphenyl) hexahydro-1H-pyrrolo[2,3-c]pyridin-
2(3H)-one (2.5fb) was purified by flash chromatography (CH2Cl2/MeOH = 20:1, v/v) as 
brown semisolid. Reaction time 8 hr; Isolated yield 66%; 
1
H-NMR (600 MHz, CDCl3) δ 
7.21 (d, J = 8.05 Hz, 2H), 6.86 (d, J = 8.64 Hz, 2H), 4.94-4.93 (br s, 1H), 3.79 (s, 3H), 
3.22 (d, J = 11.12 Hz, 1H), 3.16 (t, J = 9.22 Hz, 1H), 3.03 (d, J = 8.93 Hz, 1H), 2.56-2.53 
(m, 1H), 2.40-2.32 (m,  2H), 2.15-2.07 (m, 2H), 2.01-1.89 (m, 2H), 1.73-1.72 (m, 1H), 
0.89 (t, J = 6.88 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 177.24, 159.62, 131.92, 128.86, 
114.54, 70.48, 65.78, 55.51, 52.33, 47.70, 43.56, 38.16, 28.47, 11.28; HRMS Calculated 
for C16H22N2O2 [M+H]
+
: 275.1715, Found: 275.1754. 
 
(3aS, 7R, 7aS)-7-(4-chlorophenyl)-6-ethylhexahydro-1H-pyrrolo[2,3-c]pyridin-
2(3H)-one (2.5fc) was purified by flash chromatography (CH2Cl2/MeOH = 15:1, v/v) as 
brown semisolid. Reaction time 8 hr; Isolated yield 73%; 
1
H-NMR (600 MHz, CDCl3) δ 
7.32 (d, J = 8.64 Hz, 2H), 7.25 (d, J = 7.40 Hz, 2H), 4.90 (s, 1H), 3.22 (d, J = 12.59 Hz, 
1H), 3.12 (t, J = 9.37 Hz, 1H), 3.06 (d, J = 9.22 Hz, 1H), 2.50 (Hex, 1H), 2.40-2.30 (m, 
2H), 2.15-2.06 (m, 2H), 2.00-1.89 (m, 2H), 1.75-1.68 (m, 1H), 0.89 (t, J = 7.03 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 178.20, 138.79, 133.99, 129.41, 129.12, 70.56, 65.74, 
52.21, 47.90, 43.41, 37.99, 28.41, 11.37; HRMS Calculated for C15H19ClN2O [M+H]
+
: 
280.1156, Found: 279.1258. 
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(3aS, 7S, 7aS)-6-ethyl-7-(furan-2-yl) hexahydro-1H-pyrrolo[2,3-c]pyridin-2(3H)-one 
(2.5fd) was purified by flash chromatography (CH2Cl2/MeOH = 10:1, v/v) as yellow 
semisolid. Reaction time 8 hr; Isolated yield 61%; 
1
H-NMR (600 MHz, CDCl3) δ 7.32-
7.28 (br m, 1H), 7.04 (d, J = 4.88 Hz, 1H), 6.89 (d, J = 4.88 Hz, 1H), 4.85 (s, 1H), 4.41-
4.44 (br s, 1H), 3.95-3.97 (br s, J = 9.32 Hz, 1H), 3.67-3.65 (br m, 3H), 3.06 (d, 1H), 
2.70-2.43 (m, 1H), 2.40-2.28 (m, 1H), 2.26-1.15 (m, 1H), 2.04 (d, J = 10.73 Hz, 1H), 
1.92-1.90 (m, 1H), 0.95 (t, J = 7.03 Hz, 3H); 
13
C-NMR (150 MHz, CDCl3) δ 171.42, 
141.48, 128.47, 127.88, 126.70, 65.62, 52.03, 50.85, 48.48, 41.59, 37.84, 29.17, 11.44; 
HRMS Calculated for C13H18N2O2 [M+H]
+
: 235.1402, Found: 235.1464. 
 
(3aS, 7S, 7aS)-6-ethyl-7-(thiophen-2-yl) hexahydro-1H-pyrrolo[2,3-c]pyridin-2(3H)-
one (2.5fe) was purified by flash chromatography (CH2Cl2/MeOH = 10:1, v/v) as yellow 
semisolid. Reaction time 8 hr; Isolated yield 67%; 
1
H-NMR (600 MHz, CDCl3) δ 7.29 (d, 
J = 4.98 Hz, 2H), 6.96-6.92 (m, 1H), 5.08 (s, 1H), 3.44 (d, J = 9.22 Hz, 1H), 3.25-3.20 
(m, 2H), 2.71-2.67 (m, 1H), 2.42-2.31 (m, 2H), 2.23-2.20 (m, 1H), 2.12 (t, J = 12.73 Hz, 
1H), 1.97-1.88 (m, 2H), 1.75-1.73 (m, 1H), 0.95 (t, J = 7.03 Hz, 3H); 
13
C-NMR (150 
MHz, CDCl3) δ 178.05, 144.49, 126.60, 126.01, 125.82, 66.64, 52.42, 48.08, 43.29, 
38.14, 28.27, 11.43; HRMS Calculated for C13H18N2OS [M+H]
+
: 251.1173, Found: 
251.1212. 
 
Methyl 2-((2R,3R,4S,9aS)-3-nitro-4-phenyloctahydro-1H-quinolizin-2-yl)acetate (2.8) 
was purified by flash chromatography (Hexane/EtOAc = 8 : 1, v/v) as light yellow liquid. 
Reaction time 4 hr; Isolated yield 74 %, dr > 99:1; 
1
H-NMR (600 MHz, CDCl3) δ 7.42-
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7.18 (m, 5H), 4.45 (t, J = 10.39 Hz, 1H), 3.68 (s, 3H), 3.45 (d, J = 10.69 Hz, 1H), 3.06(br 
m, 1H); 2.66 (d, J = 7.32Hz, 1H), 2.53 (d, J = 10.83 Hz, 1H), 2.36-2.33 (dd, J = 16.54 Hz, 
12.30 Hz, 1H), 2.26-2.16 (m, 1H), 1.93 (d, J = 11.71 Hz, 1H), 1.78-1.64 (m, 2H), 1.45 (t, 
J = 12.15 Hz, 1H), 1.31-1.21 (m, 5H); 
13
C-NMR (150 MHz, CDCl3) δ 171.40, 143.39, 
138.64, 138.17, 128.72, 128.52, 95.24, 72.12, 61.64, 56.08, 53.13, 52.02, 37.18, 33.34, 
32.64, 25.97, 24.59; HRMS Calculated for C18H24N2O4 [M+H]+: 333.1770, Found: 
333.1808. 
 
(3aS, 4aS, 10S, 10aR)-10-phenyl dodecahydropyrrolo[3,2-b]quinolizine (2.9b) was 
purified by flash chromatography (CH2Cl2/MeOH = 5:1, v/v) as yellow liquid. Reaction 
time 24 hr; Isolated yield 68%; 
1
H-NMR (600 MHz, CDCl3) δ 7.50-7.11 (m, 5H), 3.18 (t, 
J = 9.78 Hz, 1H), 2.97 (d, J = 10.51 Hz, 1H), 2.71 (d, J = 8.84 Hz, 1H), 2.40-2.36 (dd, J 
= 14.25 Hz, 5.45 Hz, 1H), 2.22 (t, J = 10.28 Hz, 1H), 2.11-1.85 (m, 3H), 1.84 (d, J = 
11.48 Hz, 1H), 1.78 (t, J = 12.78 Hz, 1H), 1.69 (t, J = 11.78 Hz, 3H), 1.53-1.37 (m, 5H), 
1.30-1.24 (m, 1H); 
13
C-NMR (150 MHz, CDCl3) δ 139.06, 128.56, 128.55, 127.97, 
123.96, 69.97, 66.83, 62.42, 55.08, 52.59, 43.92, 41.52, 36.53, 33.67, 29.07, 24.64; 
HRMS Calculated for C17H24N2 [M+H]
+
: 257.1973, Found: 257.1993. 
 
3,3,3-trifluoro-2-methoxy-2-phenyl-1-((3aS, 4aS, 10S, 10aR)-10-phenyl decahydro 
pyrrolo[3,2-b]quinolizin-1(2H)-yl)propan-1-one (2.9c) was purified by flash 
chromatography (CH2Cl2/MeOH = 12:1, v/v) as solid residue. Reaction time 24 hr; 
Isolated yield 80%; 
1
H-NMR (600 MHz, CDCl3) δ 7.58-7.19 (m, 10H), 3.41 (s, 3H), 3.32 
(d, J = 8.78 Hz, 1H), 2.86-2.84 (m, 2H), 2.78 (t, J = 10.5 Hz, 1H), 2.57 (d, J = 11.27 Hz, 
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1H), 2.08 (t, J = 9.58 Hz, 1H), 1.84 (t, J = 11.56 Hz, 2H), 1.71 (t, J = 12.78 Hz, 2H), 1.65 
(t, J = 16.25 Hz, 2H), 1.41 (t, J = 12.44 Hz, 2H), 1.33 (q, J = 12.15 Hz, 3H), 1.26-1.21 (m, 
1H); 
13
C-NMR (150 MHz, CDCl3) δ 170.31, 139.05, 135.53, 129.33, 128.55, 128.21, 
128.00, 127.92, 127.39, 125.89, 123.96, 85.25, 69.97, 66.83, 62.42, 55.08, 52.59, 43.92, 
41.52, 36.53, 33.67, 29.67, 25.99, 24.64;-70.30 (br s, CF3), HRMS Calculated for 
C27H31F3N2O2 [M+H]
+
: 473.2371, Found: 473.2391, Also found as [M+H2O+Na]
+
: 
513.3951. 
 
A2.2: Enantioselective piperidine synthesis 
 
 
(2S,3S,4R)-1-((S)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitro-2-phenylpiperidin-4- 
ol (3.2a major) was purified by flash silica gel chromatography (Hexane- EtOAc, v/v 8/1) 
as white solid, yield: 72%. 
1
H NMR (600 MHz, CDCl3): δ 7.19-7.40(m, 7H), 6.76(d, J = 
8.20 Hz, 2H), 4.64(d, J = 10.10 Hz, 1H), 4.27(d, J= 10.10 Hz, 1H), 3.72(s, 3H), 3.66(q, J 
= 6.15 Hz, 1H), 2.96(s, 1H), 2.77(t, J =11.71 Hz, 1H), 2.30(d, J = 13.61 Hz, 1H), 1.71(d, 
J = 13.91 Hz, 1H), 1.51(t, J = 13.17 Hz,  1H), 1.22(s, 3H), 1.15(d, J = 6.73 Hz, 3H). 
13
C 
NMR (600 MHz, CDCl3): δ 158.5, 137.2, 135.5, 129.2, 129.0, 128.6, 113.5, 98.5, 69.5, 
63.9, 55.4, 54.5, 38.7, 37.1, 27.5, 8.9. HRMS Calculated for C21H27N2O4 [M+H]
+
: 
371.19453, Found: 371.19475. 
 
(2R,3R,4S)-2-(4-chlorophenyl)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitro-
piperidin-4-ol (3.2b major) was purified by flash silica gel chromatography (Hexane- 
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EtOAc, v/v 8/1) as white solid, yield: 75%. 
1
H NMR (600 MHz, CDCl3): δ 7.43-7.33(m, 
4H), 7.22(d, J = 8.64 Hz, 2H), 6.82(d, J = 8.78 Hz, 2H), 4.64(d, J= 10.10 Hz, 1H), 4.32(d, 
J= 10.10 Hz, 1H), 3.78(s, 3H), 3.66(q, J = 6.88 Hz, 1H), 2.94(s, 1H), 2.81(td, J =12.15,  
Hz, J =2.49 Hz,  1H), 2.36(dt, J = 11.86 Hz, J = 4.24 Hz, 1H), 1.76(dt, J = 13.76 Hz, J = 
2.49 Hz, 1H), 1.57(d, J = 6.74 Hz,  1H), 1.22(s, 3H), 1.20(d, J = 6.88 Hz, 3H). 
13
C NMR 
(600 MHz, CDCl3): δ 158.5, 136.7, 135.8, 135.1, 134.7, 129.5, 128.6, 127.5, 113.5, 98.3, 
69.5, 63.2, 55.4, 54.7, 38.7, 37.1, 27.5, 8.9. HRMS Calculated for C21H25ClN2O4 [M+H]
+
: 
405.15029, Found: 405.15120. 
 
(2R,3R,4S)-2-(4-fluorophenyl)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitro 
piperidin-4-ol(3.2c major) was purified by flash silica gel chromatography (Hexane- 
EtOAc, v/v 9/1) as white solid, yield: 73%. 
1
H NMR (600 MHz, CDCl3): δ 7.46-7.38(m, 
2H), 7.25-7.23(m, 2H), 7.05(d, J = 7.90 Hz, 2H), 6.82(d, J = 8.64 Hz, 2H), 4.64(d, J = 
7.76 Hz, 1H), 4.33(d, J = 10.10 Hz, 1H), 3.78(s, 3H), 3.67(d, J = 6.59 Hz, 3H), 2.97(s, 
1H), 2.81(t, J =11.12 Hz, 1H), 2.36(d, J = 7.17 Hz, 1H), 1.76(d, J = 15.37 Hz, 1H), 
1.50(m, 1H), 1.27(s, 3H), 1.20(d, J = 6.44 Hz, 3H). 
13
C NMR (600 MHz, CDCl3): δ 
163.0, 158.3, 136.5, 135.6, 134.9, 134.5, 129.3, 129.2, 128.3, 127.3, 113.3, 98.1, 69.2, 
63.0, 55.2, 54.4, 38.4, 36.8, 27.2, 8.7. HRMS Calculated for C21H25FN2O5 [M+H]
+
: 
389.18319, Found: 385.18361. 
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(2R,3R,4S)-2-(4-methoxyphenyl)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-
nitropiperidin-4-ol(3.2d major) was purified by flash silica gel chromatography 
(Hexane- EtOAc, v/v 8/1) as white solid, yield: 55%. 
1
H NMR (600 MHz, CDCl3): δ 
7.40-7.35(m, 4H), 6.88(d, J = 8.05 Hz, 2H), 6.81(d, J = 8.64 Hz, 2H), 4.67(d, J= 9.95 Hz, 
1H), 4.28(d, J= 10.10 Hz, 1H), 3.78(s, 3H), 3.77(s, 3H), 3.73(d, J = 6.88 Hz, 1H), 3.02(s, 
1H), 2.80(t, J =10.10,  Hz, 1H), 2.35(d, J = 15.37 Hz, 1H), 1.76(d, J = 13.76 Hz, 1H), 
1.56(d, J = 11.27 Hz,  1H), 1.27(s, 3H), 1.20(d, J = 6.73 Hz, 3H). 
13
C NMR (600 MHz, 
CDCl3): δ 159.9, 158.4, 135.6, 128.9, 128.6, 114.6, 113.5, 98.6, 69.5, 63.3, 55.4, 38.8, 
37.1, 27.5, 8.90. HRMS Calculated for C22H28N2O5 [M+H]
+
: 401.20318, Found: 
405.20352. 
 
(2R,3R,4S)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitro-2-p-tolylpiperidin-4-
ol (3.2e major) was purified by flash silica gel chromatography (Hexane- EtOAc, v/v 9/1) 
as white solid, yield: 66%. 
1
H NMR (600 MHz, CDCl3): δ 7.39-7.24(m, 4H), 7.16(d, J = 
7.90 Hz, 2H), 6.83(d, J = 8.64 Hz, 2H), 4.71(d, J = 10.10 Hz, 1H), 4.31(d, J = 9.95 Hz, 
1H), 3.79(s, 3H), 3.74(q, J = 6.73 Hz, 3H), 3.05(s, 1H), 2.82(td, J =12.29 Hz, J =2.34 Hz, 
1H), 2.36(d, J = 4.39 Hz, 1H), 2.32(s, 3H), 1.76(d, J = 13.76 Hz, 1H), 1.57(td, J = 12.88 
Hz,  J = 3.81 Hz, 1H), 1.28(s, 3H), 1.21(d, J = 6.73 Hz, 3H). 
13
C NMR (600 MHz, 
CDCl3): δ 158.4, 138.7, 135.6, 134.0, 129.9, 128.6, 126.0, 113.5, 98.5, 69.5, 63.7, 55.4, 
54.4, 38.7, 37.2, 27.5, 21.4, 8.9. HRMS Calculated for C22H28N2O4 [M+H]
+
: 385.20826, 
Found: 385.20491. 
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(2S,3R,4S)-2-(furan-2-yl)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitro 
piperidin-4-ol (3.2g major) was purified by flash silica gel chromatography (Hexane- 
EtOAc, v/v 9/1) as white solid, yield: 73%. 
1
H NMR (600 MHz, CDCl3): δ 7.34-7.33(m, 
3H), 7.05(m, 1H), 6.91(m, 1H), 6.84(d, J = 8.38 Hz, 1H), 4.71(d, J = 10.10 Hz, 1H), 
4.34(d, J = 10.10 Hz, 1H), 3.78(s, 3H), 3.72(m, 1H), 3.64(s, 1H), 2.82(t, J = 9.95 Hz, 1H), 
2.35(d, J = 14.20 Hz, 1H), 1.76(d, J = 13.76 Hz, 1H), 1.59(m, 1H), 1.27 (s, 3H), 1.21(d, J 
= 6.6.88 Hz, 3H). 
13
C NMR (600 MHz, CDCl3): δ 158.2, 136.9, 135.3, 129.0, 128.4, 
125.9, 132.0, 98.3, 69.2, 63.7, 55.2, 54.3, 38.5, 36.9, 27.3, 8.6. HRMS Calculated for 
C19H24N2O4S [M+H]
+
: 361.17188, Found: 361.17156. 
 
(2S,3R,4S)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitro-2-(thiophen-2-yl) 
piperidin-4-ol(3.2g major) was purified by flash silica gel chromatography (Hexane- 
EtOAc, v/v 9/1) as white solid, yield: 72%. 
1
H NMR (600 MHz, CDCl3): δ 7.33-7.31(m, 
3H), 7.04(m, 1H), 6.90(t, J = 4.39 Hz, 1H), 6.83(d, J = 8.64 Hz, 1H), 4.70(m, 2H), 3.78(s, 
3H), 2.97(m, 1H), 2.83(td, J =12.44 Hz, J =2.49 Hz, 1H), 2.32(d, J = 10.54 Hz, 1H), 
1.75(d, J = 13.76 Hz, 1H), 1.56(m, 1H), 1.27(s, 3H), 1.25(d, J = 6.73 Hz, 3H). 
13
C NMR 
(600 MHz, CDCl3): δ 158.4, 137.2, 135.5, 129.2, 128.6, 113.5, 98.5, 69.5, 63.9, 55.4, 
54.5, 38.7, 37.1, 27.5, 8.9. HRMS Calculated for C19H24N2O4S [M+H]
+
: 377.14903, 
Found: 377.14956. 
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(2R,3R,4S)-4-methyl-3-nitro-2-phenylpiperidin-4-ol (3.3a) was purified by flash silica 
gel chromatography (CH2Cl2-MeOH, v/v 100/1) as solid, yield: 88%. 
1
H NMR (600 MHz, 
CDCl3): δ 7.37-7.28(m, 5H), 4.56(d, J = 10.25 Hz, 1H), 4.45(d, J = 10.25 Hz, 1H), 
3.29(td, J = 12.29 Hz, J = 2.93 Hz, 1H), 2.92(ddd, J = 12.07 Hz, J = 4.83 Hz, J = 2.20 Hz, 
1H), 1.89(dt, J = 13.76 Hz, J = 2.49 Hz, 1H), 1.71(td, J = 12.59 Hz, J = 4.83 Hz, 1H), 
1.31 (s, 3H) 
13
C NMR (600 MHz, CDCl3): δ 138.2, 129.1, 129.0, 127.7, 96.9, 69.9, 60.4, 
41.5, 38.1, 27.7 HRMS Calculated for C12H16N2O3 [M+H]
+
: 237.11945, Found: 
237.11933. Enantiomeric excess of the piperidine was determined by HPLC analysis with 
a Chiralcel OD-H column (90:10 hexane: isopropanol, 0.9 mL/min, 220 nm); Racemic 
mixture tR1 = 13.8 min, tR2 = 17.8 min; Enantiopure isomer: 99% ee, tR = 19.2 min and 
[α]D
20
 -25.6 (c = 0.1, CH2Cl2). 
 
 
(2R,3R,4S)-2-(4-chlorophenyl)-4-methyl-3-nitropiperidin-4-ol(3.3b) was purified by 
flash silica gel chromatography (CH2Cl2-MeOH, v/v 100/1) as solid, yield: 92%. 
1
H 
NMR (600 MHz, CDCl3): δ 7.32-7.24(m, 4H), 4.47(d, J = 10.17 Hz, 1H), 4.43(d, J = 
10.17 Hz, 1H), 3.28(td, J = 12.52 Hz, J = 2.74 Hz, 1H), 2.90(dd, J = 11.74 Hz, J = 4.70 
Hz, 1H), 1.86(dt, J = 13.69 Hz, J = 2.74 Hz, 1H), 1.68(td, J = 12.52 Hz, J = 5.09 Hz, 1H), 
1.31 (s, 3H) 
13
C NMR (600 MHz, CDCl3): δ 136.7, 134.6, 129.0, 128.9, 96.7, 69.7, 59.6, 
41.3, 37.8, 27.4 HRMS Calculated for C12H15ClN2O3 [M+H]
+
: 272.07417, Found: 
272.07327. Enantiomeric excess of the piperidine was determined by HPLC analysis with 
a Chiralcel OD-H column (90:10 hexane: isopropanol, 0.9 mL/min, 220 nm); Racemic 
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mixture tR1 = 16.5 min, tR2 = 19.1 min; Enantiopure isomer: 99% ee, tR = 16.4 min and 
[α]D
20
 -34.4 (c = 0.1, CH2Cl2). 
 
(2R,3R,4S)-2-(4-fluorophenyl)-4-methyl-3-nitropiperidin-4-ol (3.3c) was purified by 
flash silica gel chromatography (CH2Cl2-MeOH, v/v 100/1) as solid, yield: 90%. 
1
H 
NMR (600 MHz, CDCl3): δ 7.33(t, J = 6.65 Hz, 2H), 6.99(d, J = 6.65 Hz, 2H), 4.48(d, J 
= 10.17 Hz, 1H), 4.43(d, J = 10.17 Hz, 1H), 3.28(td, J = 12.13 Hz, J = 2.74 Hz, 1H), 
2.90(dq, J = 11.74 Hz, J = 1.96 Hz, 1H), 1.87(dt, J = 13.69 Hz, J = 2.35 Hz, 1H), 1.69(td, 
J = 13.69 Hz, J = 4.70 Hz, 1H), 1.31 (s, 3H) 
13
C NMR (600 MHz, CDCl3): δ 164.3, 161.9, 
134.3, 129.5, 129.4, 116.1, 115.9, 97.2, 70.0, 59.8, 41.6, 38.1, 27.7 HRMS Calculated for 
C12H15FN2O3 [M+H]
+
: 255.1103, Found: 255.1133. Enantiomeric excess of the 
piperidine was determined by HPLC analysis with a Chiralcel OD-H column (90:10 
hexane: isopropanol, 0.9 mL/min, 220 nm); Racemic mixture tR1 = 16.6 min, tR2 = 21.4 
min; Enantiopure isomer: 99% ee, tR = 16.2 min and [α]D
20
 -39.5 (c = 0.1, CH2Cl2). 
 
(2R,3R,4S)-4-methyl-3-nitro-2-p-tolylpiperidin-4-ol (3.3d) was purified by flash silica 
gel chromatography (CH2Cl2-MeOH, v/v 100/1) as solid, yield: 77%. 
1
H NMR (600 MHz, 
CDCl3): δ 7.23(d, J = 8.22 Hz, 1H), 7.11(d, J = 8.22 Hz, 1H), 4.52(d, J = 10.17 Hz, 1H), 
4.41(d, J = 10.17 Hz, 1H), 3.28((td, J = 12.52 Hz, J = 2.74 Hz, 1H), 2.91(dd, J = 11.74 
Hz, J = 2.34 Hz, 1H), 2.30(s, 3H), 1.88(d, J = 11.74 Hz, 1H), 1.66(td, J = 13.30 Hz, J = 
4.70 Hz,  1H), 1.31 (s, 3H) 
13
C NMR (600 MHz, CDCl3): δ 138.6, 135.0, 129.4, 127.3, 
96.8, 69.7, 60.0, 41.3, 37.9, 27.4, 21.1 HRMS Calculated for C13H18N2O3 [M+H]
+
: 
251.13510, Found: 151.13531. Enantiomeric excess of the piperidine was determined by 
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HPLC analysis with a Chiralcel OD-H column (90:10 hexane: isopropanol, 0.9 mL/min, 
220 nm); Racemic mixture tR1 = 15.9 min, tR2 = 18.4 min; Enantiopure isomer: 99% ee, 
tR = 16.4 min and [α]D
20
 -29.3 (c = 0.1, CH2Cl2). 
 
(2R,3R,4S)-2-(4-methoxyphenyl)-4-methyl-3-nitropiperidin-4-ol (3.3e) was purified 
by flash silica gel chromatography (CH2Cl2-MeOH, v/v 100/1) as solid, yield: 75%. 
1
H 
NMR (600 MHz, CDCl3): δ 7.27(d, J = 9.00 Hz, 1H), 6.82(d, J = 9.00 Hz, 1H), 4.51(d, J 
= 10.17 Hz, 1H), 4.39(d, J = 10.17 Hz, 1H), 3.76(s, 3H), 3.33(s, 1H), 2.82(td, J = 12.13 
Hz, J = 2.74 Hz, 1H), 2.90(dd, J = 11.74 Hz, J = 1.96 Hz, 1H), 1.86(dt, J = 13.69 Hz, 1H), 
1.68(m, 1H), 1.31 (s, 3H) 
13
C NMR (600 MHz, CDCl3): δ 159.8, 130.1, 128.6, 114.1, 
96.9, 69.7, 59.7, 55.2, 41.4, 37.8, 27.4 HRMS Calculated for C13H18N2O4 [M+H]
+
: 
267.13001, Found: 267.13054. Enantiomeric excess of the piperidine was determined by 
HPLC analysis with a Chiralcel OD-H column (95:5 hexane: isopropanol, 0.5 mL/min, 
220 nm); Racemic mixture tR1 = 27.1 min, tR2 = 34.4 min; Enantiopure isomer: 99% ee, 
tR = 35.5 min and [α]D
20
 -42.7 (c = 0.1, CH2Cl2). 
 
(2S,3R,4S)-2-(furan-2-yl)-4-methyl-3-nitropiperidin-4-ol(3.3f) was purified by flash 
silica gel chromatography (CH2Cl2-MeOH, v/v 100/1) as solid, yield: 65%. 
1
H NMR 
(600 MHz, CDCl3): δ 7.35(m, 1H), 6.27(m, 2H), 4.67(d, J = 10.17 Hz, 1H), 4.62(d, J = 
10.17 Hz, 1H), 3.33(s, 1H), 3.26(td, J = 12.52 Hz, J = 2.74 Hz, 1H), 2.93(dd, J = 12.52 
Hz, J = 1.96 Hz, 1H), 1.88(d, J = 14.09 Hz, 1H), 1.33(s  3H), 
13
C NMR (600 MHz, 
CDCl3): δ 143.2, 110.5, 108.6, 94.6, 69.8, 53.8, 41.1, 38.5, 29.9, 27.7 HRMS Calculated 
for C10H14N2O4 [M+H]
+
: 227.09871, Found: 227.09851.  
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Enantiomeric excess of the piperidine was determined by HPLC analysis with a Chiralcel 
OD-H column (90:10 hexane: isopropanol, 1 mL/min, 220 nm); Racemic mixture tR1 = 
19.1 min, tR2 = 25.1 min; Enantiopure isomer: 99% ee, tR = 18.4 min and [α]D
20
 +57.2 (c 
= 0.1, CH2Cl2). 
 
(2S,3R,4S)-4-methyl-3-nitro-2-(thiophen-2-yl)piperidin-4-ol(3.3g) was purified by 
flash silica gel chromatography (CH2Cl2-MeOH, v/v 100/1) as solid, yield: 85%. 
1
H 
NMR (600 MHz, CDCl3): δ 7.24(d, J = 4.70 Hz, 1H), 6.94(d, J = 3.52 Hz, 2H), 6.90(t, J 
= 5.09 Hz, 1H), 4.81(d, J = 10.17 Hz, 1H), 4.47(d, J = 10.17 Hz, 1H), 3.28(td, J = 12.13 
Hz, J = 2.24 Hz, 1H), 2.90(dq, J = 11.74 Hz, J = 2.34 Hz, 1H), 1.87(dt, J = 13.69 Hz, J = 
2.74 Hz, 1H), 1.69(td, J = 12.52 Hz, J = 5.09 Hz, 1H), 1.30(s  3H), 
13
C NMR (600 MHz, 
CDCl3): δ 132.2, 126.3, 126.0, 125.9, 97.2, 69.3, 61.2, 42.2. 38.3, 27.4 HRMS Calculated 
for C10H14N2O3S[M+H]
+
: 243.07587, Found: 243.07551. Enantiomeric excess of the 
piperidine was determined by HPLC analysis with a Chiralcel OD-H column (90:10 
hexane: isopropanol, 1 mL/min, 220 nm); Racemic mixture tR1 = 20.1 min, tR2 = 26.7 
min; Enantiopure isomer: 99% ee, tR = 26.3 min and [α]D
20
 +51.8 (c = 0.1, CH2Cl2). 
 
1-(3,5-bis(trifluoromethyl)phenyl)-3-((2R,3R,4S)-4-hydroxy-1-((R)-1-(4-methoxy - 
phenyl) ethyl) -4-methyl-2-phenylpiperidin-3-yl)thiourea (3.4b) was purified by flash 
silica gel chromatography (Hexane/EtOAc, v/v 5/1 to 1/1) as solid, yield: 92%. 
1
H NMR 
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(600 MHz, CDCl3): δ 8.09 (s, 2H), 7.73 (t, J = 9.98 Hz, 1H), 7.65 (s, 1H), 7.49 (m, 2H) 
7.31(d, J = 8.80 Hz, 2H), 7.25(t, J = 7.24 Hz, 1H), 7.16(t, J = 7.24 Hz, 1H), 6.87(d, J = 
8.41 Hz, 2H), 4.93(s, 1H), 4.73(s, 2H), 4.65(t, J = 9.98 Hz, 1H), 3.73 (s, 3H), 3.70 (m, 
1H), 3.60(q, J = 6.85 Hz, 1H), 2.66(m, 2H), 2.19(m, 1H), 1.62 (m, 1H),  1.14 (s, 3H), 
1.13 (s, 3H)  
13C NMR (600 MHz, CDCl3): δ 185.7, 162.8, 147.2, 145.2, 140.8, 135.7, 
135.3, 135.0, 134.7, 133.4, 132.1, 129.7, 127.0, 126.3, 120.8, 118.4, 74.9, 70.3, 68.1, 60.1, 
58.9, 43.4, 43.0, 32.9, 13.3 HRMS Calculated for C30H31F6N3O2S [M+H]
+
: 612.20747, 
Found: 612.20711. 
 
 
(R)-4-Nitro-1,3-diphenylbutan-1-one (3.4d): White solid; [α]D
20 
= +21.0 (c=0.1 in 
CH2Cl2, 90:10 e.r.); 
1
H NMR (400 MHz, CDCl3): δ =7.91–7.89 (m, 2H), 7.57–7.54 (m, 1 
H), 7.46–7.42 (m, 2H), 7.32–7.27 (m, 5H), 4.81 (dd, J=12.5, 6.6 Hz,1H), 4.68 (dd, J=12.5, 
8.0 Hz, 1H), 4.22 (ps quint, J=7.1 Hz, 1H), 3.50-3.37 (m, 2 H); 
13
C NMR (400 MHz, 
CDCl3): δ = 196.8, 139.1, 136.3, 133.5, 129.0, 128.7, 127.4, 79.5, 41.5, 39.2; HPLC 
(Chiralpak AS-H, hexane/isopropanol 90:10, 1.0 mL/min, 220 nm): tR1 = 10.3 min, tR2 = 
13.6 min; Enantiopure isomer: ee 94:6 (en1), ee 92:8 (en2); HRMS: m/z: calcd for 
C16H15NO3[M+H]
+
: 270.10519; found: 270.10855. 
 
A2.3: Triazole gold(I) catalysis 
 
 
(E)-1-phenylhept-1-en-3-one (E-4.3.4a): (Known compound, See: N. Marion, P. 
Carlqvist, R. Gealageas, P. Fremont, F. Maseras, S. P. Nolan, Chem. Eur. J. 2007, 13, 
6437-6451) 
1
H NMR (600 MHz, CDCl3): δ 7.53-7.56 (m, 3H), 7.38-7.40 (m, 3H), 6.73 (t, 
J = 16.2 Hz, 1H), 2.66 (t, J = 7.5 Hz, 2H), 1.66 (quintet, J = 7.5 Hz, 2H), 1.37 (sextet, J = 
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7.4 Hz, 2H), 0.94 (t, J = 7.5 Hz, 3H); 
13
C NMR (150 MHz, CDCl3): δ 200.8, 142.5, 134.8, 
130.6, 129.1, 128.4, 126.5, 40.9, 26.7, 22.7, 14.1. 
 
(E)-4,4-dimethyl-1-phenylpent-1-en-3-one (E-4.3.4b): (Known compound, See: R. S. 
Ramon, S. Gaillard, A. M. Z. Slawin, A. Porta, A. D'Alfonso, G. Zanoni, S. P. Nolan, 
Organometallics 2010, 29, 3665-3668) 
1
H NMR (600 MHz, CDCl3): δ 7.69 (d, J = 16.2 
Hz, 1H, E), 7.56-7.58 (m, 2H, E), 7.53-7.54 (m, 2H, Z), 7.37-7.40 (m, 3H, E), 7.29-7.33 
(m, 3H, Z), 7.13 (d, J = 15.6 Hz, 1H, E), 6.78 (d, J = 13.0 Hz, 1H, Z), 6.45 (d, J = 13.0 
Hz, 1H, Z), 1.23 (s, 9H, E), 1.20 (s, 9H, Z). 
13
C NMR (150 MHz, CDCl3): δ 204.2, 142.9, 
140.1, 134.9, 130.2, 129.5, 128.8, 128.3, 128.1, 124.3, 120.8, 43.2, 26.3, 26.2 (Z+E). 
 
(E)-dec-6-en-5-one (E-4.3.4c): (Known compound, See: M. N. Pennell, M. G. Unthank, 
P. Turner, T. D. Sheppard, J. Org. Chem. 2011, 76, 1479-1482) 
1
H NMR (600 MHz, 
CDCl3): δ 6.82 (dt, J = 16.2, 6.6 Hz, 1H), 6.10 (dt, J = 15.6, 3.6 Hz, 1H), 2.53 (t, J = 7.8 
Hz, 2H), 2.20 (qd, J = 7.2, 1.2 Hz, 2H), 1.60 (quintet, J = 7.7 Hz, 2H), 1.50 (sextet, J = 
7.4 Hz, 2H), 1.34 (sextet, J = 7.4 Hz, 2H), 0.95 (t, J = 7.2 Hz, 3H), 0.92 (t, J = 7.2 Hz, 
3H); 
13
C NMR (150 MHz, CDCl3): δ 200.9, 146.9, 130.5, 39.8, 34.4, 26.4, 22.4, 21.3, 
13.8, 13.6. 
 
(E)-1-p-tolylhept-1-en-3-one (E-4.3.4d): (Known compound, See: N. Marion, P. 
Carlqvist, R. Gealageas, P. Fremont, F. Maseras, S. P. Nolan, Chem. Eur. J. 2007, 13, 
6437-6451) 
1
H NMR (600 MHz, CDCl3): δ 7.51 (d, J = 16.2, Hz, 1H), 7.43 (d, J = 7.8 Hz, 
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2H), 7.19 (d, J = 8.4 Hz, 2H), 6.71 (d, J = 15.6 Hz, 1H), 2.64 (t, J = 7.5 Hz, 2H), 2.37 (s, 
3H), 1.66 (quintet, J = 7.7 Hz, 2H), 1.37 (sextet, J = 7.4 Hz, 2H), 0.92 (t, J = 7.5 Hz, 3H); 
13
C NMR (150 MHz, CDCl3): δ. 200.6, 142.3, 140.8, 131.8, 129.6, 128.2, 125.3, 40.5, 
26.5, 22.4, 21.4, 13.8. 
 
(E)-1-cyclopropyl-3-phenylprop-2-en-1-one (E-4.3.4e): (Known compound, See: G. V. 
Kryshtal, G. M. Zhdankina, S. G. Zlotin, Eur. J. Org. Chem. 2005, 13, 2822-2827) 
1
H 
NMR (600 MHz, CDCl3): δ 7.63 (d, J = 16.2 Hz, 1H), � 7.55-7.57 (m, 2H), 7.38-7.40 (m, 
3H), 6.86 (d, J = 16.2 Hz, 1H), 2.22-2.27 (m, 1H), 1.15-1.17 (m, 2H), 0.95-0.99 (m, 2H); 
13
C NMR (150 MHz, CDCl3): δ 199.9, 141.9, 134.6, 130.2, 128.8, 128.2, 126.4, 19.6, 
11.3. 
 
(E)-1-phenylhex-2-en-1-one (E-4.3.4f): (Known compound, See: N. Marion, P. 
Carlqvist, R. Gealageas, P. Fremont, F. Maseras, S. P. Nolan, Chem. Eur. J. 2007, 13, 
6437-6451) 
1
H NMR (600 MHz, CDCl3): δ 7.91-7.93 (m, 2H), 7.52-7.54 (m, 1H), 7.45 (t, 
J = 7.5 Hz, 2H), 7.05 (dt, J = 15.6, 7.8 Hz, 1H), 6.86 (dt, J = 15.0, 1.5 Hz, 1H), 2.28 (m, 
2H), 1.54 (sextet, J = 7.3 Hz, 2H), 0.97 (t, J = 7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3): 
δ 190.8, 149.6, 137.9, 132.4, 128.4, 128.3, 125.9, 34.7, 21.3, 13.6. 
 
(E)-oct-2-en-4-one (E-4.3.4g): (Known compound, See: A. R. Katritzky, D. C. Oniciu, I. 
Ghiviriga, F. Soti, J. Org. Chem. 1998, 63, 2110-2115) 
1
H NMR (600 MHz, CDCl3): δ 
6.85 (dq, J = 16.2, 6.8 Hz, 1H), 6.11 (dq, J = 15.6, 1.6 Hz, 1H), 2.52 (t, J = 7.5 Hz, 2H), 
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1.90 (dd, J = 6.6, 1.8 Hz, 3H), 1.59 (quintet, J = 7.5 Hz, 2H), 1.33 (sextet, J = 7.6 Hz, 
2H), 0.91 (t, J = 7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3): δ 200.7, 142.2, 131.9, 39.8, 
26.4, 22.4, 18.2, 13.8. 
 
(E)-1-(4-fluorophenyl)hept-1-en-3-one (E-4.3.4h): (Known compound, See: N. Marion, 
P. Carlqvist, R. Gealageas, P. Fremont, F. Maseras, S. P. Nolan, Chem. Eur. J. 2007, 13, 
6437-6451) 
1
H NMR (600 MHz, CDCl3): δ 7.50-7.54 (m, 3H), 7.08 (t, J = 8.4 Hz, 2H), 
6.66 (d, J = 16.2 Hz, 1H), 2.65 (t, J = 7.5 Hz, 2H), 1.66 (quintet, J = 7.4 Hz, 2H), 1.38 
(sextet, J = 7.5 Hz, 2H), 0.94 (t, J = 7.5 Hz, 3H); 
13
C NMR (150 MHz, CDCl3): δ 200.3, 
163.0 (d, J = 249.8 Hz), 140.8, 130.8 (d, J = 1.8 Hz), 130.0 (d, J = 8.3 Hz), 125.9, 116.0 
(d, J = 21.8 Hz), 40.7, 26.4, 22.3, 13.8. 
 
2-methyloct-2-en-4-one (4.3.4i): (Known compound, See: M. Yu, G. Li, S. Wang, L. 
Zhang, Adv. Synth. Catal. 2007, 349, 871-875) 
1
H NMR (600 MHz, CDCl3): δ 6.06-6.08 
(m, 1H), 2.40 (t, J = 7.5 Hz, 2H), 2.14 (d, J = 1.2 Hz, 3H), 1.88 (d, J = 1.2 Hz, 3H), 1.57 
(quintet, J = 7.5 Hz, 2H), 1.32 (sextet, J = 7.4 Hz, 2H), 0.91 (t, J = 7.2 Hz, 3H); 
13
C NMR 
(150 MHz, CDCl3): δ 201.2, 154.5, 123.8, 43.9, 27.5, 26.4, 22.4, 20.6, 13.8. 
 
(E)-2-methylnon-3-en-5-one (E-4.3.4j): (Known compound, See: M. Yu, G. Li, S. 
Wang, L. Zhang, Adv. Synth. Catal. 2007, 349, 871-875) 
1
H NMR (600 MHz, CDCl3): δ 
6.78 (dd, J = 16.2, 6.6 Hz, 1H), 6.03 (dd, J = 16.2, 1.8 Hz, 1H), 2.53 (t, J = 7.5 Hz, 2H), 
2.41-2.48 (m, 1H), 1.59 (quintet, J = 7.4 Hz, 2H), 1.32 (sextet, J = 7.4 Hz, 2H),1.07 (d, J 
134 
 
= 6.6 Hz, 6H), 0.91 (t, J = 7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3): δ 201.2, 153.1, 
127.5, 39.8, 31.0, 26.4, 22.4, 21.3, 13.8. 
 
2-cyclohexylidene-1-phenylethanone (4.3.4k): (Known compound, See: B. Lu, C. Li, L. 
Zhang, J. Am. Chem. Soc. 2005, 127, 14180-14181) 
1
H NMR (600 MHz, CDCl3): δ 7.93-
7.95 (m, 2H), 7.51-7.54 (m, 1H), 7.43-7.46 (m, 2H), 6.60-6.61 (m, 1H), 2.76-2.78 (m, 
2H), 2.31 (td, J = 6.3, 0.6 Hz, 2H), 1.71-1.75 (m, 2H), 1.62-1.66 (m, 4H); 
13
C NMR (150 
MHz, CDCl3): δ 192.3, 162.7, 139.3, 132.3, 128.4, 128.3, 118.7, 38.4, 30.6, 28.9, 28.0, 
26.3. 
 
(E)-1-(4-methoxyphenyl)hept-1-en-3-one (E-4.3.4l): (Known compound, See: N. 
Marion, P. Carlqvist, R. Gealageas, P. Fremont, F. Maseras, S. P. Nolan, Chem. Eur. J. 
2007, 13, 6437-6451) 1H NMR (600 MHz, CDCl3): δ 7.51 (d, J = 15.6 Hz, 1H), 7.49 (d, 
J = 8.4 Hz, 2H), 6.90 (d, J = 8.4 Hz, 2H), 6.63 (d, J = 16.2 Hz, 1H), 3.83 (s, 3H), 2.63 (t, 
J = 7.5 Hz, 2H), 1.66 (quintet, J = 7.5 Hz, 2H), 1.38 (sextet, J = 7.4 Hz, 2H), 0.94 (t, J = 
7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 200.6, 161.5, 142.0, 129.9, 127.2, 124.1, 
114.3, 55.3, 40.5, 26.6, 22.4, 13.9. 
 
(E)-chalcone (E-4.3.4m): (Known compound, See: N. Marion, P. Carlqvist, R. 
Gealageas, P. Fremont, F. Maseras, S. P. Nolan, Chem. Eur. J. 2007, 13, 6437-6451) 
1
H 
NMR (600 MHz, CDCl3): δ 8.00-8.02 (m, 2H), 7.80 (d, J = 15.6 Hz, 1H), 7.62-7.63 (m, 
2H), 7.55- 7.58 (m, 1H), 7.52 (d, J = 15.6 Hz, 1H), 7.49 (t, J = 7.5 Hz, 2H), 7.38-7.41 (m, 
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3H); 
13
C NMR (150 MHz, CDCl3): δ 190.4, 144.7, 138.2, 134.8, 132.7, 130.5, 128.9, 
128.6, 128.4, 128.4, 122.1. 
 
3-methyl-1-phenylbut-2-en-1-one (4.3.4n): (Known compound, See: P. N. Chatterjee, S. 
Roy, J. Org. Chem. 2010, 75, 4413-4423) 
1
H NMR (600 MHz, CDCl3): δ 7.92-7.94 (m, 
2H), 7.50-7.53 (m, 1H), 7.42-7.45 (m, 2H), 6.74-6.75 (m, 1H), 2.21 (d, J = 1.2 Hz, 3H), 
2.01 (d, J = 1.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3): δ 191.8, 156.6, 139.2, 132.2, 
128.4, 128.1, 121.1, 27.9, 21.1. 
 
(E)-1-o-tolylhept-1-en-3-one (E-4.3.4o): (Known compound, See: N. Marion, P. 
Carlqvist, R. Gealageas, P. Fremont, F. Maseras, S. P. Nolan, Chem. Eur. J. 2007, 13, 
6437-6451) 1H NMR (600 MHz, CDCl3): δ 7.85 (d, J = 16.2 Hz, 1H), 7.56 (d, J = 7.8 
Hz, 1H), 7.25 (t, J = 7.2 Hz, 1H), 7.20 (t, J = 7.5 Hz, 2H), 6.66 (d, J = 16.2 Hz, 1H), 2.65 
(t, J = 7.2 Hz, 2H), 2.43 (s, 3H), 1.67 (quintet, J = 7.5 Hz, 2H), 1.39 (sextet, J = 7.4 Hz, 
2H), 0.95 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 200.4, 139.6, 137.8, 133.5, 
130.7, 129.9, 127.1, 126.3, 126.2, 40.9, 26.4, 22.4, 19.6, 13.8. 
 
(E)-1-phenyl-3-p-tolylprop-2-en-1-one (E-4p): (Known compound, See: Y. Zhang, Y.- 
L. Shao, H.-S. Xu, W. Wang, J. Org. Chem. 2011, 76, 1472-1474) 
1
H NMR (600 MHz, 
CDCl3): δ 8.00-8.01 (m, 2H), 7.79 (d, J = 15.6 Hz, 1H), 7.53-7.57 (m, 3H), 7.47-7.50 (m, 
3H), 7.22 (d, J = 7.8 Hz, 2H), 2.38 (s, 3H); 
13
C NMR (150 MHz, CDCl3): δ 190.6, 144.9, 
141.0, 138.4, 132.6, 132.2, 129.7, 128.5, 128.4, 121.1, 21.5. 
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(E)-1-cyclopropylhept-1-en-3-one (E-4.3.4q): (Known compound, See: M. N. Pennell, 
M. G. Unthank, P. Turner, T. D. Sheppard, J. Org. Chem. 2011, 76, 1479-1482) 
1
H NMR 
(600 MHz, CDCl3): δ 6.31 (dd, J = 15.6 Hz, 9.6 Hz, 1H), 6.21 (d, J = 15.6 Hz, 1H), 2.48 
(t, J = 7.5 Hz, 2H), 1.53-1.61 (m, 3H), 1.34 (sextet, J = 7.4 Hz, 2H), 0.95-0.99 (m, 2H), 
0.91 (t, J = 7.5 Hz, 3H), 0.64-0.66 (m, 2H); 
13
C NMR (150 MHz, CDCl3): δ 199.8, 152.0, 
127.2, 40.0, 26.5, 22.4, 14.5, 13.8, 8.8. 
 
(E)-1-(2-chloro-5-nitrophenyl)hept-1-en-3-one (E-4.3.4r): 
1
H NMR (600 MHz, CDCl3): 
δ 8.04 (d, J = 1.8 Hz, 1H), 7.67 (dd, J = 7.8 Hz, 1.8 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 
7.50 (d, J = 16.2 Hz, 1H), 6.80 (d, J = 15.6 Hz, 1H), 2.67 (t, J = 7.5 Hz, 2H), 1.67 
(quintet, J = 7.5 Hz, 2H), 1.38 (sextet, J = 7.4 Hz, 2H), 0.95 (t, J = 7.2 Hz, 3H); 
13
C NMR 
(150 MHz, CDCl3): δ 199.5, 148.3, 137.8, 134.8, 132.4, 132.0, 128.8, 128.2, 124.5, 41.3, 
26.1, 22.3, 13.8; HRMS Calculated for [C13H14ClNO3+Na]+: 290.05599, Found: 
290.05585. 
 
1-cyclohexylidenehexan-2-one (4.3.4s): (Known compound, See: M. Yu, G. Li, S. Wang, 
L. Zhang, Adv. Synth. Catal. 2007, 349, 871-875) 
1
H NMR (600 MHz, CDCl3): δ 5.97 (s, 
1H), 2.79 (t, J = 5.4 Hz, 2H), 2.40 (t, J = 7.2 Hz, 2H), 2.16 (t, J = 6.3 Hz, 2H), 1.54-1.69 
(m, 8H), 1.32 (sextet, J = 7.4 Hz, 2H), 0.91 (t, J = 7.5 Hz, 3H); 
13
C NMR (150 MHz, 
CDCl3): δ 202.1, 161.4, 121.0, 44.2, 38.1, 29.9, 28.8, 27.9, 26.4, 26.3, 22.4, 13.9. 
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(E)-1-(2-methoxyphenyl)hept-1-en-3-one (E-4.3.4t): 
1
H NMR (600 MHz, CDCl3): δ 
7.91 (d, J = 16.8 Hz, 1H), 7.53 (d, J = 7.8 Hz, 1H), 7.35 (t, J = 8.1 Hz, 1H), 6.96 (t, J = 
7.5 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.78 (d, J = 16.2 Hz, 1H), 3.89 (s, 3H), 2.67 (t, J = 
7.5 Hz, 2H), 1.66 (quintet, J = 7.5 Hz, 2H), 1.38 (sextet, J = 7.4 Hz, 2H), 0.94 (t, J = 7.5 
Hz, 3H); 
13
C NMR (150 MHz, CDCl3): δ 201.2, 158.3, 137.5, 131.5, 128.3, 126.9, 123.5, 
120.7, 111.1, 55.4, 40.1, 26.6, 22.4, 13.9. 
 
(E)-1-(naphthalen-4-yl)hept-1-en-3-one (E-4.3.4u): (Known compound, See: R. S. 
Ramón, N. Marion, S. P. Nolan, Tetrahedron, 2009, 65, 1767-1773) 
1
H NMR (600 MHz, 
CDCl3): δ 8.40 (d, J = 16.2 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.88 (t, J = 9.0 Hz, 2H), 
7.76 (d, J = 7.2 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.8 
Hz, 1H), 6.83 (d, J = 16.2 Hz, 1H), 2.73 (t, J = 7.5 Hz, 2H), 1.72 (quintet, J = 7.5 Hz, 2H), 
1.42 (sextet, J = 7.4 Hz, 2H), 0.97 (t, J = 7.5 Hz, 3H); 
13
C NMR (150 MHz, CDCl3): δ 
200.4, 139.1, 133.7, 132.0, 131.6, 130.6, 128.8, 128.7, 126.8, 126.2, 125.4, 125.0, 123.3, 
41.1, 26.5, 22.5, 13.9. 
 
1-Phenylhepta-1,2-dien-3-yl acetate (4.3.2a) (Known compound, see: Sherry, B. D.; 
Toste, F. D. J. Am. Chem. Soc. 2004, 126, 15978-15979). 
1
H NMR (600 MHz, CDCl3): δ 
7.43-7.44 (m, 2H), 7.32-7.35 (m, 2H), 7.25-7.27 (m, 1H), 6.59 (t, J = 3.0 Hz, 1H), 2.33-
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2.37 (m, 2H), 2.15 (s, 3H), 1.46-1.51 (m, 2H), 1.38-1.43 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3): δ 196.7, 168.6, 133.9, 129.2, 128.6, 127.9, 127.0, 104.5, 
31.5, 28.3, 22.1, 21.0, 13.8. 
 
3-(2-Phenylvinylidene)heptan-1-ol (4.8a): (Known compound, see: Sherry, B. D.; Toste, 
F. D. J. Am. Chem. Soc. 2004, 126, 15978-15979). 
1
H NMR (600 MHz, CDCl3): δ 7.28-
7.31 (m, 4H), 7.17-7.20 (m, 1H), 6.20 (quintet, J = 2.9 Hz, 1H), 3.78 (t, J = 6.3 Hz, 2H), 
2.32-3.39 (m, 2H), 2.10-2.14 (m, 2H), 1.63 (br s, 1H), 1.46-1.50 (m, 2H), 1.34-1.40 (m, 
2H), 0.90 (t, J = 7.5 Hz, 3H). 
13
C NMR (150 MHz, CDCl3): δ 201.9, 135.4, 128.6, 126.7, 
126.4, 105.8, 96.1, 60.9, 35.9, 32.7, 29.7, 22.4, 13.9. Enantiomeric excess was 
determined by HPLC with a Chiralcel OD-H column; λ = 254 nm; eluent: 
Hexane/Isopropanol = 95/5; Flow rate: 1.0 mL/min; tR = 6.8 min, tR = 11.4 min; 87% ee.   
 
3-(2-(4-Fluorophenyl)vinylidene)heptan-1-ol (4.8b): 
1
H NMR (600 MHz, CDCl3): δ 
7.22-7.26 (m, 2H), 6.97-6.70 (m, 2H), 6.20 (quintet, J = 2.0 Hz, 1H), 3.76 (t, J = 6.0 Hz, 
2H), 2.31-3.37 (m, 2H), 2.09-2.12 (m, 2H), 1.68 (br s, 1H), 1.43-1.49 (m, 2H), 1.34-1.40 
(m, 2H), 0.88 (t, J = 7.5 Hz, 3H). 
13
C NMR (150 MHz, CDCl3): δ 201.7, 162.6 (d, J = 
244.4 Hz), 131.3 (d, J = 3.3 Hz), 127.8 (q, J = 8.4 Hz), 115.5, 105.9, 95.08 (t, J = 8.5 Hz), 
60.9, 35.9, 32.7, 29.7, 22.4, 23.8. HRMS Calculated for [C15H19FO+Na]+: 257.1312, 
Found: 257.1312. Enantiomeric excess was determined by HPLC with a Chiralcel AS-H 
column; λ = 254 nm; eluent: Hexane/Isopropanol = 97/3; Flow rate: 0.5 mL/min; tR = 
15.5 min, tR = 21.1 min; 90% ee. 
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3-(2-(4-Nitrophenyl)vinylidene)heptan-1-ol (4.8c): 
1
H NMR (600 MHz, CDCl3): δ 
8.14-8.16 (m, 2H), 7.39-741 (m, 2H), 6.25 (quintet, J = 2.8 Hz, 1H), 3.79 (t, J = 6.3 Hz, 
2H), 2.36-2.44 (m, 2H), 2.14-2.17 (m, 2H), 1.61 (br s, 1H), 1.43-1.53 (m, 2H), 1.34-1.40 
(m, 2H), 0.89 (t, J = 7.5 Hz, 3H). 
13
C NMR (150 MHz, CDCl3): δ 204.4, 146.4, 142.9, 
126.8, 124.1, 106.9, 94.9, 60.7, 35.7, 32.4, 29.6, 22.4, 13.8. Calculated for 
[C15H19NO3+Na]
+
: 284.1257, Found: 284.1257. Enantiomeric excess was determined by 
HPLC with a Chiralcel AS-H column; λ = 254 nm; eluent: Hexane/Isopropanol = 90/10; 
Flow rate: 1 mL/min; tR = 10.7 min, tR = 15.8 min; 99% ee. 
 
Methyl 4-(3-(2-hydroxyethyl)hepta-1,2-dienyl)benzoate (4.8d): 
1
H NMR (600 MHz, 
CDCl3): δ 7.95-7.96 (m, 2H), 7.31-7.33 (m, 2H), 6.22 (quintet, J = 3.0 Hz, 1H), 3.90 (s, 
3H), 3.77 (t, J = 6.3 Hz, 2H), 2.34-2.42 (m, 2H), 2.11-2.15 (m, 2H), 1.68 (br s, 1H), 1.42-
1.50 (m, 2H), 1.34-1.39 (m, 2H), 0.88 (t, J = 7.5 Hz, 3H). 
13
C NMR (150 MHz, CDCl3): 
δ 203.3, 166.9, 140.5, 129.9, 128.2, 126.2, 106.2, 95.5, 60.8, 51.9, 35.7, 32.5, 29.7, 22.4, 
13.9. Calculated for [C17H22O3+Na]
+
: 297.1461, Found: 297.1462. Enantiomeric excess 
was determined by HPLC with a Chiralcel AS-H column; λ = 254 nm; eluent: 
Hexane/Isopropanol = 96/4; Flow rate: 1 mL/min; tR = 16.3 min, tR = 18.2 min; 97% ee. 
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5-(3-Nitrophenyl)penta-3,4-dien-1-ol (4.8e): 
1
H NMR (600 MHz, CDCl3): δ 8.12-8.13 
(m, 1H), 8.02 (dd, J = 7.8 Hz, 1.8 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.43-7.46 (m, 1H), 
6.23 (quintet, J = 3.0 Hz, 1H), 5.71 (q, J = 6.6 Hz, 1H), 3.80 (t, J = 6.0 Hz, 2H), 2.42-
2.45 (m, 2H). 
13
C NMR (150 MHz, CDCl3): δ 206.5, 136.9, 132.4, 129.4, 121.6, 121.3, 
93.7, 92.9, 61.8, 31.8. Calculated for [C11H11NO3+Na]
+
: 228.0631, Found: 228.0628. 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; λ = 254 
nm; eluent: Hexane/Isopropanol = 95/5; Flow rate: 1.0 mL/min; tR = 14.4 min, tR = 17.5 
min; 99% ee. 
 
3-(Trimethylsilyl)-5-phenylpenta-3,4-dien-1-ol (4.8f): 
1
H NMR (600 MHz, CDCl3): δ 
7.26-7.30 (m, 2H), 7.21-7.23 (m, 2H), 7.13-7.16 ( m, 1H), 5.95 (t, J = 3.3 Hz, 1H), 3.80 (t, 
J = 6.3 Hz, 2H), 2.33-2.43 (m, 2H), 1.60 (brs, 1H), 0.16 (s, 9H). 
13
C NMR (150 MHz, 
CDCl3): δ 204.9, 135.4, 128.7, 126.1, 125.8, 98.1, 90.3, 62.2, 32.5, -1.5. Calculated for 
[C14H20OSi+Na]
+
: 255.1176, Found: 255.1175. Enantiomeric excess was determined by 
HPLC with a Chiralcel OD-H column; λ = 254 nm; eluent: Hexane/Isopropanol = 95/5; 
Flow rate: 0.8 mL/min; tR = 7.5 min, tR = 13.4 min; 92% ee. 
 
3-(Trimethylsilyl)-(2-(3-Nitrophenyl)vinylidene)pentan-1-ol (4.8g): 
1
H NMR (600 
MHz, CDCl3): δ 8.11-8.12 (m, 1H), 8.00-8.02 (m, 1H), 7.57-7.59 (m, 1H), 7.44 (t, J = 7.8 
Hz, 1H), 6.24 (quintet, J = 2.9 Hz, 1H), 3.79 (t, J = 6.3 Hz, 2H), 2.35-2.45 (m, 2H), 2.12-
2.19 (m, 2H), 1.66 (brs, 1H), 1.44-1.59 (m, 2H), 1.34-1.43 (m, 2H), 0.20 (s, 9H). 
13
C 
NMR (150 MHz, CDCl3): δ 203.1, 148.7, 137.8, 132.1, 129.4, 121.3, 121.0, 107.1, 94.5, 
60.7, 35.7. Calculated for [C11H19NO3+Na]
+
: 284.1257, Found: 284.1257. Enantiomeric 
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excess was determined by HPLC with a Chiralcel AS-H column; λ = 254 nm; eluent: 
Hexane/Isopropanol = 95/5; Flow rate: 1.0 mL/min; tR = 13.4 min, tR = 25.0 min; 95% ee. 
 
5-Phenylpenta-3,4-dien-1-ol (4.8h): (Known compound, see: Sherry, B. D.; Toste, F. D. 
J. Am. Chem. Soc. 2004, 126, 15978-15979). 
1
H NMR (600 MHz, CDCl3): δ 7.28-7.30 
(m, 4H), 7.18-7.21 (m, 1H), 6.19 (quintet, J = 3.0 Hz, 1H), 5.61 (q, J = 6.6 Hz, 1H), 3.79 
(t, J = 6.3 Hz, 2H), 2.38-2.42 (m, 2H), 1.50 (brs, 1H). 
13
C NMR (150 MHz, CDCl3): δ 
205.7, 134.4, 128.7, 126.9, 126.7, 95.2, 91.5, 61.9, 32.1. Enantiomeric excess was 
determined by HPLC with a Chiralcel OD-H column; λ = 254 nm; eluent: 
Hexane/Isopropanol = 97/3; Flow rate: 0.5 mL/min; tR = 28.6 min, tR = 32.4 min; 90% ee. 
 
5-(4-Fluorophenyl)penta-3,4-dien-1-ol (4.8i): 
1
H NMR (600 MHz, CDCl3): δ 7.23-7.26 
(m, 2H), 6.97-7.00 (m, 2H), 6.15 (quintet, J = 3.2 Hz, 1H), 5.61 (q, J = 6.8 Hz, 1H), 3.77 
(t, J = 6.3 Hz, 2H), 2.37-2.41 (m, 2H), 1.68 (brs, 1H). 
13
C NMR (150 MHz, CDCl3): δ 
205.5, 161.1 (d, J = 244.2 Hz), 130.4 (d, J = 2.7 Hz), 128.0 (d, J = 7.7 Hz), 115.5 (d, J = 
21.3 Hz), 94.1, 91.7, 61.9, 32.0. Calculated for [C11H11FO+Na]
+
: 201.0686, Found: 
201.0687. Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; 
λ = 254 nm; eluent: Hexane/Isopropanol = 98/2; Flow rate: 0.6 mL/min; tR = 24.3 min, tR 
= 26.6 min; 94% ee. 
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3-(2-p-Tolylvinylidene)heptan-1-ol (4.8j): 
1
H NMR (600 MHz, CDCl3): δ 7.16-7.18 (m, 
2H), 7.10-7.13 (m, 2H), 6.17 (quintet, J = 3.2 Hz, 1H), 3.76 (t, J = 6.0 Hz, 2H), 2.29-2.39 
(m, 2H), 2.33 (s, 3H), 2.08-2.12 (m, 2H), 1.65 (br s, 1H), 1.42-1.51 (m, 2H), 1.32-1.39 (m, 
2H), 0.88 (t, J = 7.2 Hz, 3H). 
13
C NMR (150 MHz, CDCl3): δ 201.4, 136.5, 132.3, 129.4, 
126.3, 105.6, 95.9, 60.9, 35.9, 32.8, 29.7, 22.4, 21.1, 13.9. Calculated for [C16H22O+Na]
+
: 
253.1563, Found: 253.1559. Enantiomeric excess was determined by HPLC with a 
Chiralcel OD-H column; λ = 254 nm; eluent: Hexane/Isopropanol = 97/3; Flow rate: 0.5 
mL/min; tR = 14.8 min, tR = 17.3 min; 87% ee. 
 
2-((t-Butyl)dimethylsilane-oxy-methyl)-3-(2-phenylvinylidene)heptan-1-ol (4.10b): 
(Ref. see: Sherry, B. D.; Toste, F. D. J. Am. Chem. Soc. 2004, 126, 15978-15979). 
1
H 
NMR (600 MHz, CDCl3): δ 7.54-7.55 (m, 1H), 7.24-7.39 ( m, 3H), 7.16-7.19 (m, 1H), 
6.19 (q, J = 2.8 Hz, 1H), 3.90 (dd, J = 9.6 Hz, 4.2 Hz, 1H), 3.71-3.83 (m, 2H), 2.68 (br s, 
1H), 2.41-2.45 (m, 1H), 2.28 (dt, J = 8.1 Hz, 1.8 Hz, 1H), 2.08-2.17 (m, 2H), 1.32-1.55 
(m, 4H), 0.89 (s, 9H), 0.88 (t, J = 7.8 Hz, 3H), 0.06 (s, 3H), 0.05 (s, 3H). 
13
C NMR (150 
MHz, CDCl3): δ 202.1, 135.2, 128.5, 126.7, 126.4, 106.6, 97.0, 66.0, 65.4, 46.8, 32.2, 
30.7, 29.8, 25.8, 18.5, 18.2, 13.9. Calculated for [C22H36O2Si+Na]
+
: 383.2377, Found: 
383.2377. Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; 
λ = 254 nm; eluent: Hexane/Isopropanol = 98/2; Flow rate: 1.0 mL/min; tR = 4.8 min, tR 
= 5.6 min; 99% ee. 
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Appendix 3: 
1
H NMR, 
13
C NMR, HPLC Spectra and Crystal Structure 
A3.1: ORTEP Drawing of Crystal Structure of 2.5ba 
 
Figure A1:  Perspective view of the molecular structure of C16H20N2O with the 
atom labeling scheme.  The thermal ellipsoids are scaled to enclose 30% 
probability.  CCDC number: 904686 
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A3.2: NMR Spectra of New Compounds 
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Detail 1 D and 2 D Analysis of 2.3aa and 2.5ba 
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A3.3: HPLC Profiles: Racemates and Enantiopure products 
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